Perceptive Life Sciences Master Fund Ltd

Acrivon Therapeutics, Inc.

US ˙ NasdaqGM ˙ US0048901096

Introdução

Esta página fornece uma análise abrangente do histórico conhecido de negociações internas de Perceptive Life Sciences Master Fund Ltd. Insiders são oficiais, diretores ou investidores significativos em uma empresa. É ilegal para insiders realizarem negociações em suas próprias empresas baseados em informações específicas, não públicas. Isso não significa que seja ilegal para eles realizarem qualquer negociação em suas próprias empresas. No entanto, eles devem reportar todas as negociações à SEC através de um Formulário 4. Apesar dessas restrições, pesquisas acadêmicas sugerem que insiders - em geral - tendem a superar o mercado em suas próprias empresas.

Rentabilidade Média de Negociação

A rentabilidade média de negociação é o retorno médio de todas as compras de mercado abertas feitas pelo insider nos últimos três anos. Para calcular isso, examinamos cada compra de mercado aberto, não planejada, feita pelo insider, excluindo todas as negociações que foram marcadas como parte de um plano de negociação 10b5-1. Em seguida, calculamos o desempenho médio dessas negociações ao longo de 3, 6 e 12 meses, fazendo a média de cada uma dessas durações para gerar uma métrica de desempenho final para cada negociação. Finalmente, fazemos a média de todas as métricas de desempenho para calcular uma métrica de desempenho para o insider. Esta lista inclui apenas insiders que fizeram pelo menos três negociações nos últimos dois anos.

Se a rentabilidade de negociação deste insider é "N/A", então o insider ou não fez quaisquer compras de mercado aberto nos últimos três anos, ou as negociações que eles fizeram são muito recentes para calcular uma métrica de desempenho confiável.

Frequência de Atualização: Diariamente

Veja a lista dos negociantes internos mais rentáveis.

Veja os Insiders com Maior Classificação

Empresas com Posições Internas Reportadas

As declarações à SEC indicam que Perceptive Life Sciences Master Fund Ltd reportou posses ou negociações nas seguintes empresas:

Ativo	Título	Últimas Posições Reportadas
US:MGTX / MeiraGTx Holdings plc	Director, 10% Owner	10,786,658
US:IMTX / Immatics N.V.	Director	10,383,456
US:ATHA / LeonaBio, Inc.	Director, 10% Owner	329,756
US:LYRA / Lyra Therapeutics, Inc.	10% Owner	14,026
US:OBIO / Orchestra BioMed Holdings, Inc.	10% Owner	5,292,556
US:ACRV / Acrivon Therapeutics, Inc.	10% Owner	3,104,139
US:ALDX / Aldeyra Therapeutics, Inc.	10% Owner	5,875,851
US:SLDB / Solid Biosciences Inc.	Director, 10% Owner	11,833,539
	Director, 10% Owner	9,675,684
US:CERE / Cerevel Therapeutics Holdings, Inc.	Director	0
US:LIAN / LianBio - Depositary Receipt (Common Stock)	Director, 10% Owner	17,082
US:ATXS / Astria Therapeutics, Inc.	Director	4,873,721
US:VRCA / Verrica Pharmaceuticals Inc.	10% Owner	7,099,182
US:CRGX / CARGO Therapeutics, Inc.		333,333
US:SLNO / Soleno Therapeutics, Inc.	10% Owner	3,074,542
US:VBIV / VBI Vaccines Inc.	10% Owner	41,440,729
US:QTNT / Quotient Ltd	10% Owner	7,945,211
US:ALBO / Albireo Pharma Inc	10% Owner	1,939,723
US:CRNX / Crinetics Pharmaceuticals, Inc.	10% Owner	5,321,032
US:NAUT / Nautilus Biotechnology, Inc.	10% Owner	9,111,151
US:AGRX / Agile Therapeutics, Inc.	10% Owner	2,687,280
US:ISO / IsoPlexis Corp	10% Owner	0
	10% Owner	2,487,019
US:ADMA / ADMA Biologics, Inc.	10% Owner	13,262,375
US:LPTX / Cypherpunk Technologies Inc.	10% Owner	3,508,771
US:LABP / Landos Biopharma, Inc.	Director	25,291
US:VYNE / VYNE Therapeutics Inc.	10% Owner	4,935,057
US:RXDX / Prometheus Biosciences Inc	10% Owner	0
US:SCYX / SCYNEXIS, Inc.	10% Owner	2,400,000
US:MOTS / Motus GI Holdings, Inc.	10% Owner	2,660,542
US:ATNX / Athenex Inc	10% Owner	13,532,467
US:KDMN / Kadmon Holdings Inc	10% Owner	14,636,334
US:DOVA / Dova Pharmaceuticals, Inc.	10% Owner	0
US:FOMX / Foamix Pharmaceuticals Ltd.	10% Owner	22,407,762
US:LJPC / La Jolla Pharmaceutical Co.	10% Owner	2,253,376
US:CORI / Corium International, Inc.	10% Owner	2,724,686
US:FOLD / Amicus Therapeutics, Inc.	10% Owner	20,724,424
US:ZGNX / Zogenix Inc	10% Owner	4,070,357
US:GBT / Global Blood Therapeutics Inc.	10% Owner	4,889,066
US:VSAR / Versartis, Inc..	10% Owner	2,099,563
US:ACRX / Talphera, Inc.	10% Owner	4,533,728
	10% Owner	2,068,824
US:AEGR / Aegerion Pharmaceuticals, Inc.	10% Owner	2,823,426
	10% Owner	22,000
US:XTLB / XTL Biopharmaceuticals Ltd. - Depositary Receipt (Common Stock)	10% Owner	20,580,260
US:BPA /	10% Owner	209,100
US:AIS / Tidal Trust III - VistaShares Artificial Intelligence Supercycle ETF	10% Owner	2,700,000

Como Interpretar os Gráficos

Os gráficos a seguir mostram o desempenho das ações dos a ativos ubsequentes a cada transação de mercado aberto, não planejada feita por Perceptive Life Sciences Master Fund Ltd. Transações não planejadas são negociações que não foram feitas como parte de um plano de negociação 10b5-1. O desempenho das ações é representado como mudança percentual cumulativa no preço das ações. Por exemplo, se uma transação interna foi feita em 1 de janeiro de 2019, o gráfico mostrará a mudança percentual diária da segurança até o dia presente. Se o preço da ação passasse de $10 para $15 durante este período, a mudança percentual cumulativa no preço das ações seria de 50%. Uma mudança no preço de $10 para $20 seria de 100%, e uma mudança no preço de $10 para $5 seria de -50%.

Ultimamente, estamos tentando determinar quão estreitamente as negociações do interno correlacionam-se a retornos excessivos (positivos ou negativos) no preço da ação para ver se o interno está cronometrando suas transações para lucrar com informações internas. Considere a situação onde um interno estava fazendo isso. Nesta situação, esperaríamos (a) retornos positivos após compras, ou (b) retornos negativos após vendas. No caso de (a), o gráfico de COMPRA mostraria uma série de curvas ascendentes, indicando retornos positivos após cada transação de compra. No caso de (b), o gráfico de VENDA mostraria uma série de curvas descendentes, indicando retornos negativos após cada transação de venda.

No entanto, isso sozinho não é suficiente para tirar conclusões. Se, por exemplo, o preço da ação da empresa estivesse em uma escalada não cíclica ao longo de muitos anos, então esperaríamos que todos os gráficos pós-compra tivessem uma inclinação ascendente. Da mesma forma, declínios não cíclicos ao longo de muitos anos resultariam em gráficos pós-negociação inclinados para baixo. Nenhum desses gráficos sugeriria atividade de negociação interna.

O indicador mais forte seria uma situação em que o preço da ação fosse extremamente cíclico, e houvesse sinais positivos no gráfico de COMPRA e gráficos negativos no gráfico de VENDA. Esta situação seria altamente sugestiva de um interno que estava cronometrando transações para sua vantagem financeira.

Compras Internas ACRV / Acrivon Therapeutics, Inc. - Análise de Lucro de Curto Prazo

Nesta seção, analisamos a lucratividade de cada compra interna de mercado aberto, não planejada, feita em ACRV / Acrivon Therapeutics, Inc.. Esta análise ajuda a entender se o interno gera consistentemente retornos anormais, e vale a pena seguir. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.

A tabela a seguir mostra as compras de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.

Data de Negociação	Ticker	Insider	Ações Reportadas	Preço Reportado	Ações Ajustadas	Preço Ajustado	Base de Custos	Dias para Máx	Preço em Máx	Lucro Máx ($)	Retorno Máx (%)
2024-04-11	ACRV	PERCEPTIVE ADVISORS LLC	2,353,000	8.5000	2,353,000	8.5000	20,000,500	7	10.5400	4,800,120	24.00

O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.

Vendas Internas ACRV / Acrivon Therapeutics, Inc. - Análise de Perda de Curto Prazo

Nesta seção, analisamos a evitação de perdas de curto prazo de cada venda interna de mercado aberto, não planejada feita em ACRV / Acrivon Therapeutics, Inc.. Um padrão consistente de evitação de perdas pode sugerir que transações futuras de venda possam prever declínios no preço. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.

A tabela a seguir mostra as vendas de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.

Data de Negociação Ticker Insider Ações
Reportadas Preço
Reportado Ações
Ajustadas Preço
Ajustado Base de Custos Dias para
Mín Preço em
Mín Máxima Perda
Evitada ($) Máxima Perda
Evitada (%)

2025-05-01 ACRV PERCEPTIVE ADVISORS LLC 298,886 1.3400 298,886 1.3400 400,507 29 1.0500 -86,677 -21.64

2025-04-30 ACRV PERCEPTIVE ADVISORS LLC 437,881 1.4100 437,881 1.4100 617,412

2025-04-29 ACRV PERCEPTIVE ADVISORS LLC 250,000 1.4100 250,000 1.4100 352,500

2025-04-28 ACRV PERCEPTIVE ADVISORS LLC 215,283 1.5600 215,283 1.5600 335,841

2025-04-25 ACRV PERCEPTIVE ADVISORS LLC 1,054,669 1.9500 1,054,669 1.9500 2,056,605

O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.

Compras Internas ADMA / ADMA Biologics, Inc. - Análise de Lucro de Curto Prazo

Nesta seção, analisamos a lucratividade de cada compra interna de mercado aberto, não planejada, feita em ACRV / Acrivon Therapeutics, Inc.. Esta análise ajuda a entender se o interno gera consistentemente retornos anormais, e vale a pena seguir. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.

A tabela a seguir mostra as compras de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.

Data de Negociação Ticker Insider Ações
Reportadas Preço
Reportado Ações
Ajustadas Preço
Ajustado Base de Custos Dias para
Máx Preço em
Máx Lucro
Máx ($) Retorno Máx (%)

2020-03-19 ADMA PERCEPTIVE ADVISORS LLC 500,000 2.1000 500,000 2.1000 1,050,000 133 3.7400 820,000 78.10

2020-02-11 ADMA PERCEPTIVE ADVISORS LLC 4,563,700 3.5000 4,563,700 3.5000 15,972,950

2019-05-21 ADMA PERCEPTIVE ADVISORS LLC 4,000,000 4.0000 4,000,000 4.0000 16,000,000

O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.

Vendas Internas ADMA / ADMA Biologics, Inc. - Análise de Perda de Curto Prazo

Nesta seção, analisamos a evitação de perdas de curto prazo de cada venda interna de mercado aberto, não planejada feita em ACRV / Acrivon Therapeutics, Inc.. Um padrão consistente de evitação de perdas pode sugerir que transações futuras de venda possam prever declínios no preço. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.

A tabela a seguir mostra as vendas de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.

Data de Negociação Ticker Insider Ações
Reportadas Preço
Reportado Ações
Ajustadas Preço
Ajustado Base de Custos Dias para
Mín Preço em
Mín Máxima Perda
Evitada ($) Máxima Perda
Evitada (%)

2021-09-30 ADMA PERCEPTIVE ADVISORS LLC 137,495 1.1200 137,495 1.1200 153,994 11 1.09 -4,124 -2.68

2021-09-29 ADMA PERCEPTIVE ADVISORS LLC 82,505 1.1600 82,505 1.1600 95,706

2021-09-28 ADMA PERCEPTIVE ADVISORS LLC 40,603 1.2200 40,603 1.2200 49,536

2021-09-27 ADMA PERCEPTIVE ADVISORS LLC 250,000 1.2300 250,000 1.2300 307,500

2021-09-24 ADMA PERCEPTIVE ADVISORS LLC 250,000 1.2600 250,000 1.2600 315,000

2021-09-23 ADMA PERCEPTIVE ADVISORS LLC 780,000 1.2700 780,000 1.2700 990,600

2021-08-19 ADMA PERCEPTIVE ADVISORS LLC 350,352 1.2400 350,352 1.2400 434,436

2021-08-18 ADMA PERCEPTIVE ADVISORS LLC 552,380 1.2900 552,380 1.2900 712,570

2021-08-17 ADMA PERCEPTIVE ADVISORS LLC 879,092 1.3500 879,092 1.3500 1,186,774

O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.

Compras Internas AIS / Tidal Trust III - VistaShares Artificial Intelligence Supercycle ETF - Análise de Lucro de Curto Prazo

Nesta seção, analisamos a lucratividade de cada compra interna de mercado aberto, não planejada, feita em ACRV / Acrivon Therapeutics, Inc.. Esta análise ajuda a entender se o interno gera consistentemente retornos anormais, e vale a pena seguir. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.

A tabela a seguir mostra as compras de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.

Data de Negociação Ticker Insider Ações
Reportadas Preço
Reportado Ações
Ajustadas Preço
Ajustado Base de Custos Dias para
Máx Preço em
Máx Lucro
Máx ($) Retorno Máx (%)

Não há negociações abertas de mercado não planejadas conhecidas para esta combinação de insider e ativo

O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.

Vendas Internas AIS / Tidal Trust III - VistaShares Artificial Intelligence Supercycle ETF - Análise de Perda de Curto Prazo

Nesta seção, analisamos a evitação de perdas de curto prazo de cada venda interna de mercado aberto, não planejada feita em ACRV / Acrivon Therapeutics, Inc.. Um padrão consistente de evitação de perdas pode sugerir que transações futuras de venda possam prever declínios no preço. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.

A tabela a seguir mostra as vendas de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.

Data de Negociação Ticker Insider Ações
Reportadas Preço
Reportado Ações
Ajustadas Preço
Ajustado Base de Custos Dias para
Mín Preço em
Mín Máxima Perda
Evitada ($) Máxima Perda
Evitada (%)

Não há negociações abertas de mercado não planejadas conhecidas para esta combinação de insider e ativo

O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.

Compras Internas ALDX / Aldeyra Therapeutics, Inc. - Análise de Lucro de Curto Prazo

Nesta seção, analisamos a lucratividade de cada compra interna de mercado aberto, não planejada, feita em ACRV / Acrivon Therapeutics, Inc.. Esta análise ajuda a entender se o interno gera consistentemente retornos anormais, e vale a pena seguir. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.

A tabela a seguir mostra as compras de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.

Data de Negociação Ticker Insider Ações
Reportadas Preço
Reportado Ações
Ajustadas Preço
Ajustado Base de Custos Dias para
Máx Preço em
Máx Lucro
Máx ($) Retorno Máx (%)

2024-04-05 ALDX PERCEPTIVE ADVISORS LLC 37,712 4.7400 37,712 4.7400 178,755 341 6.9800 84,476 47.26

2024-04-04 ALDX PERCEPTIVE ADVISORS LLC 140,281 4.6700 140,281 4.6700 655,112

2024-04-03 ALDX PERCEPTIVE ADVISORS LLC 309,847 4.0900 309,847 4.0900 1,267,274

2024-04-02 ALDX PERCEPTIVE ADVISORS LLC 186,051 3.4400 186,051 3.4400 640,015

2024-04-01 ALDX PERCEPTIVE ADVISORS LLC 8,374 3.2500 8,374 3.2500 27,216

2022-08-10 ALDX PERCEPTIVE ADVISORS LLC 15,000 7.8500 15,000 7.8500 117,750

2022-08-09 ALDX PERCEPTIVE ADVISORS LLC 100,000 7.5000 100,000 7.5000 750,000

2022-08-08 ALDX PERCEPTIVE ADVISORS LLC 97,000 7.2400 97,000 7.2400 702,280

2022-08-05 ALDX PERCEPTIVE ADVISORS LLC 141,000 6.9500 141,000 6.9500 979,950

2022-08-04 ALDX PERCEPTIVE ADVISORS LLC 95,100 6.1700 95,100 6.1700 586,767

2022-08-03 ALDX PERCEPTIVE ADVISORS LLC 100,000 5.8400 100,000 5.8400 584,000

2022-08-02 ALDX PERCEPTIVE ADVISORS LLC 412,406 5.5900 412,406 5.5900 2,305,350

2022-08-01 ALDX PERCEPTIVE ADVISORS LLC 144,185 5.0500 144,185 5.0500 728,134

2022-07-29 ALDX PERCEPTIVE ADVISORS LLC 222,123 5.0300 222,123 5.0300 1,117,279

2022-07-28 ALDX PERCEPTIVE ADVISORS LLC 119,392 5.0000 119,392 5.0000 596,960

2021-05-03 ALDX PERCEPTIVE ADVISORS LLC 1,200,000 12.5000 1,200,000 12.5000 15,000,000

2021-01-19 ALDX PERCEPTIVE ADVISORS LLC 1,368,421 9.5000 1,368,421 9.5000 13,000,000

2021-01-08 ALDX PERCEPTIVE ADVISORS LLC 347,332 9.2100 347,332 9.2100 3,198,928

2021-01-08 ALDX PERCEPTIVE ADVISORS LLC 152,668 10.2100 152,668 10.2100 1,558,740

2021-01-08 ALDX PERCEPTIVE ADVISORS LLC 50,000 7.6000 50,000 7.6000 380,000

2021-01-07 ALDX PERCEPTIVE ADVISORS LLC 500,000 8.1300 500,000 8.1300 4,065,000

2020-07-09 ALDX PERCEPTIVE ADVISORS LLC 3,200,000 4.2500 3,200,000 4.2500 13,600,000

2017-09-19 ALDX PERCEPTIVE ADVISORS LLC 200,000 7.2500 200,000 7.2500 1,450,000

2017-06-30 ALDX PERCEPTIVE ADVISORS LLC 296,007 4.6000 296,007 4.6000 1,361,632

2017-02-14 ALDX PERCEPTIVE ADVISORS LLC 893,025 4.5000 893,025 4.5000 4,018,612

2016-05-26 ALDX PERCEPTIVE ADVISORS LLC 700,000 5.0000 700,000 5.0000 3,500,000

2015-10-28 ALDX PERCEPTIVE ADVISORS LLC 45,100 6.5000 45,100 6.5000 293,150

2015-10-26 ALDX PERCEPTIVE ADVISORS LLC 50,000 6.4630 50,000 6.4630 323,150

2015-10-22 ALDX PERCEPTIVE ADVISORS LLC 18,020 6.4740 18,020 6.4740 116,661

2015-10-20 ALDX PERCEPTIVE ADVISORS LLC 14,348 6.2960 14,348 6.2960 90,335

2015-10-20 ALDX PERCEPTIVE ADVISORS LLC 22,797 6.4420 22,797 6.4420 146,858

O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.

Vendas Internas ALDX / Aldeyra Therapeutics, Inc. - Análise de Perda de Curto Prazo

Nesta seção, analisamos a evitação de perdas de curto prazo de cada venda interna de mercado aberto, não planejada feita em ACRV / Acrivon Therapeutics, Inc.. Um padrão consistente de evitação de perdas pode sugerir que transações futuras de venda possam prever declínios no preço. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.

A tabela a seguir mostra as vendas de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.

Data de Negociação Ticker Insider Ações
Reportadas Preço
Reportado Ações
Ajustadas Preço
Ajustado Base de Custos Dias para
Mín Preço em
Mín Máxima Perda
Evitada ($) Máxima Perda
Evitada (%)

2025-04-03 ALDX PERCEPTIVE ADVISORS LLC 3,400,000 1.4200 3,400,000 1.4200 4,828,000 348 1.2400 -612,000 -12.68

2023-10-18 ALDX PERCEPTIVE ADVISORS LLC 306,499 1.7400 306,499 1.7400 533,308

2023-10-16 ALDX PERCEPTIVE ADVISORS LLC 2,450,000 1.6000 2,450,000 1.6000 3,920,000

O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.

Compras Internas ANIP / ANI Pharmaceuticals, Inc. - Análise de Lucro de Curto Prazo

Nesta seção, analisamos a lucratividade de cada compra interna de mercado aberto, não planejada, feita em ACRV / Acrivon Therapeutics, Inc.. Esta análise ajuda a entender se o interno gera consistentemente retornos anormais, e vale a pena seguir. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.

A tabela a seguir mostra as compras de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.

Data de Negociação Ticker Insider Ações
Reportadas Preço
Reportado Ações
Ajustadas Preço
Ajustado Base de Custos Dias para
Máx Preço em
Máx Lucro
Máx ($) Retorno Máx (%)

2004-12-02 BPA EDELMAN JOSEPH 2,000 3.9800 2,000 3.9800 7,960 730

2004-10-08 BPA EDELMAN JOSEPH 1,000 9.8652 1,000 9.8652 9,865

2004-10-08 BPA EDELMAN JOSEPH 14,900 9.8652 14,900 9.8652 146,991

2004-10-07 BPA EDELMAN JOSEPH 1,000 10.1071 1,000 10.1071 10,107

2004-10-07 BPA EDELMAN JOSEPH 9,000 10.1071 9,000 10.1071 90,964

2004-10-06 BPA EDELMAN JOSEPH 1,000 9.9013 1,000 9.9013 9,901

2004-10-06 BPA EDELMAN JOSEPH 9,000 9.9013 9,000 9.9013 89,112

2004-10-05 BPA EDELMAN JOSEPH 1,700 9.8998 1,700 9.8998 16,830

2004-10-05 BPA EDELMAN JOSEPH 15,800 9.8998 15,800 9.8998 156,417

2004-10-04 BPA EDELMAN JOSEPH 1,400 9.7207 1,400 9.7207 13,609

2004-10-04 BPA EDELMAN JOSEPH 13,100 9.7207 13,100 9.7207 127,341

2004-10-01 BPA EDELMAN JOSEPH 2,100 9.5900 2,100 9.5900 20,139

2004-10-01 BPA EDELMAN JOSEPH 19,400 9.5900 19,400 9.5900 186,046

2004-09-30 BPA EDELMAN JOSEPH 1,000 8.9645 1,000 8.9645 8,964

2004-09-30 BPA EDELMAN JOSEPH 9,000 8.9645 9,000 8.9645 80,680

2004-09-14 BPA EDELMAN JOSEPH 2,400 7.6852 2,400 7.6852 18,444

2004-09-14 BPA EDELMAN JOSEPH 22,100 7.6852 22,100 7.6852 169,843

2004-09-13 BPA EDELMAN JOSEPH 2,500 7.1681 2,500 7.1681 17,920

2004-09-13 BPA EDELMAN JOSEPH 23,400 7.1681 23,400 7.1681 167,734

2004-09-09 BPA EDELMAN JOSEPH 400 6.8500 400 6.8500 2,740

2004-09-09 BPA EDELMAN JOSEPH 4,300 6.8500 4,300 6.8500 29,455

2004-08-31 BPA EDELMAN JOSEPH 9,000 6.8403 9,000 6.8403 61,563

2004-08-30 BPA EDELMAN JOSEPH 1,000 6.8374 1,000 6.8374 6,837

2004-08-30 BPA EDELMAN JOSEPH 9,000 6.8374 9,000 6.8374 61,537

2004-08-19 BPA EDELMAN JOSEPH 6,200 5.8446 6,200 5.8446 36,237

2004-08-19 BPA EDELMAN JOSEPH 700 5.8446 700 5.8446 4,091

2004-08-18 BPA EDELMAN JOSEPH 40,500 5.8253 40,500 5.8253 235,925

2004-08-18 BPA EDELMAN JOSEPH 4,500 5.8253 4,500 5.8253 26,214

2004-08-16 BPA EDELMAN JOSEPH 200 5.1000 200 5.1000 1,020

2004-08-12 BPA EDELMAN JOSEPH 2,500 4.7500 2,500 4.7500 11,875

2004-08-11 BPA EDELMAN JOSEPH 21,300 4.7175 21,300 4.7175 100,483

2004-08-11 BPA EDELMAN JOSEPH 2,300 4.7175 2,300 4.7175 10,850

2004-07-19 BPA EDELMAN JOSEPH 25,652 5.6747 25,652 5.6747 145,567

2004-07-19 BPA EDELMAN JOSEPH 2,800 5.6747 2,800 5.6747 15,889

2004-07-16 BPA EDELMAN JOSEPH 12,648 5.8877 12,648 5.8877 74,468

2004-07-16 BPA EDELMAN JOSEPH 1,400 5.8870 1,400 5.8870 8,242

2004-07-15 BPA EDELMAN JOSEPH 6,750 5.9633 6,750 5.9633 40,252

2004-07-15 BPA EDELMAN JOSEPH 750 5.9633 750 5.9633 4,472

2004-05-14 BPA EDELMAN JOSEPH 650,000 6.0000 650,000 6.0000 3,900,000

O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.

Vendas Internas ANIP / ANI Pharmaceuticals, Inc. - Análise de Perda de Curto Prazo

Nesta seção, analisamos a evitação de perdas de curto prazo de cada venda interna de mercado aberto, não planejada feita em ACRV / Acrivon Therapeutics, Inc.. Um padrão consistente de evitação de perdas pode sugerir que transações futuras de venda possam prever declínios no preço. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.

A tabela a seguir mostra as vendas de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.

Data de Negociação Ticker Insider Ações
Reportadas Preço
Reportado Ações
Ajustadas Preço
Ajustado Base de Custos Dias para
Mín Preço em
Mín Máxima Perda
Evitada ($) Máxima Perda
Evitada (%)

2004-12-03 BPA EDELMAN JOSEPH 30,000 4.3500 30,000 4.3500 130,500 730

2004-12-03 BPA EDELMAN JOSEPH 50,000 4.5500 50,000 4.5500 227,500

2004-12-03 BPA EDELMAN JOSEPH 1,315,000 4.7150 1,315,000 4.7150 6,200,225

2004-12-02 BPA EDELMAN JOSEPH 28,550 4.4680 28,550 4.4680 127,561

2004-12-02 BPA EDELMAN JOSEPH 70,900 4.4680 70,900 4.4680 316,781

2004-12-02 BPA EDELMAN JOSEPH 25,000 4.9000 25,000 4.9000 122,500

2004-12-02 BPA EDELMAN JOSEPH 2,000 4.4680 2,000 4.4680 8,936

2004-12-02 BPA EDELMAN JOSEPH 273,550 4.4680 273,550 4.4680 1,222,221

2004-08-16 BPA EDELMAN JOSEPH 200 5.5000 200 5.5000 1,100

2004-02-03 BPA EDELMAN JOSEPH 87,400 6.4368 87,400 6.4368 562,576

2004-01-23 BPA EDELMAN JOSEPH 35,000 5.6200 35,000 5.6200 196,700

2004-01-22 BPA EDELMAN JOSEPH 100,000 5.6800 100,000 5.6800 568,000

2004-01-21 BPA EDELMAN JOSEPH 100,000 5.6600 100,000 5.6600 566,000

2004-01-21 BPA EDELMAN JOSEPH 15,000 5.8400 15,000 5.8400 87,600

2004-01-21 BPA EDELMAN JOSEPH 5,000 5.6500 5,000 5.6500 28,250

O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.

Compras Internas CRNX / Crinetics Pharmaceuticals, Inc. - Análise de Lucro de Curto Prazo

Nesta seção, analisamos a lucratividade de cada compra interna de mercado aberto, não planejada, feita em ACRV / Acrivon Therapeutics, Inc.. Esta análise ajuda a entender se o interno gera consistentemente retornos anormais, e vale a pena seguir. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.

A tabela a seguir mostra as compras de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.

Data de Negociação Ticker Insider Ações
Reportadas Preço
Reportado Ações
Ajustadas Preço
Ajustado Base de Custos Dias para
Máx Preço em
Máx Lucro
Máx ($) Retorno Máx (%)

2022-04-18 CRNX PERCEPTIVE ADVISORS LLC 157,515 22.2200 157,515 22.2200 3,499,983 2 23.2200 157,515 4.50

2021-10-25 CRNX PERCEPTIVE ADVISORS LLC 1,200,000 19.8000 1,200,000 19.8000 23,760,000

2021-04-08 CRNX PERCEPTIVE ADVISORS LLC 304,136 16.4400 304,136 16.4400 4,999,996

2020-04-17 CRNX PERCEPTIVE ADVISORS LLC 1,071,428 14.0000 1,071,428 14.0000 14,999,992

2018-07-20 CRNX PERCEPTIVE ADVISORS LLC 400,000 17.0000 400,000 17.0000 6,800,000

2018-07-20 CRNX PERCEPTIVE ADVISORS LLC 400,000 17.0000 400,000 17.0000 6,800,000

2018-07-18 CRNX PERCEPTIVE ADVISORS LLC 307,648 21.3000 307,648 21.3000 6,552,902

O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.

Vendas Internas CRNX / Crinetics Pharmaceuticals, Inc. - Análise de Perda de Curto Prazo

Nesta seção, analisamos a evitação de perdas de curto prazo de cada venda interna de mercado aberto, não planejada feita em ACRV / Acrivon Therapeutics, Inc.. Um padrão consistente de evitação de perdas pode sugerir que transações futuras de venda possam prever declínios no preço. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.

A tabela a seguir mostra as vendas de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.

Data de Negociação Ticker Insider Ações
Reportadas Preço
Reportado Ações
Ajustadas Preço
Ajustado Base de Custos Dias para
Mín Preço em
Mín Máxima Perda
Evitada ($) Máxima Perda
Evitada (%)

Não há negociações abertas de mercado não planejadas conhecidas para esta combinação de insider e ativo

O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.

Compras Internas CYPH / Cypherpunk Technologies Inc. - Análise de Lucro de Curto Prazo

Nesta seção, analisamos a lucratividade de cada compra interna de mercado aberto, não planejada, feita em ACRV / Acrivon Therapeutics, Inc.. Esta análise ajuda a entender se o interno gera consistentemente retornos anormais, e vale a pena seguir. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.

A tabela a seguir mostra as compras de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.

Data de Negociação Ticker Insider Ações
Reportadas Preço
Reportado Ações
Ajustadas Preço
Ajustado Base de Custos Dias para
Máx Preço em
Máx Lucro
Máx ($) Retorno Máx (%)

2020-06-22 LPTX PERCEPTIVE ADVISORS LLC 1,750,000 2.0000 175,000 20.0000 3,500,000 240 301 49,175,000 1,405.00

O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.

Vendas Internas CYPH / Cypherpunk Technologies Inc. - Análise de Perda de Curto Prazo

Nesta seção, analisamos a evitação de perdas de curto prazo de cada venda interna de mercado aberto, não planejada feita em ACRV / Acrivon Therapeutics, Inc.. Um padrão consistente de evitação de perdas pode sugerir que transações futuras de venda possam prever declínios no preço. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.

A tabela a seguir mostra as vendas de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.

Data de Negociação Ticker Insider Ações
Reportadas Preço
Reportado Ações
Ajustadas Preço
Ajustado Base de Custos Dias para
Mín Preço em
Mín Máxima Perda
Evitada ($) Máxima Perda
Evitada (%)

Não há negociações abertas de mercado não planejadas conhecidas para esta combinação de insider e ativo

O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.

Compras Internas IMTX / Immatics N.V. - Análise de Lucro de Curto Prazo

Nesta seção, analisamos a lucratividade de cada compra interna de mercado aberto, não planejada, feita em ACRV / Acrivon Therapeutics, Inc.. Esta análise ajuda a entender se o interno gera consistentemente retornos anormais, e vale a pena seguir. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.

A tabela a seguir mostra as compras de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.

Data de Negociação Ticker Insider Ações
Reportadas Preço
Reportado Ações
Ajustadas Preço
Ajustado Base de Custos Dias para
Máx Preço em
Máx Lucro
Máx ($) Retorno Máx (%)

Não há negociações abertas de mercado não planejadas conhecidas para esta combinação de insider e ativo

O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.

Vendas Internas IMTX / Immatics N.V. - Análise de Perda de Curto Prazo

Nesta seção, analisamos a evitação de perdas de curto prazo de cada venda interna de mercado aberto, não planejada feita em ACRV / Acrivon Therapeutics, Inc.. Um padrão consistente de evitação de perdas pode sugerir que transações futuras de venda possam prever declínios no preço. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.

A tabela a seguir mostra as vendas de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.

Data de Negociação Ticker Insider Ações
Reportadas Preço
Reportado Ações
Ajustadas Preço
Ajustado Base de Custos Dias para
Mín Preço em
Mín Máxima Perda
Evitada ($) Máxima Perda
Evitada (%)

Não há negociações abertas de mercado não planejadas conhecidas para esta combinação de insider e ativo

O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.

Compras Internas LONA / LeonaBio, Inc. - Análise de Lucro de Curto Prazo

Nesta seção, analisamos a lucratividade de cada compra interna de mercado aberto, não planejada, feita em ACRV / Acrivon Therapeutics, Inc.. Esta análise ajuda a entender se o interno gera consistentemente retornos anormais, e vale a pena seguir. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.

A tabela a seguir mostra as compras de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.

Data de Negociação Ticker Insider Ações
Reportadas Preço
Reportado Ações
Ajustadas Preço
Ajustado Base de Custos Dias para
Máx Preço em
Máx Lucro
Máx ($) Retorno Máx (%)

2023-12-29 ATHA PERCEPTIVE ADVISORS LLC 163,954 2.3800 16,395 23.8000 390,211 69 4.1500 -322,171 -82.56

2023-12-28 ATHA PERCEPTIVE ADVISORS LLC 409,598 2.4400 40,960 24.4000 999,419

2023-12-27 ATHA PERCEPTIVE ADVISORS LLC 32,134 2.2800 3,213 22.8000 73,266

2022-06-30 ATHA PERCEPTIVE ADVISORS LLC 1,101,362 2.9900 110,136 29.9000 3,293,072

2022-06-29 ATHA PERCEPTIVE ADVISORS LLC 270,000 2.9900 27,000 29.9000 807,300

2021-01-25 ATHA PERCEPTIVE ADVISORS LLC 311,111 22.5000 31,111 225.0000 6,999,998

2020-09-22 ATHA PERCEPTIVE ADVISORS LLC 1,058,824 17.0000 105,882 170.0000 18,000,008

O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.

Vendas Internas LONA / LeonaBio, Inc. - Análise de Perda de Curto Prazo

Nesta seção, analisamos a evitação de perdas de curto prazo de cada venda interna de mercado aberto, não planejada feita em ACRV / Acrivon Therapeutics, Inc.. Um padrão consistente de evitação de perdas pode sugerir que transações futuras de venda possam prever declínios no preço. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.

A tabela a seguir mostra as vendas de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.

Data de Negociação Ticker Insider Ações
Reportadas Preço
Reportado Ações
Ajustadas Preço
Ajustado Base de Custos Dias para
Mín Preço em
Mín Máxima Perda
Evitada ($) Máxima Perda
Evitada (%)

Não há negociações abertas de mercado não planejadas conhecidas para esta combinação de insider e ativo

O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.

Compras Internas LYRA / Lyra Therapeutics, Inc. - Análise de Lucro de Curto Prazo

Nesta seção, analisamos a lucratividade de cada compra interna de mercado aberto, não planejada, feita em ACRV / Acrivon Therapeutics, Inc.. Esta análise ajuda a entender se o interno gera consistentemente retornos anormais, e vale a pena seguir. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.

A tabela a seguir mostra as compras de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.

Data de Negociação Ticker Insider Ações
Reportadas Preço
Reportado Ações
Ajustadas Preço
Ajustado Base de Custos Dias para
Máx Preço em
Máx Lucro
Máx ($) Retorno Máx (%)

2023-05-31 LYRA PERCEPTIVE ADVISORS LLC 3,610,832 2.4925 72,217 124.6250 8,999,999 301 6.5300 -8,528,428 -94.76

2022-04-12 LYRA PERCEPTIVE ADVISORS LLC 5,924,170 4.2200 118,483 211.0000 24,999,997

2020-05-05 LYRA PERCEPTIVE ADVISORS LLC 625,000 16.0000 12,500 800.0000 10,000,000

O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.

Vendas Internas LYRA / Lyra Therapeutics, Inc. - Análise de Perda de Curto Prazo

Nesta seção, analisamos a evitação de perdas de curto prazo de cada venda interna de mercado aberto, não planejada feita em ACRV / Acrivon Therapeutics, Inc.. Um padrão consistente de evitação de perdas pode sugerir que transações futuras de venda possam prever declínios no preço. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.

A tabela a seguir mostra as vendas de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.

Data de Negociação Ticker Insider Ações
Reportadas Preço
Reportado Ações
Ajustadas Preço
Ajustado Base de Custos Dias para
Mín Preço em
Mín Máxima Perda
Evitada ($) Máxima Perda
Evitada (%)

2025-11-13 LYRA PERCEPTIVE ADVISORS LLC 28,597 3.9001 28,597 3.9001 111,531 123 0.4950 -97,375 -87.31

2025-11-13 LYRA PERCEPTIVE ADVISORS LLC 3,213 3.9001 3,213 3.9001 12,531

2025-11-12 LYRA PERCEPTIVE ADVISORS LLC 7,862 4.0594 7,862 4.0594 31,915

2025-11-12 LYRA PERCEPTIVE ADVISORS LLC 883 4.0594 883 4.0594 3,584

2025-11-11 LYRA PERCEPTIVE ADVISORS LLC 4,783 4.3146 4,783 4.3146 20,637

2025-11-11 LYRA PERCEPTIVE ADVISORS LLC 537 4.3146 537 4.3146 2,317

2025-11-10 LYRA PERCEPTIVE ADVISORS LLC 16,633 4.5398 16,633 4.5398 75,510

2025-11-10 LYRA PERCEPTIVE ADVISORS LLC 1,869 4.5398 1,869 4.5398 8,485

2025-11-07 LYRA PERCEPTIVE ADVISORS LLC 17,746 4.7467 17,746 4.7467 84,235

2025-11-07 LYRA PERCEPTIVE ADVISORS LLC 1,993 4.7467 1,993 4.7467 9,460

2025-11-06 LYRA PERCEPTIVE ADVISORS LLC 28,902 5.1799 28,902 5.1799 149,709

2025-11-06 LYRA PERCEPTIVE ADVISORS LLC 3,247 5.1799 3,247 5.1799 16,819

O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.

Compras Internas MGTX / MeiraGTx Holdings plc - Análise de Lucro de Curto Prazo

Nesta seção, analisamos a lucratividade de cada compra interna de mercado aberto, não planejada, feita em ACRV / Acrivon Therapeutics, Inc.. Esta análise ajuda a entender se o interno gera consistentemente retornos anormais, e vale a pena seguir. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.

A tabela a seguir mostra as compras de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.

Data de Negociação Ticker Insider Ações
Reportadas Preço
Reportado Ações
Ajustadas Preço
Ajustado Base de Custos Dias para
Máx Preço em
Máx Lucro
Máx ($) Retorno Máx (%)

2024-08-12 MGTX PERCEPTIVE ADVISORS LLC 1,250,000 4.0000 1,250,000 4.0000 5,000,000 336 8.8900 6,112,500 122.25

2023-05-05 MGTX PERCEPTIVE ADVISORS LLC 4,347,826 5.7500 4,347,826 5.7500 25,000,000

2020-11-23 MGTX PERCEPTIVE ADVISORS LLC 500,000 12.8500 500,000 12.8500 6,425,000

2019-08-12 MGTX PERCEPTIVE ADVISORS LLC 425,531 23.5000 425,531 23.5000 9,999,978

2019-03-01 MGTX PERCEPTIVE LIFE SCIENCES MASTER FUND LTD 1,304,348 13.8000 1,304,348 13.8000 18,000,002

2018-06-12 MGTX PERCEPTIVE ADVISORS LLC 1,333,333 15.0000 1,333,333 15.0000 19,999,995

2018-06-08 MGTX PERCEPTIVE ADVISORS LLC 50,000 15.2200 50,000 15.2200 761,000

O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.

Vendas Internas MGTX / MeiraGTx Holdings plc - Análise de Perda de Curto Prazo

Nesta seção, analisamos a evitação de perdas de curto prazo de cada venda interna de mercado aberto, não planejada feita em ACRV / Acrivon Therapeutics, Inc.. Um padrão consistente de evitação de perdas pode sugerir que transações futuras de venda possam prever declínios no preço. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.

A tabela a seguir mostra as vendas de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.

Data de Negociação Ticker Insider Ações
Reportadas Preço
Reportado Ações
Ajustadas Preço
Ajustado Base de Custos Dias para
Mín Preço em
Mín Máxima Perda
Evitada ($) Máxima Perda
Evitada (%)

Não há negociações abertas de mercado não planejadas conhecidas para esta combinação de insider e ativo

O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.

Compras Internas NAUT / Nautilus Biotechnology, Inc. - Análise de Lucro de Curto Prazo

Nesta seção, analisamos a lucratividade de cada compra interna de mercado aberto, não planejada, feita em ACRV / Acrivon Therapeutics, Inc.. Esta análise ajuda a entender se o interno gera consistentemente retornos anormais, e vale a pena seguir. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.

A tabela a seguir mostra as compras de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.

Data de Negociação Ticker Insider Ações
Reportadas Preço
Reportado Ações
Ajustadas Preço
Ajustado Base de Custos Dias para
Máx Preço em
Máx Lucro
Máx ($) Retorno Máx (%)

2021-12-08 NAUT PERCEPTIVE ADVISORS LLC 200,000 5.3600 200,000 5.3600 1,072,000 15 6.04 136,000 12.69

2021-06-09 NAUT PERCEPTIVE ADVISORS LLC 5,500,000 10.0000 5,500,000 10.0000 55,000,000

2021-06-03 ARYA PERCEPTIVE ADVISORS LLC 330,050 10.0500 330,050 10.0500 3,317,002

2021-05-24 NAUT PERCEPTIVE ADVISORS LLC 7,063 10.0500 7,063 10.0500 70,983

2021-05-20 ARYA PERCEPTIVE ADVISORS LLC 159,925 10.0500 159,925 10.0500 1,607,246

O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.

Vendas Internas NAUT / Nautilus Biotechnology, Inc. - Análise de Perda de Curto Prazo

Nesta seção, analisamos a evitação de perdas de curto prazo de cada venda interna de mercado aberto, não planejada feita em ACRV / Acrivon Therapeutics, Inc.. Um padrão consistente de evitação de perdas pode sugerir que transações futuras de venda possam prever declínios no preço. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.

A tabela a seguir mostra as vendas de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.

Data de Negociação Ticker Insider Ações
Reportadas Preço
Reportado Ações
Ajustadas Preço
Ajustado Base de Custos Dias para
Mín Preço em
Mín Máxima Perda
Evitada ($) Máxima Perda
Evitada (%)

Não há negociações abertas de mercado não planejadas conhecidas para esta combinação de insider e ativo

O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.

Compras Internas OBIO / Orchestra BioMed Holdings, Inc. - Análise de Lucro de Curto Prazo

Nesta seção, analisamos a lucratividade de cada compra interna de mercado aberto, não planejada, feita em ACRV / Acrivon Therapeutics, Inc.. Esta análise ajuda a entender se o interno gera consistentemente retornos anormais, e vale a pena seguir. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.

A tabela a seguir mostra as compras de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.

Data de Negociação Ticker Insider Ações
Reportadas Preço
Reportado Ações
Ajustadas Preço
Ajustado Base de Custos Dias para
Máx Preço em
Máx Lucro
Máx ($) Retorno Máx (%)

2025-08-01 OBIO PERCEPTIVE ADVISORS LLC 700,000 2.7500 700,000 2.7500 1,925,000 116 5.3500 1,820,000 94.55

O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.

Vendas Internas OBIO / Orchestra BioMed Holdings, Inc. - Análise de Perda de Curto Prazo

Nesta seção, analisamos a evitação de perdas de curto prazo de cada venda interna de mercado aberto, não planejada feita em ACRV / Acrivon Therapeutics, Inc.. Um padrão consistente de evitação de perdas pode sugerir que transações futuras de venda possam prever declínios no preço. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.

A tabela a seguir mostra as vendas de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.

Data de Negociação Ticker Insider Ações
Reportadas Preço
Reportado Ações
Ajustadas Preço
Ajustado Base de Custos Dias para
Mín Preço em
Mín Máxima Perda
Evitada ($) Máxima Perda
Evitada (%)

Não há negociações abertas de mercado não planejadas conhecidas para esta combinação de insider e ativo

O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.

Compras Internas SCYX / SCYNEXIS, Inc. - Análise de Lucro de Curto Prazo

Nesta seção, analisamos a lucratividade de cada compra interna de mercado aberto, não planejada, feita em ACRV / Acrivon Therapeutics, Inc.. Esta análise ajuda a entender se o interno gera consistentemente retornos anormais, e vale a pena seguir. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.

A tabela a seguir mostra as compras de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.

Data de Negociação Ticker Insider Ações
Reportadas Preço
Reportado Ações
Ajustadas Preço
Ajustado Base de Custos Dias para
Máx Preço em
Máx Lucro
Máx ($) Retorno Máx (%)

Não há negociações abertas de mercado não planejadas conhecidas para esta combinação de insider e ativo

O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.

Vendas Internas SCYX / SCYNEXIS, Inc. - Análise de Perda de Curto Prazo

Nesta seção, analisamos a evitação de perdas de curto prazo de cada venda interna de mercado aberto, não planejada feita em ACRV / Acrivon Therapeutics, Inc.. Um padrão consistente de evitação de perdas pode sugerir que transações futuras de venda possam prever declínios no preço. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.

A tabela a seguir mostra as vendas de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.

Data de Negociação Ticker Insider Ações
Reportadas Preço
Reportado Ações
Ajustadas Preço
Ajustado Base de Custos Dias para
Mín Preço em
Mín Máxima Perda
Evitada ($) Máxima Perda
Evitada (%)

2021-01-22 SCYX PERCEPTIVE ADVISORS LLC 285,151 8.1600 35,644 65.2800 2,326,832 257 4.94 -2,150,756 -92.43

2021-01-22 SCYX PERCEPTIVE ADVISORS LLC 33,849 8.9500 4,231 71.6000 302,949

2021-01-21 SCYX PERCEPTIVE ADVISORS LLC 95,000 7.3800 11,875 59.0400 701,100

2021-01-20 SCYX PERCEPTIVE ADVISORS LLC 185,000 7.4300 23,125 59.4400 1,374,550

O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.

Compras Internas SLDB / Solid Biosciences Inc. - Análise de Lucro de Curto Prazo

Nesta seção, analisamos a lucratividade de cada compra interna de mercado aberto, não planejada, feita em ACRV / Acrivon Therapeutics, Inc.. Esta análise ajuda a entender se o interno gera consistentemente retornos anormais, e vale a pena seguir. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.

A tabela a seguir mostra as compras de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.

Data de Negociação Ticker Insider Ações
Reportadas Preço
Reportado Ações
Ajustadas Preço
Ajustado Base de Custos Dias para
Máx Preço em
Máx Lucro
Máx ($) Retorno Máx (%)

2025-02-19 SLDB PERCEPTIVE ADVISORS LLC 5,000,000 4.0300 5,000,000 4.0300 20,150,000 160 7.0700 15,200,000 75.43

2024-01-11 SLDB PERCEPTIVE ADVISORS LLC 3,410,713 5.5300 3,410,713 5.5300 18,861,243

2021-03-23 SLDB PERCEPTIVE ADVISORS LLC 2,608,695 5.7500 173,913 86.2500 14,999,996

2019-07-25 SLDB PERCEPTIVE ADVISORS LLC 2,822,581 4.6500 188,172 69.7500 13,125,002

2018-01-30 SLDB PERCEPTIVE ADVISORS LLC 1,000,000 16.0000 66,667 240.0000 16,000,000

2018-01-30 SLDB PERCEPTIVE ADVISORS LLC 20,000 27.3260 1,333 409.8900 546,520

O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.

Vendas Internas SLDB / Solid Biosciences Inc. - Análise de Perda de Curto Prazo

Nesta seção, analisamos a evitação de perdas de curto prazo de cada venda interna de mercado aberto, não planejada feita em ACRV / Acrivon Therapeutics, Inc.. Um padrão consistente de evitação de perdas pode sugerir que transações futuras de venda possam prever declínios no preço. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.

A tabela a seguir mostra as vendas de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.

Data de Negociação Ticker Insider Ações
Reportadas Preço
Reportado Ações
Ajustadas Preço
Ajustado Base de Custos Dias para
Mín Preço em
Mín Máxima Perda
Evitada ($) Máxima Perda
Evitada (%)

Não há negociações abertas de mercado não planejadas conhecidas para esta combinação de insider e ativo

O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.

Compras Internas TLPH / Talphera, Inc. - Análise de Lucro de Curto Prazo

Nesta seção, analisamos a lucratividade de cada compra interna de mercado aberto, não planejada, feita em ACRV / Acrivon Therapeutics, Inc.. Esta análise ajuda a entender se o interno gera consistentemente retornos anormais, e vale a pena seguir. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.

A tabela a seguir mostra as compras de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.

Data de Negociação Ticker Insider Ações
Reportadas Preço
Reportado Ações
Ajustadas Preço
Ajustado Base de Custos Dias para
Máx Preço em
Máx Lucro
Máx ($) Retorno Máx (%)

2013-11-07 ACRX PERCEPTIVE ADVISORS LLC 93,500 6.4981 4,675 129.9620 607,572 118 260.6 610,733 100.52

2013-11-07 ACRX PERCEPTIVE ADVISORS LLC 6,500 6.4981 325 129.9620 42,238

2013-11-06 ACRX PERCEPTIVE ADVISORS LLC 93,500 6.5166 4,675 130.3320 609,302

2013-11-06 ACRX PERCEPTIVE ADVISORS LLC 6,500 6.5166 325 130.3320 42,358

2013-11-04 ACRX PERCEPTIVE ADVISORS LLC 98,175 6.8804 4,909 137.6080 675,483

2013-11-04 ACRX PERCEPTIVE ADVISORS LLC 6,825 6.8804 341 137.6080 46,959

2013-11-04 ACRX PERCEPTIVE ADVISORS LLC 46,750 6.8370 2,338 136.7400 319,630

2013-11-04 ACRX PERCEPTIVE ADVISORS LLC 3,250 6.8370 162 136.7400 22,220

2013-11-01 ACRX PERCEPTIVE ADVISORS LLC 10,442 7.1698 522 143.3960 74,867

2013-11-01 ACRX PERCEPTIVE ADVISORS LLC 150,218 7.1698 7,511 143.3960 1,077,033

2013-10-31 ACRX PERCEPTIVE ADVISORS LLC 192,000 6.6932 9,600 133.8640 1,285,094

2013-10-31 ACRX PERCEPTIVE ADVISORS LLC 8,000 6.6932 400 133.8640 53,546

2013-07-23 ACRX PERCEPTIVE ADVISORS LLC 850,000 11.6500 42,500 233.0000 9,902,500

O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.

Vendas Internas TLPH / Talphera, Inc. - Análise de Perda de Curto Prazo

Nesta seção, analisamos a evitação de perdas de curto prazo de cada venda interna de mercado aberto, não planejada feita em ACRV / Acrivon Therapeutics, Inc.. Um padrão consistente de evitação de perdas pode sugerir que transações futuras de venda possam prever declínios no preço. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.

A tabela a seguir mostra as vendas de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.

Data de Negociação Ticker Insider Ações
Reportadas Preço
Reportado Ações
Ajustadas Preço
Ajustado Base de Custos Dias para
Mín Preço em
Mín Máxima Perda
Evitada ($) Máxima Perda
Evitada (%)

2017-06-19 ACRX PERCEPTIVE ADVISORS LLC 875,000 2.4000 43,750 48.0000 2,100,000 235 34 -612,500 -29.17

2016-09-29 ACRX PERCEPTIVE ADVISORS LLC 97,200 3.8798 4,860 77.5960 377,117

2016-09-28 ACRX PERCEPTIVE ADVISORS LLC 119,300 3.9596 5,965 79.1920 472,380

2016-09-15 ACRX PERCEPTIVE ADVISORS LLC 276,927 3.7277 13,846 74.5540 1,032,301

2016-09-15 ACRX PERCEPTIVE ADVISORS LLC 115,923 3.6275 5,796 72.5500 420,511

2015-11-18 ACRX PERCEPTIVE ADVISORS LLC 42,300 5.3459 2,115 106.9180 226,132

2015-11-17 ACRX PERCEPTIVE ADVISORS LLC 133,900 5.3578 6,695 107.1560 717,409

2015-11-06 ACRX PERCEPTIVE ADVISORS LLC 17,100 4.4658 855 89.3160 76,365

2015-11-05 ACRX PERCEPTIVE ADVISORS LLC 75,000 4.6168 3,750 92.3360 346,260

2015-09-09 ACRX PERCEPTIVE ADVISORS LLC 310,000 4.1767 15,500 83.5340 1,294,777

O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.

Compras Internas VRCA / Verrica Pharmaceuticals Inc. - Análise de Lucro de Curto Prazo

Nesta seção, analisamos a lucratividade de cada compra interna de mercado aberto, não planejada, feita em ACRV / Acrivon Therapeutics, Inc.. Esta análise ajuda a entender se o interno gera consistentemente retornos anormais, e vale a pena seguir. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.

A tabela a seguir mostra as compras de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.

Data de Negociação Ticker Insider Ações
Reportadas Preço
Reportado Ações
Ajustadas Preço
Ajustado Base de Custos Dias para
Máx Preço em
Máx Lucro
Máx ($) Retorno Máx (%)

2023-12-29 VRCA PERCEPTIVE ADVISORS LLC 115,774 7.2400 11,577 72.4000 838,204 136 9.5600 -727,527 -86.80

2023-12-28 VRCA PERCEPTIVE ADVISORS LLC 126,116 7.0800 12,612 70.8000 892,901

2023-12-27 VRCA PERCEPTIVE ADVISORS LLC 79,726 7.2000 7,973 72.0000 574,027

2023-12-26 VRCA PERCEPTIVE ADVISORS LLC 54,652 6.4900 5,465 64.9000 354,691

2023-12-22 VRCA PERCEPTIVE ADVISORS LLC 250,000 6.6700 25,000 66.7000 1,667,500

2023-12-21 VRCA PERCEPTIVE ADVISORS LLC 200,000 6.1700 20,000 61.7000 1,234,000

2023-12-19 VRCA PERCEPTIVE ADVISORS LLC 277,008 5.3600 27,701 53.6000 1,484,763

2023-12-18 VRCA PERCEPTIVE ADVISORS LLC 456,923 5.4100 45,692 54.1000 2,471,953

2023-12-15 VRCA PERCEPTIVE ADVISORS LLC 500,000 5.9700 50,000 59.7000 2,985,000

2022-07-05 VRCA PERCEPTIVE ADVISORS LLC 1,428,571 2.1000 142,857 21.0000 2,999,999

2018-06-19 VRCA PERCEPTIVE ADVISORS LLC 1,000,000 15.0000 100,000 150.0000 15,000,000

O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.

Vendas Internas VRCA / Verrica Pharmaceuticals Inc. - Análise de Perda de Curto Prazo

Nesta seção, analisamos a evitação de perdas de curto prazo de cada venda interna de mercado aberto, não planejada feita em ACRV / Acrivon Therapeutics, Inc.. Um padrão consistente de evitação de perdas pode sugerir que transações futuras de venda possam prever declínios no preço. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.

A tabela a seguir mostra as vendas de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.

Data de Negociação Ticker Insider Ações
Reportadas Preço
Reportado Ações
Ajustadas Preço
Ajustado Base de Custos Dias para
Mín Preço em
Mín Máxima Perda
Evitada ($) Máxima Perda
Evitada (%)

Não há negociações abertas de mercado não planejadas conhecidas para esta combinação de insider e ativo

O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.

Compras Internas VYNE / VYNE Therapeutics Inc. - Análise de Lucro de Curto Prazo

Nesta seção, analisamos a lucratividade de cada compra interna de mercado aberto, não planejada, feita em ACRV / Acrivon Therapeutics, Inc.. Esta análise ajuda a entender se o interno gera consistentemente retornos anormais, e vale a pena seguir. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.

A tabela a seguir mostra as compras de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.

Data de Negociação Ticker Insider Ações
Reportadas Preço
Reportado Ações
Ajustadas Preço
Ajustado Base de Custos Dias para
Máx Preço em
Máx Lucro
Máx ($) Retorno Máx (%)

2021-01-28 VYNE PERCEPTIVE ADVISORS LLC 4,219,409 2.3700 383,583 26.0700 9,999,999 19 182.16 59,873,298 598.73

2020-06-09 MNLO PERCEPTIVE ADVISORS LLC 2,702,702 1.8500 245,700 20.3500 4,999,999

O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.

Vendas Internas VYNE / VYNE Therapeutics Inc. - Análise de Perda de Curto Prazo

Nesta seção, analisamos a evitação de perdas de curto prazo de cada venda interna de mercado aberto, não planejada feita em ACRV / Acrivon Therapeutics, Inc.. Um padrão consistente de evitação de perdas pode sugerir que transações futuras de venda possam prever declínios no preço. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.

A tabela a seguir mostra as vendas de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.

Data de Negociação Ticker Insider Ações
Reportadas Preço
Reportado Ações
Ajustadas Preço
Ajustado Base de Custos Dias para
Mín Preço em
Mín Máxima Perda
Evitada ($) Máxima Perda
Evitada (%)

2021-08-16 VYNE PERCEPTIVE ADVISORS LLC 250,000 1.7400 13,889 31.3200 435,000 360 5.472 -359,005 -82.53

2021-08-13 VYNE PERCEPTIVE ADVISORS LLC 250,000 1.8400 13,889 33.1200 460,000

2021-08-12 VYNE PERCEPTIVE ADVISORS LLC 338,897 2.2300 18,828 40.1400 755,740

2021-05-06 VYNE PERCEPTIVE ADVISORS LLC 1,000,000 3.6700 55,556 66.0600 3,670,000

O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.

Histórico de Negociações Insider

Esta tabela mostra a lista completa de negociações insider realizadas por Perceptive Life Sciences Master Fund Ltd conforme divulgadas para a Comissão de Valores Mobiliários (SEC).

Data do Arquivo Data da Transação Formulário Ticker Ativo Código 10b5-1 Ações Ações Restantes Variação
Percentual Preço
da Ação Valor
da Transação Valor
Restante

2026-04-23 2026-04-17 4 MGTX MeiraGTx Holdings plc
Ordinary Shares A - Award 555,555 10,786,658 5.43 9.00 4,999,995 97,079,922

2026-03-18 3 IMTX Immatics N.V.
Ordinary Shares, nominal value EUR 0.01 per share 10,383,456

2026-01-02 2025-12-31 4 MGTX MeiraGTx Holdings plc
Ordinary Shares D - Sale to Issuer -2,300,000 10,231,103 -18.35 7.91 -18,193,000 80,928,025

2025-12-23 2025-12-23 4 ATHA Athira Pharma, Inc.
Common Stock A - Award 329,756 329,756 6.35 2,093,951 2,093,951

2025-12-23 2025-12-23 4 ATHA Athira Pharma, Inc.
Common Stock A - Award 989,270 1,529,566 183.10 6.35 6,281,864 9,712,744

2025-11-13 2025-11-13 4 LYRA Lyra Therapeutics, Inc.
Common Stock S - Sale -3,213 14,026 -18.64 3.90 -12,531 54,703

2025-11-13 2025-11-13 4 LYRA Lyra Therapeutics, Inc.
Common Stock S - Sale -28,597 124,859 -18.64 3.90 -111,531 486,963

2025-11-13 2025-11-12 4 LYRA Lyra Therapeutics, Inc.
Common Stock S - Sale -883 17,239 -4.87 4.06 -3,584 69,980

2025-11-13 2025-11-12 4 LYRA Lyra Therapeutics, Inc.
Common Stock S - Sale -7,862 153,456 -4.87 4.06 -31,915 622,939

2025-11-13 2025-11-11 4 LYRA Lyra Therapeutics, Inc.
Common Stock S - Sale -537 18,122 -2.88 4.31 -2,317 78,189

2025-11-13 2025-11-11 4 LYRA Lyra Therapeutics, Inc.
Common Stock S - Sale -4,783 161,318 -2.88 4.31 -20,637 696,023

2025-11-10 2025-11-10 4 LYRA Lyra Therapeutics, Inc.
Common Stock S - Sale -1,869 18,659 -9.10 4.54 -8,485 84,708

2025-11-10 2025-11-10 4 LYRA Lyra Therapeutics, Inc.
Common Stock S - Sale -16,633 166,101 -9.10 4.54 -75,510 754,065

2025-11-10 2025-11-07 4 LYRA Lyra Therapeutics, Inc.
Common Stock S - Sale -1,993 20,528 -8.85 4.75 -9,460 97,440

2025-11-10 2025-11-07 4 LYRA Lyra Therapeutics, Inc.
Common Stock S - Sale -17,746 182,734 -8.85 4.75 -84,235 867,383

2025-11-10 2025-11-06 4 LYRA Lyra Therapeutics, Inc.
Common Stock S - Sale -3,247 22,521 -12.60 5.18 -16,819 116,657

2025-11-10 2025-11-06 4 LYRA Lyra Therapeutics, Inc.
Common Stock S - Sale -28,902 200,480 -12.60 5.18 -149,709 1,038,466

2025-08-05 2025-08-01 4 OBIO Orchestra BioMed Holdings, Inc.
Common Stock P - Purchase 700,000 5,292,556 15.24 2.75 1,925,000 14,554,529

2025-05-01 2025-05-01 4 ACRV Acrivon Therapeutics, Inc.
Common Stock S - Sale -298,886 3,104,139 -8.78 1.34 -400,507 4,159,546

2025-05-01 2025-04-30 4 ACRV Acrivon Therapeutics, Inc.
Common Stock S - Sale -437,881 3,403,025 -11.40 1.41 -617,412 4,798,265

2025-04-29 2025-04-29 4 ACRV Acrivon Therapeutics, Inc.
Common Stock S - Sale -250,000 3,840,906 -6.11 1.41 -352,500 5,415,677

2025-04-29 2025-04-28 4 ACRV Acrivon Therapeutics, Inc.
Common Stock S - Sale -215,283 4,090,906 -5.00 1.56 -335,841 6,381,813

2025-04-29 2025-04-25 4 ACRV Acrivon Therapeutics, Inc.
Common Stock S - Sale -1,054,669 4,306,189 -19.67 1.95 -2,056,605 8,397,069

2025-04-07 2025-04-03 4 ALDX Aldeyra Therapeutics, Inc.
Common Stock S - Sale -3,400,000 5,875,851 -36.65 1.42 -4,828,000 8,343,708

2025-02-21 2025-02-19 4 SLDB Solid Biosciences Inc.
Common Stock P - Purchase 5,000,000 11,833,539 73.17 4.03 20,150,000 47,689,162

2025-02-14 2025-01-22 4 ADGM Adagio Medical Holdings, Inc.
Common Stock A - Award 64,167 9,675,684 0.67

2024-08-14 2024-08-12 4 MGTX MeiraGTx Holdings plc
Ordinary Shares P - Purchase 1,250,000 12,531,103 11.08 4.00 5,000,000 50,124,412

2024-08-01 3 ADGM Adagio Medical Holdings, Inc.
Common stock 7,160,397

2024-07-17 3 OBIO Orchestra BioMed Holdings, Inc.
Common Stock, $0.0001 par value per share 4,592,556

2024-04-15 2024-04-11 4 ACRV Acrivon Therapeutics, Inc.
Common Stock P - Purchase 2,353,000 5,360,858 78.23 8.50 20,000,500 45,567,293

2024-04-08 2024-04-05 4 ALDX Aldeyra Therapeutics, Inc.
Common Stock P - Purchase 37,712 9,275,851 0.41 4.74 178,755 43,967,534

2024-04-08 2024-04-04 4 ALDX Aldeyra Therapeutics, Inc.
Common Stock P - Purchase 140,281 9,238,139 1.54 4.67 655,112 43,142,109

2024-04-03 2024-04-03 4 ALDX Aldeyra Therapeutics, Inc.
Common Stock P - Purchase 309,847 9,097,858 3.53 4.09 1,267,274 37,210,239

2024-04-03 2024-04-02 4 ALDX Aldeyra Therapeutics, Inc.
Common Stock P - Purchase 186,051 8,788,011 2.16 3.44 640,015 30,230,758

2024-04-03 2024-04-01 4 ALDX Aldeyra Therapeutics, Inc.
Common Stock P - Purchase 8,374 8,601,960 0.10 3.25 27,216 27,956,370

2024-02-21 2024-02-20 4 CERE Cerevel Therapeutics Holdings, Inc.
Common Stock G - Gift -170,317 0 -100.00

2024-02-20 2024-02-15 4 LIAN LianBio
Ordinary Shares F - Taxes -19,218 17,082 -52.94 4.76 -91,478 81,310

2024-02-20 2024-02-15 4 LIAN LianBio
Ordinary Shares F - Taxes -19,218 17,082 -52.94 4.76 -91,478 81,310

2024-02-20 2024-02-15 4 LIAN LianBio
Ordinary Shares M - Exercise 36,300 36,300 2.52 91,476 91,476

2024-02-20 2024-02-15 4 LIAN LianBio
Ordinary Shares M - Exercise 36,300 36,300 2.52 91,476 91,476

2024-02-05 2024-02-01 4 ATXS Astria Therapeutics, Inc.
Common Stock P - Purchase 2,481,350 4,873,721 103.72 12.09 29,999,522 58,923,287

2024-01-12 2024-01-11 4 SLDB Solid Biosciences Inc.
Common Stock P - Purchase 3,410,713 6,833,539 99.65 5.53 18,861,243 37,789,471

2023-12-29 2023-12-29 4 ATHA Athira Pharma, Inc.
Common Stock P - Purchase 163,954 5,402,964 3.13 2.38 390,211 12,859,054

2023-12-29 2023-12-28 4 ATHA Athira Pharma, Inc.
Common Stock P - Purchase 409,598 5,239,010 8.48 2.44 999,419 12,783,184

2023-12-29 2023-12-27 4 ATHA Athira Pharma, Inc.
Common Stock P - Purchase 32,134 4,829,412 0.67 2.28 73,266 11,011,059

2023-12-29 2023-12-29 4 VRCA Verrica Pharmaceuticals Inc.
Common Stock P - Purchase 115,774 7,099,182 1.66 7.24 838,204 51,398,078

2023-12-29 2023-12-28 4 VRCA Verrica Pharmaceuticals Inc.
Common Stock P - Purchase 126,116 6,983,408 1.84 7.08 892,901 49,442,529

2023-12-29 2023-12-27 4 VRCA Verrica Pharmaceuticals Inc.
Common Stock P - Purchase 79,726 6,857,292 1.18 7.20 574,027 49,372,502

2023-12-26 2023-12-26 4 VRCA Verrica Pharmaceuticals Inc.
Common Stock P - Purchase 54,652 6,777,566 0.81 6.49 354,691 43,986,403

2023-12-26 2023-12-22 4 VRCA Verrica Pharmaceuticals Inc.
Common Stock P - Purchase 250,000 6,722,914 3.86 6.67 1,667,500 44,841,836

2023-12-26 2023-12-21 4 VRCA Verrica Pharmaceuticals Inc.
Common Stock P - Purchase 200,000 6,472,914 3.19 6.17 1,234,000 39,937,879

2023-12-22 2023-12-21 4 ATXS Astria Therapeutics, Inc.
Common Stock P - Purchase 740,000 2,392,371 44.78 6.20 4,588,000 14,832,700

2023-12-19 2023-12-19 4 VRCA Verrica Pharmaceuticals Inc.
Common Stock P - Purchase 277,008 6,272,914 4.62 5.36 1,484,763 33,622,819

2023-12-19 2023-12-18 4 VRCA Verrica Pharmaceuticals Inc.
Common Stock P - Purchase 456,923 5,995,906 8.25 5.41 2,471,953 32,437,851

2023-12-19 2023-12-15 4 VRCA Verrica Pharmaceuticals Inc.
Common Stock P - Purchase 500,000 5,538,983 9.92 5.97 2,985,000 33,067,729

2023-11-14 2023-11-14 4 CRGX CARGO Therapeutics, Inc.
Common Stock P - Purchase 333,333 333,333 15.00 4,999,995 4,999,995

2023-11-14 2023-11-14 4 CRGX CARGO Therapeutics, Inc.
Common Stock P - Purchase 333,333 333,333 15.00 4,999,995 4,999,995

2023-11-14 2023-11-14 4 CRGX CARGO Therapeutics, Inc.
Common Stock C - Conversion 2,579,502 2,579,502

2023-10-18 2023-10-16 4 ATXS Astria Therapeutics, Inc.
Common Stock P - Purchase 460,546 1,611,699 40.01 6.51 2,999,997 10,498,607

2023-10-18 2023-10-16 4 ATXS Astria Therapeutics, Inc.
Common Stock P - Purchase 614,062 1,652,371 59.14 6.51 4,000,000 10,763,545

2023-10-18 2023-10-18 4 ALDX Aldeyra Therapeutics, Inc.
Common Stock S - Sale -306,499 8,593,586 -3.44 1.74 -533,308 14,952,840

2023-10-18 2023-10-16 4 ALDX Aldeyra Therapeutics, Inc.
Common Stock S - Sale -2,450,000 8,900,085 -21.59 1.60 -3,920,000 14,240,136

2023-10-17 2023-10-16 4 CERE Cerevel Therapeutics Holdings, Inc.
Common Stock P - Purchase 876,808 10,794,876 8.84 22.81 19,999,990 246,231,122

2023-09-28 2023-09-28 4 SLNO SOLENO THERAPEUTICS INC
Common Stock P - Purchase 250,000 3,074,542 8.85 20.00 5,000,000 61,490,840

2023-09-28 2023-09-26 4 SLNO SOLENO THERAPEUTICS INC
Common Stock P - Purchase 36,939 2,824,542 1.33 21.00 775,719 59,315,382

2023-09-28 2023-09-26 4 SLNO SOLENO THERAPEUTICS INC
Common Stock P - Purchase 117,996 2,787,603 4.42 20.03 2,363,460 55,835,688

2023-09-28 2023-09-26 4 SLNO SOLENO THERAPEUTICS INC
Common Stock P - Purchase 88,685 2,669,607 3.44 19.11 1,694,770 51,016,190

2023-09-28 2023-09-26 4 SLNO SOLENO THERAPEUTICS INC
Common Stock P - Purchase 52,691 2,580,922 2.08 18.24 961,084 47,076,017

2023-09-28 2023-09-26 4 SLNO SOLENO THERAPEUTICS INC
Common Stock P - Purchase 75,477 2,528,231 3.08 17.28 1,304,243 43,687,832

2023-09-28 2023-09-26 4 SLNO SOLENO THERAPEUTICS INC
Common Stock P - Purchase 27,769 2,452,754 1.15 16.00 444,304 39,244,064

2023-09-28 2023-09-26 4 SLNO SOLENO THERAPEUTICS INC
Common Stock P - Purchase 3,326 2,424,985 0.14 14.61 48,593 35,429,031

2023-09-28 2023-09-26 4 SLNO SOLENO THERAPEUTICS INC
Common Stock P - Purchase 30,511 2,421,659 1.28 13.92 424,713 33,709,493

2023-09-28 2023-09-26 4 SLNO SOLENO THERAPEUTICS INC
Common Stock P - Purchase 42,838 2,391,148 1.82 12.84 550,040 30,702,340

2023-09-28 2023-09-26 4 SLNO SOLENO THERAPEUTICS INC
Common Stock P - Purchase 77,837 2,348,310 3.43 11.81 919,255 27,733,541

2023-09-28 2023-09-26 4 SLNO SOLENO THERAPEUTICS INC
Common Stock P - Purchase 37,911 2,270,473 1.70 11.05 418,917 25,088,727

2023-09-28 2023-09-26 4 SLNO SOLENO THERAPEUTICS INC
Common Stock P - Purchase 5,419 2,232,562 0.24 9.52 51,589 21,253,990

2023-09-28 2023-09-26 4 SLNO SOLENO THERAPEUTICS INC
Common Stock P - Purchase 13,687 2,227,143 0.62 8.30 113,602 18,485,287

2023-09-28 2023-09-26 4 SLNO SOLENO THERAPEUTICS INC
Common Stock P - Purchase 5,703 2,213,456 0.26 7.65 43,628 16,932,938

2023-06-06 2023-06-06 4 SLNO SOLENO THERAPEUTICS INC
Common Stock P - Purchase 200 2,207,753 0.01 5.93 1,186 13,091,975

2023-06-06 2023-06-05 4 SLNO SOLENO THERAPEUTICS INC
Common Stock P - Purchase 78,468 2,207,553 3.69 5.98 469,239 13,201,167

2023-06-06 2023-06-02 4 SLNO SOLENO THERAPEUTICS INC
Common Stock P - Purchase 64,630 2,129,085 3.13 5.93 383,256 12,625,474

2023-06-02 2023-05-31 4 LYRA Lyra Therapeutics, Inc.
Common Stock P - Purchase 3,610,832 11,469,117 45.95 2.49 8,999,999 28,586,774

2023-06-01 2023-06-01 4 SLNO SOLENO THERAPEUTICS INC
Common Stock P - Purchase 7,500 2,064,455 0.36 5.59 41,925 11,540,303

2023-06-01 2023-05-31 4 SLNO SOLENO THERAPEUTICS INC
Common Stock P - Purchase 10,000 2,056,955 0.49 5.28 52,800 10,860,722

2023-06-01 2023-05-30 4 SLNO SOLENO THERAPEUTICS INC
Common Stock P - Purchase 17,500 2,046,955 0.86 5.34 93,450 10,930,740

2023-05-26 2023-05-26 4 SLNO SOLENO THERAPEUTICS INC
210859 P - Purchase 22,500 2,029,455 1.12 5.27 118,575 10,695,228

2023-05-26 2023-05-25 4 SLNO SOLENO THERAPEUTICS INC
210859 P - Purchase 37,500 2,006,955 1.90 5.18 194,250 10,396,027

2023-05-26 2023-05-24 4 SLNO SOLENO THERAPEUTICS INC
210859 P - Purchase 25,000 1,969,455 1.29 5.48 137,000 10,792,613

2023-05-23 2023-05-23 4 SLNO SOLENO THERAPEUTICS INC
Common Stock P - Purchase 27,500 1,944,455 1.43 5.45 149,875 10,597,280

2023-05-23 2023-05-22 4 SLNO SOLENO THERAPEUTICS INC
Common Stock P - Purchase 27,300 1,916,955 1.44 5.12 139,776 9,814,810

2023-05-23 2023-05-19 4 SLNO SOLENO THERAPEUTICS INC
Common Stock P - Purchase 25,200 1,889,655 1.35 4.62 116,424 8,730,206

2023-05-18 3 SLNO SOLENO THERAPEUTICS INC
Common Stock 1,864,455

2023-05-15 2023-05-05 4 MGTX MeiraGTx Holdings plc
Ordinary Shares P - Purchase 4,347,826 11,281,103 62.71 5.75 25,000,000 64,866,342

2023-04-06 2023-04-06 4 VBIV VBI Vaccines Inc/BC
Common Stock S - Sale -4,251,563 41,440,729 -9.30 0.11 -467,672 4,558,480

2023-04-06 2023-04-05 4 VBIV VBI Vaccines Inc/BC
Common Stock S - Sale -1,832,563 45,691,816 -3.86 0.13 -238,233 5,939,936

2023-04-06 2023-04-04 4 VBIV VBI Vaccines Inc/BC
Common Stock S - Sale -4,810,623 47,524,379 -9.19 0.16 -769,700 7,603,901

2022-12-21 2022-12-19 4 ATXS Astria Therapeutics, Inc.
Common Stock P - Purchase 908,265 1,038,309 698.43 11.01 9,999,998 11,431,782

2022-12-06 2022-12-02 4 SLDB Solid Biosciences Inc.
Common Stock A - Award 73,107 73,107

2022-12-06 2022-12-02 4 SLDB Solid Biosciences Inc.
Common Stock A - Award 365,536 3,422,826 11.96

2022-12-06 2022-12-02 4 SLDB Solid Biosciences Inc.
Common Stock A - Award 2,163,120 3,057,290 241.91 7.05 15,249,996 21,553,894

2022-11-18 3 ACRV Acrivon Therapeutics, Inc.
Common Stock 3,007,858

2022-11-02 2022-10-31 4 QTNT Quotient Ltd
Ordinary Shares, nil par value S - Sale -8,255,607 7,945,211 -50.96 0.08 -660,449 635,617

2022-10-13 2022-10-13 4 ALBO ALBIREO PHARMA, INC.
Common Stock S - Sale -406 1,939,723 -0.02 22.79 -9,253 44,206,287

2022-10-13 2022-10-13 4 ALBO ALBIREO PHARMA, INC.
Common Stock S - Sale -178,726 1,940,129 -8.44 22.01 -3,933,759 42,702,239

2022-10-13 2022-10-12 4 ALBO ALBIREO PHARMA, INC.
Common Stock S - Sale -7,240 2,118,855 -0.34 23.23 -168,185 49,221,002

2022-10-13 2022-10-12 4 ALBO ALBIREO PHARMA, INC.
Common Stock S - Sale -89,979 2,126,095 -4.06 22.26 -2,002,933 47,326,875

2022-10-13 2022-10-11 4 ALBO ALBIREO PHARMA, INC.
Common Stock S - Sale -5,415 2,216,074 -0.24 24.78 -134,184 54,914,314

2022-10-13 2022-10-11 4 ALBO ALBIREO PHARMA, INC.
Common Stock S - Sale -38,310 2,221,489 -1.70 24.18 -926,336 53,715,604

2022-10-13 2022-10-11 4 ALBO ALBIREO PHARMA, INC.
Common Stock S - Sale -100,340 2,259,799 -4.25 23.23 -2,330,898 52,495,131

2022-08-22 2022-08-18 4 LIAN LianBio
American Depositary Shares P - Purchase 998,240 3,728,491 36.56 2.40 2,395,776 8,948,378

2022-08-18 2022-08-16 4 CERE Cerevel Therapeutics Holdings, Inc.
Common Stock P - Purchase 1,425,000 6,511,727 28.01 35.00 49,875,000 227,910,445

2022-08-11 2022-08-10 4 ALDX Aldeyra Therapeutics, Inc.
Common Stock P - Purchase 15,000 11,350,085 0.13 7.85 117,750 89,098,167

2022-08-11 2022-08-09 4 ALDX Aldeyra Therapeutics, Inc.
Common Stock P - Purchase 100,000 11,335,085 0.89 7.50 750,000 85,013,138

2022-08-10 2022-08-08 4 ALDX Aldeyra Therapeutics, Inc.
Common Stock P - Purchase 97,000 11,235,085 0.87 7.24 702,280 81,342,015

2022-08-09 2022-08-05 4 ALDX Aldeyra Therapeutics, Inc.
Common Stock P - Purchase 141,000 11,138,085 1.28 6.95 979,950 77,409,691

2022-08-08 2022-08-04 4 ALDX Aldeyra Therapeutics, Inc.
Common Stock P - Purchase 95,100 10,997,085 0.87 6.17 586,767 67,852,014

2022-08-05 2022-08-03 4 ALDX Aldeyra Therapeutics, Inc.
Common Stock P - Purchase 100,000 10,901,985 0.93 5.84 584,000 63,667,592

2022-08-04 2022-08-02 4 ALDX Aldeyra Therapeutics, Inc.
Common Stock P - Purchase 412,406 10,801,985 3.97 5.59 2,305,350 60,383,096

2022-08-03 2022-08-01 4 ALDX Aldeyra Therapeutics, Inc.
Common Stock P - Purchase 144,185 10,389,579 1.41 5.05 728,134 52,467,374

2022-08-02 2022-07-29 4 ALDX Aldeyra Therapeutics, Inc.
Common Stock P - Purchase 222,123 10,245,394 2.22 5.03 1,117,279 51,534,332

2022-08-01 2022-07-28 4 ALDX Aldeyra Therapeutics, Inc.
Common Stock P - Purchase 119,392 10,023,271 1.21 5.00 596,960 50,116,355

2022-07-05 2022-07-05 4 VRCA Verrica Pharmaceuticals Inc.
Common Stock P - Purchase 1,428,571 5,038,983 39.57 2.10 2,999,999 10,581,864

2022-07-01 2022-06-30 4 ATHA Athira Pharma, Inc.
Common Stock P - Purchase 1,101,362 4,797,278 29.80 2.99 3,293,072 14,343,861

2022-07-01 2022-06-29 4 ATHA Athira Pharma, Inc.
Common Stock P - Purchase 270,000 3,695,916 7.88 2.99 807,300 11,050,789

2022-05-27 2022-05-26 4 LIAN LianBio
American Depositary Shares P - Purchase 69,000 2,730,251 2.59 3.13 215,970 8,545,686

2022-05-27 2022-05-20 4 ATHA Athira Pharma, Inc.
Stock Option (Right to Buy) A - Award 13,871 13,871

2022-05-25 2022-05-25 4 LIAN LianBio
American Depositary Shares P - Purchase 120,000 2,661,251 4.72 2.63 315,600 6,999,090

2022-05-25 2022-05-24 4 LIAN LianBio
American Depositary Shares P - Purchase 42,551 2,541,251 1.70 2.47 105,101 6,276,890

2022-05-25 2022-05-23 4 LIAN LianBio
American Depositary Shares P - Purchase 8,700 2,498,700 0.35 2.49 21,663 6,221,763

2022-04-18 2022-04-18 4 CRNX Crinetics Pharmaceuticals, Inc.
Common Stock P - Purchase 157,515 5,321,032 3.05 22.22 3,499,983 118,233,331

2022-04-14 2022-04-12 4 LYRA Lyra Therapeutics, Inc.
Common Stock P - Purchase 5,924,170 7,858,285 306.30 4.22 24,999,997 33,161,963

2021-12-10 2021-12-08 4 NAUT Nautilus Biotechnology, Inc.
Common Stock P - Purchase 200,000 9,111,151 2.24 5.36 1,072,000 48,835,769

2021-12-03 2021-12-01 4 VBIV VBI Vaccines Inc/BC
Common Stock S - Sale -2,707,463 52,334,993 -4.92 3.31 -8,961,703 173,228,827

2021-11-05 2021-11-03 4 LIAN LianBio
Ordinary Shares P - Purchase 20,000 27,858,895 0.07 13.51 270,200 376,373,671

2021-11-05 2021-11-03 4 LIAN LianBio
Ordinary Shares P - Purchase 2,250,000 27,838,895 8.79 16.00 36,000,000 445,422,320

2021-11-03 2021-11-03 4 LIAN LianBio
Series A Preferred Shares C - Conversion -423,579 0 -100.00

2021-11-03 2021-11-03 4 LIAN LianBio
Series Seed Preferred Shares C - Conversion -500,000 0 -100.00

2021-11-03 2021-11-03 4 LIAN LianBio
Series Seed Preferred Shares C - Conversion -2,500,000 0 -100.00

2021-11-03 2021-11-03 4 LIAN LianBio
Series Seed Preferred Shares C - Conversion -2,500,000 0 -100.00

2021-11-03 2021-11-03 4 LIAN LianBio
Series A Preferred Shares C - Conversion -635,369 0 -100.00

2021-11-03 2021-11-03 4 LIAN LianBio
Ordinary Shares C - Conversion 2,477,005 2,477,005

2021-11-03 2021-11-03 4 LIAN LianBio
Ordinary Shares C - Conversion 2,923,000 4,330,675 207.65

2021-11-03 2021-11-03 4 LIAN LianBio
Ordinary Shares C - Conversion 14,619,500 21,653,385 207.84

2021-11-03 2021-11-03 4 LIAN LianBio
Ordinary Shares C - Conversion 14,619,500 21,653,385 207.84

2021-11-03 2021-11-03 4 LIAN LianBio
Ordinary Shares C - Conversion 3,715,510 10,969,395 51.22

2021-11-03 2021-11-02 4 LIAN LianBio
Ordinary Shares P - Purchase 100,000 7,253,885 1.40 13.50 1,350,000 97,927,448

2021-11-03 2021-11-01 4 LIAN LianBio
Ordinary Shares P - Purchase 120,000 7,153,885 1.71 15.50 1,860,000 110,885,218

2021-10-29 3 LIAN LianBio
Ordinary Shares 7,033,885

2021-10-29 3 LIAN LianBio
Ordinary Shares 7,033,885

2021-10-29 3 LIAN LianBio
Ordinary Shares 1,406,775

2021-10-25 2021-10-25 4 CRNX Crinetics Pharmaceuticals, Inc.
Common Stock P - Purchase 1,200,000 5,163,517 30.28 19.80 23,760,000 102,237,637

2021-10-15 2021-10-13 4 AGRX AGILE THERAPEUTICS INC
Warrants (right to buy) P - Purchase 2,687,280 2,687,280

2021-10-15 2021-10-13 4 AGRX AGILE THERAPEUTICS INC
Common Stock P - Purchase 5,734,560 21,654,485 36.02 0.85 4,874,376 18,406,312

2021-10-14 2021-10-12 4 ISO IsoPlexis Corp
Series D Redeemable Convertible Preferred Stock C - Conversion -24,629 0 -100.00

2021-10-14 2021-10-12 4 ISO IsoPlexis Corp
Series D Redeemable Convertible Preferred Stock C - Conversion -40,373 0 -100.00

2021-10-14 2021-10-12 4 ISO IsoPlexis Corp
Series D Redeemable Convertible Preferred Stock C - Conversion -325,014 0 -100.00

2021-10-14 2021-10-12 4 ISO IsoPlexis Corp
Common Stock P - Purchase 850,000 3,554,587 31.43 15.00 12,750,000 53,318,805

2021-10-14 2021-10-12 4 ISO IsoPlexis Corp
Common Stock C - Conversion 204,949 204,949

2021-10-14 2021-10-12 4 ISO IsoPlexis Corp
Common Stock C - Conversion 335,962 335,962

2021-10-14 2021-10-12 4 ISO IsoPlexis Corp
Common Stock C - Conversion 2,704,587 2,704,587

2021-10-13 2021-10-12 4 RAIN Rain Therapeutics Inc.
Common Stock S - Sale -7,306 2,487,019 -0.29 13.40 -97,900 33,326,055

2021-10-13 2021-10-11 4 RAIN Rain Therapeutics Inc.
Common Stock S - Sale -9,351 2,494,325 -0.37 13.15 -122,966 32,800,374

2021-10-13 2021-10-11 4 RAIN Rain Therapeutics Inc.
Common Stock S - Sale -12,475 2,503,676 -0.50 12.03 -150,074 30,119,222

2021-10-13 2021-10-08 4 RAIN Rain Therapeutics Inc.
Common Stock S - Sale -2,462 2,516,151 -0.10 13.66 -33,631 34,370,623

2021-10-13 2021-10-08 4 RAIN Rain Therapeutics Inc.
Common Stock S - Sale -5,038 2,518,613 -0.20 12.90 -64,990 32,490,108

2021-10-13 2021-10-07 4 RAIN Rain Therapeutics Inc.
Common Stock S - Sale -286 2,523,651 -0.01 15.05 -4,304 37,980,948

2021-10-13 2021-10-07 4 RAIN Rain Therapeutics Inc.
Common Stock S - Sale -13,082 2,523,937 -0.52 14.80 -193,614 37,354,268

2021-09-30 2021-09-30 4 ADMA ADMA BIOLOGICS, INC.
Common Stock S - Sale -137,495 13,262,375 -1.03 1.12 -153,994 14,853,860

2021-09-30 2021-09-29 4 ADMA ADMA BIOLOGICS, INC.
Common Stock S - Sale -82,505 13,399,870 -0.61 1.16 -95,706 15,543,849

2021-09-30 2021-09-28 4 ADMA ADMA BIOLOGICS, INC.
Common Stock S - Sale -40,603 13,482,375 -0.30 1.22 -49,536 16,448,498

2021-09-29 2021-09-27 4 ADMA ADMA BIOLOGICS, INC.
Common Stock S - Sale -250,000 13,522,978 -1.82 1.23 -307,500 16,633,263

2021-09-29 2021-09-24 4 ADMA ADMA BIOLOGICS, INC.
Common Stock S - Sale -250,000 13,772,978 -1.78 1.26 -315,000 17,353,952

2021-09-28 2021-09-24 4 LPTX LEAP THERAPEUTICS, INC.
Warrants (right to buy) P - Purchase 3,508,771 3,508,771 2.85 9,996,489 9,996,489

2021-09-28 2021-09-23 4 ADMA ADMA BIOLOGICS, INC.
Common Stock S - Sale -780,000 14,022,978 -5.27 1.27 -990,600 17,809,182

2021-08-31 2021-08-26 4 CERE Cerevel Therapeutics Holdings, Inc.
Common Stock P - Purchase 68,047 5,086,727 1.36 30.23 2,057,061 153,771,757

2021-08-31 2021-08-27 4 LABP Landos Biopharma, Inc.
Stock Option (Right to Buy) A - Award 25,291 25,291

2021-08-25 2021-08-25 4 CERE Cerevel Therapeutics Holdings, Inc.
Common Stock P - Purchase 61,387 5,018,680 1.24 28.57 1,753,827 143,383,688

2021-08-25 2021-08-24 4 CERE Cerevel Therapeutics Holdings, Inc.
Common Stock P - Purchase 69,761 4,957,293 1.43 27.73 1,934,473 137,465,735

2021-08-25 2021-08-23 4 CERE Cerevel Therapeutics Holdings, Inc.
Common Stock P - Purchase 44,437 4,887,532 0.92 25.78 1,145,586 126,000,575

2021-08-19 2021-08-19 4 ADMA ADMA BIOLOGICS, INC.
Common Stock S - Sale -350,352 14,802,978 -2.31 1.24 -434,436 18,355,693

2021-08-19 2021-08-18 4 ADMA ADMA BIOLOGICS, INC.
Common Stock S - Sale -552,380 15,153,330 -3.52 1.29 -712,570 19,547,796

2021-08-19 2021-08-17 4 ADMA ADMA BIOLOGICS, INC.
Common Stock S - Sale -879,092 15,705,710 -5.30 1.35 -1,186,774 21,202,708

2021-08-18 2021-08-16 4 VYNE VYNE Therapeutics Inc.
Common Stock S - Sale -250,000 4,935,057 -4.82 1.74 -435,000 8,586,999

2021-08-17 2021-08-13 4 VYNE VYNE Therapeutics Inc.
Common Stock S - Sale -250,000 5,185,057 -4.60 1.84 -460,000 9,540,505

2021-08-16 2021-08-12 4 VYNE VYNE Therapeutics Inc.
Common Stock S - Sale -338,897 5,435,057 -5.87 2.23 -755,740 12,120,177

2021-07-09 2021-07-07 4 CERE Cerevel Therapeutics Holdings, Inc.
Common Stock P - Purchase 200,000 4,843,095 4.31 25.00 5,000,000 121,077,375

2021-06-30 2021-06-29 4 VBIV VBI Vaccines Inc/BC
Common Stock S - Sale -145,548 0 -100.00 3.80 -553,082

2021-06-30 2021-06-29 4 VBIV VBI Vaccines Inc/BC
Common Stock S - Sale -500,709 0 -100.00 3.80 -1,902,694

2021-06-14 2021-06-10 4 MGTX MeiraGTx Holdings plc
Stock Option (right to buy) A - Award 15,000 15,000

2021-06-14 2021-06-10 4 MGTX MeiraGTx Holdings plc
Restricted Share Units A - Award 15,000 15,000

2021-06-11 2021-06-09 4 NAUT Nautilus Biotechnology, Inc.
Common Stock J - Other 2,914,113 8,911,151 48.59

2021-06-11 2021-06-09 4 NAUT Nautilus Biotechnology, Inc.
Common Stock P - Purchase 5,500,000 5,997,038 1,106.56 10.00 55,000,000 59,970,380

2021-06-11 2021-05-24 4 NAUT Nautilus Biotechnology, Inc.
Common Stock P - Purchase 7,063 497,038 1.44 10.05 70,983 4,995,232

2021-06-11 2021-06-09 4 VBIV VBI Vaccines Inc/BC
Warrant (right to buy) X - Other -465,936 0 -100.00

2021-06-11 2021-06-09 4 VBIV VBI Vaccines Inc/BC
Warrant (right to buy) X - Other -1,602,888 0 -100.00

2021-06-11 2021-06-09 4 VBIV VBI Vaccines Inc/BC
Common Stock S - Sale -320,388 145,548 -68.76 4.00 -1,281,552 582,192

2021-06-11 2021-06-09 4 VBIV VBI Vaccines Inc/BC
Common Stock S - Sale -1,102,179 500,709 -68.76 4.00 -4,408,716 2,002,836

2021-06-11 2021-06-09 4 VBIV VBI Vaccines Inc/BC
Common Stock X - Other 465,936 465,936 2.75 1,281,324 1,281,324

2021-06-11 2021-06-09 4 VBIV VBI Vaccines Inc/BC
Common Stock X - Other 1,602,888 1,602,888 2.75 4,407,942 4,407,942

2021-06-03 2021-06-03 4 ARYA ARYA Sciences Acquisition Corp III
Class A Ordinary Shares P - Purchase 330,050 489,975 206.38 10.05 3,317,002 4,924,249

2021-06-01 2021-05-28 4 ATHA Athira Pharma, Inc.
Stock Option (Right to Buy) A - Award 13,871 13,871

2021-05-24 2021-05-20 4 ARYA ARYA Sciences Acquisition Corp III
Class A Ordinary Shares P - Purchase 159,925 159,925 10.05 1,607,246 1,607,246

2021-05-07 2021-05-06 4 VYNE VYNE Therapeutics Inc.
Common Stock S - Sale -1,000,000 5,773,954 -14.76 3.67 -3,670,000 21,190,411

2021-05-04 2021-05-03 4 ALDX Aldeyra Therapeutics, Inc.
Common Stock P - Purchase 1,200,000 9,903,879 13.79 12.50 15,000,000 123,798,488

2021-04-27 2021-04-27 4 RAIN Rain Therapeutics Inc.
Series B Convertible Preferred Stock C - Conversion -1,195,792 0 -100.00

2021-04-27 2021-04-27 4 RAIN Rain Therapeutics Inc.
Series A Convertible Preferred Stock C - Conversion -949,992 0 -100.00

2021-04-27 2021-04-27 4 RAIN Rain Therapeutics Inc.
Common Stock P - Purchase 550,000 2,537,019 27.68 17.00 9,350,000 43,129,323

2021-04-27 2021-04-27 4 RAIN Rain Therapeutics Inc.
Common Stock C - Conversion 1,107,316 1,987,019 125.87

2021-04-27 2021-04-27 4 RAIN Rain Therapeutics Inc.
Common Stock C - Conversion 879,703 879,703

2021-04-09 2021-04-08 4 CRNX Crinetics Pharmaceuticals, Inc.
Common Stock P - Purchase 304,136 3,963,517 8.31 16.44 4,999,996 65,160,219

2021-04-06 2021-02-26 4 AGRX AGILE THERAPEUTICS INC
Warrants (right to buy) J - Other 450,000 450,000

2021-03-23 2021-03-23 4 SLDB Solid Biosciences Inc.
Common Stock P - Purchase 2,608,695 13,412,552 24.15 5.75 14,999,996 77,122,174

2021-03-16 2021-03-16 4 RXDX Prometheus Biosciences, Inc.
Series D-2 Convertible Preferred Stock C - Conversion -14,462,623 0 -100.00

2021-03-16 2021-03-16 4 RXDX Prometheus Biosciences, Inc.
Series D-1 Convertible Preferred Stock C - Conversion -10,177,703 0 -100.00

2021-03-16 2021-03-16 4 RXDX Prometheus Biosciences, Inc.
Common Stock P - Purchase 850,000 3,314,032 34.50 19.00 16,150,000 62,966,608

2021-03-16 2021-03-16 4 RXDX Prometheus Biosciences, Inc.
Common Stock C - Conversion 1,446,262 2,464,032 142.10

2021-03-16 2021-03-16 4 RXDX Prometheus Biosciences, Inc.
Common Stock C - Conversion 1,017,770 1,017,770

2021-02-09 2021-02-09 4 LABP Landos Biopharma, Inc.
Common Stock P - Purchase 34,951 7,299,751 0.48 14.60 510,285 106,576,365

2021-02-09 2021-02-09 4 LABP Landos Biopharma, Inc.
Common Stock P - Purchase 64,730 7,264,800 0.90 13.80 893,274 100,254,240

2021-02-09 2021-02-08 4 LABP Landos Biopharma, Inc.
Common Stock P - Purchase 1,771 7,200,070 0.02 13.10 23,200 94,320,917

2021-02-09 2021-02-08 4 LABP Landos Biopharma, Inc.
Common Stock P - Purchase 86,671 7,198,299 1.22 12.53 1,085,988 90,194,686

2021-02-09 2021-02-08 4 LABP Landos Biopharma, Inc.
Common Stock P - Purchase 34,611 7,111,628 0.49 11.38 393,873 80,930,327

2021-02-09 2021-02-05 4 LABP Landos Biopharma, Inc.
Common Stock P - Purchase 27,453 7,077,017 0.39 11.14 305,826 78,837,969

2021-02-08 2021-02-08 4 LABP Landos Biopharma, Inc.
Series B Preferred Stock C - Conversion -1,770,600 0 -100.00

2021-02-08 2021-02-08 4 LABP Landos Biopharma, Inc.
Series B Preferred Stock C - Conversion -2,857,795 0 -100.00

2021-02-08 2021-02-08 4 LABP Landos Biopharma, Inc.
Series B Preferred Stock C - Conversion -2,857,795 0 -100.00

2021-02-08 2021-02-08 4 LABP Landos Biopharma, Inc.
Series A Preferred Stock C - Conversion -2,941,769 0 -100.00

2021-02-08 2021-02-08 4 LABP Landos Biopharma, Inc.
Series A Preferred Stock C - Conversion -2,941,769 0 -100.00

2021-02-08 2021-02-08 4 LABP Landos Biopharma, Inc.
Common Stock P - Purchase 1,250,000 7,049,564 21.55 16.00 20,000,000 112,793,024

2021-02-08 2021-02-08 4 LABP Landos Biopharma, Inc.
Common Stock C - Conversion 1,770,600 1,770,600

2021-02-08 2021-02-08 4 LABP Landos Biopharma, Inc.
Common Stock C - Conversion 2,857,795 5,799,564 97.15

2021-02-08 2021-02-08 4 LABP Landos Biopharma, Inc.
Common Stock C - Conversion 2,857,795 5,799,564 97.15

2021-02-08 2021-02-08 4 LABP Landos Biopharma, Inc.
Common Stock C - Conversion 2,941,769 2,941,769

2021-02-08 2021-02-08 4 LABP Landos Biopharma, Inc.
Common Stock C - Conversion 2,941,769 2,941,769

2021-02-03 3 LABP Landos Biopharma, Inc.
Common Stock 3,090,924

2021-02-03 3 CATB CATABASIS PHARMACEUTICALS INC
Common Stock 543,373

2021-02-03 3 CATB CATABASIS PHARMACEUTICALS INC
Common Stock 1,933,551

2021-02-03 2021-02-01 4 CATB CATABASIS PHARMACEUTICALS INC
Series X Convertible Preferred Stock A - Award 1,617 30,920 5.52 3,009.53 4,866,410 93,054,668

2021-02-03 2021-02-01 4 CATB CATABASIS PHARMACEUTICALS INC
Series X Convertible Preferred Stock A - Award 4,851 4,851 3,009.53 14,599,230 14,599,230

2021-02-01 2021-01-28 4 VYNE VYNE Therapeutics Inc.
Common Stock P - Purchase 4,219,409 27,095,819 18.44 2.37 9,999,999 64,217,091

2021-01-27 2021-01-25 4 ATHA Athira Pharma, Inc.
Common Stock P - Purchase 311,111 3,425,916 9.99 22.50 6,999,998 77,083,110

2021-01-26 3 SCYX SCYNEXIS INC
Common Stock 2,400,000

2021-01-26 2021-01-22 4 SCYX SCYNEXIS INC
Common Stock S - Sale -33,849 1,800,000 -1.85 8.95 -302,949 16,110,000

2021-01-26 2021-01-22 4 SCYX SCYNEXIS INC
Common Stock S - Sale -285,151 1,833,849 -13.46 8.16 -2,326,832 14,964,208

2021-01-26 2021-01-21 4 SCYX SCYNEXIS INC
Common Stock S - Sale -95,000 2,120,000 -4.29 7.38 -701,100 15,645,600

2021-01-26 2021-01-20 4 SCYX SCYNEXIS INC
Common Stock S - Sale -185,000 2,215,000 -7.71 7.43 -1,374,550 16,457,450

2021-01-22 2021-01-22 4 MOTS Motus GI Holdings, Inc.
Common Stock S - Sale -550,000 2,660,542 -17.13 1.48 -814,000 3,937,602

2021-01-22 2021-01-21 4 MOTS Motus GI Holdings, Inc.
Common Stock S - Sale -674,352 3,210,542 -17.36 1.68 -1,132,911 5,393,711

2021-01-22 2021-01-20 4 MOTS Motus GI Holdings, Inc.
Common Stock S - Sale -325,648 3,884,894 -7.73 1.80 -586,166 6,992,809

2021-01-21 2021-01-19 4 ALDX Aldeyra Therapeutics, Inc.
Common Stock P - Purchase 1,368,421 8,703,879 18.65 9.50 13,000,000 82,686,850

2021-01-11 2021-01-08 4 ALDX Aldeyra Therapeutics, Inc.
Common Stock P - Purchase 50,000 7,335,458 0.69 7.60 380,000 55,749,481

2021-01-11 2021-01-08 4 ALDX Aldeyra Therapeutics, Inc.
Common Stock P - Purchase 152,668 7,285,458 2.14 10.21 1,558,740 74,384,526

2021-01-11 2021-01-08 4 ALDX Aldeyra Therapeutics, Inc.
Common Stock P - Purchase 347,332 7,132,790 5.12 9.21 3,198,928 65,692,996

2021-01-11 2021-01-07 4 ALDX Aldeyra Therapeutics, Inc.
Common Stock P - Purchase 500,000 6,785,458 7.95 8.13 4,065,000 55,165,774

2020-12-15 2020-12-10 4 SLDB Solid Biosciences Inc.
Common Stock A - Award 4,054,054 10,803,857 60.06 3.70 15,000,000 39,974,271

2020-11-24 2020-11-23 4 MGTX MeiraGTx Holdings plc
Ordinary Shares P - Purchase 500,000 6,933,277 7.77 12.85 6,425,000 89,092,609

2020-10-29 2020-10-27 4 CERE Cerevel Therapeutics Holdings, Inc.
Common stock P - Purchase 3,000,000 3,157,295 1,907.24 10.00 30,000,000 31,572,950

2020-10-22 2020-10-21 4 ARYB ARYA Sciences Acquisition Corp II
Class A ordinary shares P - Purchase 43,195 157,295 37.86 10.09 435,838 1,587,107

2020-10-22 2020-10-20 4 ARYB ARYA Sciences Acquisition Corp II
Class A ordinary shares P - Purchase 114,100 114,100 10.00 1,141,000 1,141,000

2020-09-22 2020-09-22 4 ATHA Athira Pharma, Inc.
Series B Preferred Stock C - Conversion -1,644,785 0 -100.00

2020-09-22 2020-09-22 4 ATHA Athira Pharma, Inc.
Common Stock P - Purchase 1,058,824 3,114,805 51.50 17.00 18,000,008 52,951,685

2020-09-22 2020-09-22 4 ATHA Athira Pharma, Inc.
Common Stock C - Conversion 1,644,785 2,055,981 400.00

2020-09-17 3 ATHA Athira Pharma, Inc.
Common Stock 411,196

2020-09-16 2020-09-15 4 QTNT Quotient Ltd
Ordinary Shares P - Purchase 2,911,764 16,200,818 21.91 4.25 12,374,997 68,853,476

2020-09-15 2020-09-14 4 ALBO ALBIREO PHARMA, INC.
Common Stock P - Purchase 400,000 2,360,139 20.41 40.00 16,000,000 94,405,560

2020-09-14 2020-09-14 4 ATNX Athenex, Inc.
Common Stock P - Purchase 1,800,000 13,532,467 15.34 11.00 19,800,000 148,857,137

2020-09-14 2020-09-10 4 ATNX Athenex, Inc.
Common Stock P - Purchase 200,000 11,732,467 1.73 11.24 2,248,000 131,872,929

2020-07-13 2020-07-09 4 ALDX Aldeyra Therapeutics, Inc.
Common Stock P - Purchase 3,200,000 6,285,458 103.71 4.25 13,600,000 26,713,196

2020-06-24 2020-06-22 4 LPTX LEAP THERAPEUTICS, INC.
Common Stock P - Purchase 1,750,000 8,476,496 26.02 2.00 3,500,000 16,952,992

2020-06-11 3 MNLO Menlo Therapeutics Inc.
Common Stock 40,347,416

2020-06-11 3 MNLO Menlo Therapeutics Inc.
Common Stock 40,347,416

2020-06-11 3 MNLO Menlo Therapeutics Inc.
Common Stock 40,347,416

2020-06-11 3 MNLO Menlo Therapeutics Inc.
Common Stock 40,347,416

2020-06-11 3 MNLO Menlo Therapeutics Inc.
Common Stock 40,347,416

2020-06-11 2020-06-09 4 MNLO Menlo Therapeutics Inc.
Common Stock P - Purchase 2,702,702 22,876,410 13.40 1.85 4,999,999 42,321,358

2020-05-29 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Common Stock P - Purchase 625,000 1,934,115 47.74 16.00 10,000,000 30,945,840

2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Common Warrants X - Other -339,604 0 -100.00

2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Common Warrants X - Other -141,221 0 -100.00

2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Series C Convertible Preferred Stock C - Conversion -16,232,511 0 -100.00

2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Series C Convertible Preferred Stock C - Conversion -39,035,325 0 -100.00

2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Series B Convertible Preferred Stock C - Conversion -26,666,666 0 -100.00

2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Common Stock F - Taxes -183,174 1,288,446 -12.45 16.00 -2,930,784 20,615,136

2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Common Stock X - Other 339,604 1,471,620 30.00 8.63 2,930,783 12,700,081

2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Common Stock F - Taxes -76,172 1,309,115 -5.50 16.00 -1,218,752 20,945,840

2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Common Stock X - Other 141,221 1,385,287 11.35 8.63 1,218,737 11,955,027

2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Common Stock C - Conversion 470,739 1,244,066 60.87

2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Common Stock C - Conversion 1,132,016 1,132,016

2020-05-06 2020-05-05 4 LYRA Lyra Therapeutics, Inc.
Common Stock C - Conversion 773,327 773,327

2020-04-28 2020-04-24 4 VBIV VBI Vaccines Inc/BC
Common Stock P - Purchase 9,090,909 55,042,456 19.78 1.10 10,000,000 60,546,702

2020-04-20 3 LPTX LEAP THERAPEUTICS, INC.
Common Stock 13,452,992

2020-04-20 3 LPTX LEAP THERAPEUTICS, INC.
Common Stock 13,452,992

2020-04-20 3 LPTX LEAP THERAPEUTICS, INC.
Common Stock 13,452,992

2020-04-20 3 LPTX LEAP THERAPEUTICS, INC.
Common Stock 13,452,992

2020-04-20 3 LPTX LEAP THERAPEUTICS, INC.
Common Stock 13,452,992

2020-04-20 2020-04-17 4 CRNX Crinetics Pharmaceuticals, Inc.
Common Stock P - Purchase 1,071,428 3,659,381 41.40 14.00 14,999,992 51,231,334

2020-03-23 2020-03-19 4 ADMA ADMA BIOLOGICS, INC.
Common Stock P - Purchase 500,000 16,584,802 3.11 2.10 1,050,000 34,828,084

2020-03-17 2020-03-13 4 AGRX AGILE THERAPEUTICS INC
Common Stock P - Purchase 1,000,000 15,919,925 6.70 1.75 1,750,000 27,859,869

2020-02-25 2020-02-25 4 AGRX AGILE THERAPEUTICS INC
Common Stock P - Purchase 3,000,000 14,919,925 25.17 3.00 9,000,000 44,759,775

2020-02-25 2020-02-10 4 AGRX AGILE THERAPEUTICS INC
Warrants (right to buy) J - Other 700,000 700,000

2020-02-25 2020-02-10 4 AGRX AGILE THERAPEUTICS INC
Warrants (right to buy) J - Other 700,000 700,000

2020-02-11 2020-02-11 4 ADMA ADMA BIOLOGICS, INC.
Common Stock P - Purchase 4,563,700 16,084,802 39.61 3.50 15,972,950 56,296,807

2020-02-04 2020-02-03 4 ALBO ALBIREO PHARMA, INC.
Common Stock P - Purchase 255,809 1,960,139 15.01 21.00 5,371,989 41,162,919

2019-12-27 2019-12-24 4 ATNX Athenex, Inc.
Common Stock P - Purchase 73,698 11,532,467 0.64 14.39 1,060,514 165,952,200

2019-12-26 2019-12-23 4 ATNX Athenex, Inc.
Common Stock P - Purchase 153,237 11,458,769 1.36 14.30 2,191,289 163,860,397

2019-12-26 2019-12-20 4 ATNX Athenex, Inc.
Common Stock P - Purchase 189,322 11,305,532 1.70 14.14 2,677,013 159,860,222

2019-12-26 2019-12-19 4 ATNX Athenex, Inc.
Common Stock P - Purchase 120,931 11,116,210 1.10 13.86 1,676,104 154,070,671

2019-12-26 2019-12-19 4 ATNX Athenex, Inc.
Common Stock P - Purchase 142,812 10,995,279 1.32 13.72 1,959,381 150,855,228

2019-11-18 2019-11-18 4 KDMN Kadmon Holdings, Inc.
Common Stock P - Purchase 1,470,588 14,636,334 11.17 3.40 4,999,999 49,763,536

2019-11-18 2019-11-15 4 AGRX AGILE THERAPEUTICS INC
Common Stock P - Purchase 333,800 11,919,925 2.88 1.74 580,812 20,740,670

2019-11-18 2019-11-15 4 AGRX AGILE THERAPEUTICS INC
Common Stock P - Purchase 2,000,000 11,586,125 20.86 1.60 3,200,000 18,537,800

2019-11-18 2019-11-15 4 AGRX AGILE THERAPEUTICS INC
Common Stock P - Purchase 3,000,000 9,586,125 45.55 1.72 5,160,000 16,488,135

2019-11-18 2019-11-14 4 AGRX AGILE THERAPEUTICS INC
Common Stock P - Purchase 435,015 6,586,125 7.07 1.69 735,175 11,130,551

2019-11-15 2019-11-12 4 DOVA Dova Pharmaceuticals Inc.
Common Stock J - Other -3,125,851 0 -100.00

2019-11-12 2019-11-07 4 QTNT Quotient Ltd
Ordinary Shares P - Purchase 2,500,000 13,289,054 23.17 7.00 17,500,000 93,023,378

2019-10-31 2019-10-29 4 AGRX AGILE THERAPEUTICS INC
Common Stock S - Sale -760,291 6,151,110 -11.00 0.44 -334,528 2,706,488

2019-10-30 2019-10-28 4 AGRX AGILE THERAPEUTICS INC
Common Stock S - Sale -3,815,349 6,911,401 -35.57 0.51 -1,945,828 3,524,815

2019-10-30 2019-08-06 4 AGRX AGILE THERAPEUTICS INC
Common Stock P - Purchase 2,300,000 10,726,750 27.29 0.95 2,185,000 10,190,412

2019-10-21 2019-10-17 4 ATNX Athenex, Inc.
Common Stock P - Purchase 50,000 10,852,467 0.46 10.93 546,500 118,617,464

2019-10-18 2019-10-16 4 ATNX Athenex, Inc.
Common Stock P - Purchase 67,222 10,802,467 0.63 10.29 691,714 111,157,385

2019-09-24 2019-09-23 4 VBIV VBI Vaccines Inc/BC
Common Stock P - Purchase 20,000,000 45,951,556 77.07 0.50 10,000,000 22,975,778

2019-09-18 2019-09-16 4 ATNX Athenex, Inc.
Common Stock P - Purchase 30,000 10,735,245 0.28 13.58 407,400 145,784,627

2019-09-16 2019-09-13 4 ATNX Athenex, Inc.
Common Stock P - Purchase 56,416 10,705,245 0.53 14.27 805,056 152,763,846

2019-09-16 2019-09-12 4 ATNX Athenex, Inc.
Common Stock P - Purchase 13,584 10,648,829 0.13 14.05 190,855 149,616,047

2019-08-20 2019-08-12 4 MGTX MeiraGTx Holdings plc
Ordinary Shares P - Purchase 425,531 6,433,277 7.08 23.50 9,999,978 151,182,010

2019-08-16 2019-08-16 4 ATNX Athenex, Inc.
Common Stock P - Purchase 20,000 10,635,245 0.19 14.96 299,200 159,103,265

2019-08-16 2019-08-15 4 ATNX Athenex, Inc.
Common Stock P - Purchase 30,000 10,615,245 0.28 15.00 450,000 159,228,675

2019-08-09 2019-08-08 4 ATNX Athenex, Inc.
Common Stock P - Purchase 30,000 10,585,245 0.28 15.76 472,800 166,823,461

2019-08-09 2019-08-07 4 ATNX Athenex, Inc.
Common Stock P - Purchase 37,764 10,555,245 0.36 15.79 596,294 166,667,319

2019-08-09 2019-08-07 4 ATNX Athenex, Inc.
Common Stock P - Purchase 248,752 10,517,481 2.42 15.04 3,741,230 158,182,914

2019-08-09 2019-08-07 4 ATNX Athenex, Inc.
Common Stock P - Purchase 371,756 10,268,729 3.76 14.14 5,256,630 145,199,828

2019-08-09 2019-08-07 4 ATNX Athenex, Inc.
Common Stock P - Purchase 74,855 9,896,973 0.76 13.12 982,098 129,848,286

2019-08-09 2019-06-25 4 ATNX Athenex, Inc.
Common Stock P - Purchase 1,495 9,822,118 0.02 17.89 26,746 175,717,691

2019-08-09 2019-06-24 4 ATNX Athenex, Inc.
Common Stock P - Purchase 20,786 9,820,623 0.21 17.90 372,069 175,789,152

2019-08-09 2019-06-21 4 ATNX Athenex, Inc.
Common Stock P - Purchase 23,073 9,799,837 0.24 17.85 411,853 174,927,090

2019-08-06 3 FOMX Foamix Pharmaceuticals Ltd.
Common Stock 22,407,762

2019-08-06 3 FOMX Foamix Pharmaceuticals Ltd.
Common Stock 22,407,762

2019-08-06 3 FOMX Foamix Pharmaceuticals Ltd.
Common Stock 22,407,762

2019-08-06 3 FOMX Foamix Pharmaceuticals Ltd.
Common Stock 22,407,762

2019-08-06 3 FOMX Foamix Pharmaceuticals Ltd.
Common Stock 22,407,762

2019-07-29 2019-07-25 4 SLDB Solid Biosciences Inc.
Common Stock P - Purchase 2,822,581 6,749,803 71.87 4.65 13,125,002 31,386,584

2019-07-11 2019-07-11 4 DOVA Dova Pharmaceuticals Inc.
Common Stock P - Purchase 42,916 3,708,705 1.17 16.67 715,410 61,824,112

2019-07-11 2019-07-10 4 DOVA Dova Pharmaceuticals Inc.
Common Stock P - Purchase 12,354 3,665,789 0.34 16.89 208,659 61,915,176

2019-07-11 2019-07-09 4 DOVA Dova Pharmaceuticals Inc.
Common Stock P - Purchase 29,834 3,653,435 0.82 16.61 495,543 60,683,555

2019-07-09 2019-07-05 4 DOVA Dova Pharmaceuticals Inc.
Common Stock P - Purchase 50,000 3,632,601 1.40 16.46 823,000 59,792,612

2019-07-03 2019-07-03 4 DOVA Dova Pharmaceuticals Inc.
Common Stock P - Purchase 1,705 3,573,601 0.05 16.67 28,422 59,571,929

2019-07-03 2019-07-02 4 DOVA Dova Pharmaceuticals Inc.
Common Stock P - Purchase 715 3,571,896 0.02 16.14 11,540 57,650,401

2019-07-03 2019-07-01 4 DOVA Dova Pharmaceuticals Inc.
Common Stock P - Purchase 18,121 3,571,181 0.51 14.24 258,043 50,853,617

2019-07-01 2019-06-28 4 DOVA Dova Pharmaceuticals Inc.
Common Stock P - Purchase 39,383 3,553,060 1.12 14.48 570,266 51,448,309

2019-07-01 2019-06-28 4 DOVA Dova Pharmaceuticals Inc.
Common Stock P - Purchase 60,617 3,513,560 1.76 13.97 846,819 49,084,433

2019-07-01 2019-06-27 4 DOVA Dova Pharmaceuticals Inc.
Common Stock P - Purchase 186,696 3,453,060 5.72 13.58 2,535,332 46,892,555

2019-07-01 2019-06-27 4 DOVA Dova Pharmaceuticals Inc.
Common Stock P - Purchase 140,513 3,266,364 4.50 12.46 1,750,792 40,698,895

2019-07-01 2019-06-27 4 MOTS Motus GI Holdings, Inc.
Common Stock P - Purchase 1,000,000 4,210,542 31.15 3.00 3,000,000 12,631,626

2019-06-20 2019-06-18 4 VBIV VBI Vaccines Inc/BC
Common Stock P - Purchase 1,000,000 25,951,556 4.01 0.65 650,000 16,868,511

2019-06-20 2019-06-18 4 ATNX Athenex, Inc.
Common Stock P - Purchase 50,742 9,776,764 0.52 17.73 899,656 173,342,026

2019-06-19 2019-06-17 4 ATNX Athenex, Inc.
Common Stock P - Purchase 130,000 9,726,022 1.35 17.94 2,332,200 174,484,835

2019-06-18 2019-06-17 4 VBIV VBI Vaccines Inc/BC
Common Stock P - Purchase 1,000,000 24,951,556 4.18 0.62 618,000 15,420,062

2019-06-18 2019-06-14 4 ATNX Athenex, Inc.
Common Stock P - Purchase 324,290 9,596,022 3.50 17.69 5,736,690 169,753,629

2019-06-17 2019-06-13 4 ATNX Athenex, Inc.
Common Stock P - Purchase 75,710 9,271,732 0.82 17.05 1,290,856 158,083,031

2019-05-23 2019-05-21 4 ADMA ADMA BIOLOGICS, INC.
Common Stock P - Purchase 4,000,000 11,521,102 53.18 4.00 16,000,000 46,084,408

2019-05-23 2019-05-03 4 ADMA ADMA BIOLOGICS, INC.
Warrants (right to buy) P - Purchase 250,000 250,000

2019-05-23 2019-02-11 4 ADMA ADMA BIOLOGICS, INC.
Warrants (right to buy) P - Purchase 1,360,000 1,360,000

2019-05-08 3 ATNX Athenex, Inc.
Common Stock 18,192,044

2019-05-08 3 ATNX Athenex, Inc.
Common Stock 18,192,044

2019-05-08 3 ATNX Athenex, Inc.
Common Stock 18,192,044

2019-05-08 3 ATNX Athenex, Inc.
Common Stock 18,192,044

2019-05-08 3 ATNX Athenex, Inc.
Common Stock 18,192,044

2019-05-08 2019-05-06 4 ATNX Athenex, Inc.
Common Stock P - Purchase 77,010 9,196,022 0.84 12.90 993,429 118,628,684

2019-05-08 2019-05-06 4 ATNX Athenex, Inc.
Common Stock P - Purchase 22,990 9,119,012 0.25 12.08 277,719 110,157,665

2019-03-06 3 AGRX AGILE THERAPEUTICS INC
Common Stock 16,853,500

2019-03-06 3 AGRX AGILE THERAPEUTICS INC
Common Stock 16,853,500

2019-03-06 3 AGRX AGILE THERAPEUTICS INC
Common Stock 16,853,500

2019-03-06 3 AGRX AGILE THERAPEUTICS INC
Common Stock 16,853,500

2019-03-06 3 AGRX AGILE THERAPEUTICS INC
Common Stock 16,853,500

2019-03-05 2019-03-01 4 MGTX MeiraGTx Holdings plc
Ordinary Shares P - Purchase 1,304,348 6,007,746 27.73 13.80 18,000,002 82,906,895

2019-01-17 2018-12-24 4 MOTS Motus GI Holdings, Inc.
Common Stock P - Purchase 400,000 3,210,541 14.23 2.70 1,080,000 8,668,461

2019-01-17 2018-02-14 4 MOTS Motus GI Holdings, Inc.
Common Stock P - Purchase 10,000 2,810,541 0.36 5.00 50,000 14,052,705

2019-01-09 2019-01-08 4 LJPC LA JOLLA PHARMACEUTICAL CO
Common Stock S - Sale -450,235 2,253,376 -16.65 5.26 -2,368,236 11,852,758

2019-01-09 2019-01-08 4 LJPC LA JOLLA PHARMACEUTICAL CO
Common Stock S - Sale -800,000 2,703,611 -22.83 5.25 -4,200,000 14,193,958

2019-01-09 2019-01-07 4 LJPC LA JOLLA PHARMACEUTICAL CO
Common Stock S - Sale -25,800 3,503,611 -0.73 6.46 -166,668 22,633,327

2019-01-09 2019-01-07 4 LJPC LA JOLLA PHARMACEUTICAL CO
Common Stock S - Sale -25,800 3,503,611 -0.73 6.46 -166,668 22,633,327

2019-01-09 2019-01-07 4 LJPC LA JOLLA PHARMACEUTICAL CO
Common Stock S - Sale -4,200 3,529,411 -0.12 5.26 -22,092 18,564,702

2019-01-09 2019-01-07 4 LJPC LA JOLLA PHARMACEUTICAL CO
Common Stock S - Sale -4,200 3,529,411 -0.12 5.26 -22,092 18,564,702

2019-01-09 2019-01-07 4 LJPC LA JOLLA PHARMACEUTICAL CO
Common Stock S - Sale -4,592 3,563,611 -0.13 9.52 -43,716 33,925,577

2019-01-09 2019-01-07 4 LJPC LA JOLLA PHARMACEUTICAL CO
Common Stock S - Sale -34,401 3,568,203 -0.95 9.05 -311,329 32,292,237

2019-01-09 2019-01-07 4 LJPC LA JOLLA PHARMACEUTICAL CO
Common Stock S - Sale -131,866 3,602,604 -3.53 7.56 -996,907 27,235,686

2019-01-09 2019-01-07 4 LJPC LA JOLLA PHARMACEUTICAL CO
Common Stock S - Sale -147,497 3,734,470 -3.80 6.67 -983,805 24,908,915

2019-01-09 2019-01-07 4 LJPC LA JOLLA PHARMACEUTICAL CO
Common Stock S - Sale -431,644 3,881,967 -10.01 5.64 -2,434,472 21,894,294

2018-12-17 2018-12-13 4 VBIV VBI Vaccines Inc/BC
Common Stock P - Purchase 14,285,714 23,631,439 152.86 1.40 20,000,000 33,084,015

2018-12-10 2018-12-07 4 QTNT Quotient Ltd
Ordinary Shares P - Purchase 2,000,000 10,789,054 22.76 6.50 13,000,000 70,128,851

2018-10-15 2018-10-12 4 CORI Corium International, Inc.
Common Stock S - Sale -2,350,000 2,724,686 -46.31 12.52 -29,422,000 34,113,069

2018-10-15 2018-10-12 4 CORI Corium International, Inc.
Common Stock S - Sale -500,000 5,074,686 -8.97 12.51 -6,255,000 63,484,322

2018-10-15 2018-10-11 4 CORI Corium International, Inc.
Common Stock S - Sale -500,000 5,574,686 -8.23 12.50 -6,250,000 69,683,575

2018-10-15 2018-10-11 4 CORI Corium International, Inc.
Common Stock S - Sale -282,447 6,074,686 -4.44 12.51 -3,533,412 75,994,322

2018-10-05 2018-10-03 4 FOLD AMICUS THERAPEUTICS INC
Common Stock P - Purchase 30,000 20,724,424 0.14 12.69 380,700 262,992,941

2018-10-05 2018-09-24 4 FOLD AMICUS THERAPEUTICS INC
Common Stock P - Purchase 20,000 20,694,424 0.10 12.45 249,000 257,645,579

2018-09-25 2018-09-21 4 FOLD AMICUS THERAPEUTICS INC
Common Stock P - Purchase 50,000 20,674,424 0.24 12.53 626,500 259,050,533

2018-09-17 2018-09-13 4 FOLD AMICUS THERAPEUTICS INC
Common Stock P - Purchase 100,000 20,624,424 0.49 11.74 1,174,000 242,130,738

2018-09-14 2018-09-12 4 FOLD AMICUS THERAPEUTICS INC
Common Stock P - Purchase 500,000 20,524,424 2.50 12.00 6,001,500 246,354,661

2018-08-27 2018-07-20 4/A CRNX Crinetics Pharmaceuticals, Inc.
Series B Preferred Stock C - Conversion -6,186,205 0 -100.00

2018-08-27 2018-07-20 4/A CRNX Crinetics Pharmaceuticals, Inc.
Common Stock P - Purchase 400,000 2,587,953 18.28 17.00 6,800,000 43,995,201

2018-08-27 2018-07-20 4/A CRNX Crinetics Pharmaceuticals, Inc.
Common Stock C - Conversion 1,880,305 2,187,953 611.19

2018-08-27 2018-07-18 4/A CRNX Crinetics Pharmaceuticals, Inc.
Common Stock P - Purchase 307,648 307,648 21.30 6,552,902 6,552,902

2018-08-14 2018-08-10 4 ZGNX ZOGENIX, INC.
Common Stock P - Purchase 100,000 4,070,357 2.52 52.00 5,200,000 211,658,564

2018-08-01 2018-06-19 4 VRCA Verrica Pharmaceuticals Inc.
Series C Preferred Stock C - Conversion -2,193,463 0 -100.00

2018-08-01 2018-06-19 4 VRCA Verrica Pharmaceuticals Inc.
Series B Preferred Stock C - Conversion -1,937,984 0 -100.00

2018-08-01 2018-06-19 4 VRCA Verrica Pharmaceuticals Inc.
Common Stock P - Purchase 1,000,000 3,410,412 41.49 15.00 15,000,000 51,156,180

2018-08-01 2018-06-19 4 VRCA Verrica Pharmaceuticals Inc.
Common Stock C - Conversion 1,279,733 2,410,412 113.18

2018-08-01 2018-06-19 4 VRCA Verrica Pharmaceuticals Inc.
Common Stock C - Conversion 1,130,679 1,130,679

2018-07-26 2018-07-26 4 AGRX AGILE THERAPEUTICS INC
Common Stock S - Sale -298,628 3,231,372 -8.46 0.30 -89,439 967,796

2018-07-20 2018-07-18 4 QTNT Quotient Ltd
Warrants (right to buy) X - Other -2,306,034 0 -100.00

2018-07-20 2018-07-18 4 QTNT Quotient Ltd
Ordinary Shares X - Other 2,306,034 8,789,054 35.57 5.80 13,374,997 50,976,513

2018-07-20 2018-07-20 4 CRNX Crinetics Pharmaceuticals, Inc.
Series B Preferred Stock C - Conversion -6,186,205 0 -100.00

2018-07-20 2018-07-20 4 CRNX Crinetics Pharmaceuticals, Inc.
Common Stock P - Purchase 400,000 2,280,305 21.27 17.00 6,800,000 38,765,185

2018-07-20 2018-07-20 4 CRNX Crinetics Pharmaceuticals, Inc.
Common Stock C - Conversion 1,880,305 1,880,305

2018-06-22 3 KDMN Kadmon Holdings, Inc.
Common Stock 26,331,492

2018-06-22 3 KDMN Kadmon Holdings, Inc.
Common Stock 26,331,492

2018-06-22 3 KDMN Kadmon Holdings, Inc.
Common Stock 26,331,492

2018-06-22 3 KDMN Kadmon Holdings, Inc.
Common Stock 26,331,492

2018-06-22 3 KDMN Kadmon Holdings, Inc.
Common Stock 26,331,492

2018-06-13 2018-06-11 4 DOVA Dova Pharmaceuticals, Inc.
Common Stock P - Purchase 5,591 3,125,851 0.18 29.82 166,724 93,212,877

2018-06-13 2018-06-11 4 DOVA Dova Pharmaceuticals, Inc.
Common Stock P - Purchase 14,109 3,120,260 0.45 29.18 411,701 91,049,187

2018-06-12 2018-06-08 4 DOVA Dova Pharmaceuticals, Inc.
Common Stock P - Purchase 2,000 3,106,151 0.06 28.97 57,940 89,985,194

2018-06-12 2018-06-08 4 DOVA Dova Pharmaceuticals, Inc.
Common Stock P - Purchase 23,000 3,104,151 0.75 28.62 658,260 88,840,802

2018-06-12 2018-06-12 4 MGTX MeiraGTx Holdings plc
Ordinary Shares P - Purchase 1,333,333 4,703,398 39.56 15.00 19,999,995 70,550,970

2018-06-12 2018-06-08 4 MGTX MeiraGTx Holdings plc
Ordinary Shares P - Purchase 50,000 3,370,065 1.51 15.22 761,000 51,292,389

2018-06-11 2018-06-07 4 DOVA Dova Pharmaceuticals, Inc.
Common Stock P - Purchase 8,400 3,081,151 0.27 29.16 244,944 89,846,363

2018-06-11 2018-06-07 4 DOVA Dova Pharmaceuticals, Inc.
Common Stock P - Purchase 19,223 3,072,751 0.63 28.40 545,933 87,266,128

2018-06-11 2018-06-07 4 DOVA Dova Pharmaceuticals, Inc.
Common Stock P - Purchase 22,377 3,053,528 0.74 27.63 618,277 84,368,979

2018-06-08 2018-06-06 4 DOVA Dova Pharmaceuticals, Inc.
Common Stock P - Purchase 51,763 3,031,151 1.74 28.99 1,500,609 87,873,067

2018-06-08 2018-06-06 4 DOVA Dova Pharmaceuticals, Inc.
Common Stock P - Purchase 48,237 2,979,388 1.65 28.30 1,365,107 84,316,680

2018-06-08 3 MGTX MeiraGTx Holdings plc
Ordinary shares 6,640,130

2018-06-08 3 MGTX MeiraGTx Holdings plc
Ordinary shares 6,640,130

2018-06-08 3 MGTX MeiraGTx Holdings plc
Ordinary shares 6,640,130

2018-06-08 3 MGTX MeiraGTx Holdings plc
Ordinary shares 6,640,130

2018-06-08 3 MGTX MeiraGTx Holdings plc
Ordinary shares 6,640,130

2018-06-07 2018-06-05 4 DOVA Dova Pharmaceuticals, Inc.
Common Stock P - Purchase 3,168 2,931,151 0.11 27.13 85,948 79,522,127

2018-06-07 2018-06-05 4 DOVA Dova Pharmaceuticals, Inc.
Common Stock P - Purchase 56,162 2,927,983 1.96 26.31 1,477,622 77,035,233

2018-06-07 2018-06-05 4 DOVA Dova Pharmaceuticals, Inc.
Common Stock P - Purchase 40,670 2,871,821 1.44 25.45 1,035,052 73,087,844

2018-06-06 2018-06-04 4 DOVA Dova Pharmaceuticals, Inc.
Common Stock P - Purchase 10,000 2,831,151 0.35 25.07 250,700 70,976,956

2018-06-06 3 DOVA Dova Pharmaceuticals, Inc.
Common Stock 5,642,302

2018-06-06 3 DOVA Dova Pharmaceuticals, Inc.
Common Stock 5,642,302

2018-06-06 3 DOVA Dova Pharmaceuticals, Inc.
Common Stock 5,642,302

2018-06-06 3 DOVA Dova Pharmaceuticals, Inc.
Common Stock 5,642,302

2018-06-06 3 DOVA Dova Pharmaceuticals, Inc.
Common Stock 5,642,302

2018-05-24 2018-05-23 4 QTNT Quotient Ltd
Ordinary Shares P - Purchase 231,992 6,483,020 3.71 6.65 1,542,747 43,112,083

2018-05-24 2018-05-22 4 QTNT Quotient Ltd
Ordinary Shares P - Purchase 218,008 6,251,028 3.61 6.24 1,360,370 39,006,415

2018-03-28 3 AGRX AGILE THERAPEUTICS INC
Common Stock 7,060,000

2018-03-28 3 AGRX AGILE THERAPEUTICS INC
Common Stock 7,060,000

2018-03-28 3 AGRX AGILE THERAPEUTICS INC
Common Stock 7,060,000

2018-03-28 3 AGRX AGILE THERAPEUTICS INC
Common Stock 7,060,000

2018-03-28 3 AGRX AGILE THERAPEUTICS INC
Common Stock 7,060,000

2018-03-26 2018-03-15 4 LJPC LA JOLLA PHARMACEUTICAL CO
Common Stock P - Purchase 700,000 4,313,611 19.37 29.50 20,650,000 127,251,524

2018-03-07 2018-03-05 4 FOLD AMICUS THERAPEUTICS INC
Common Stock P - Purchase 335,827 18,424,424 1.86 13.56 4,553,814 249,835,189

2018-03-06 2018-03-02 4 FOLD AMICUS THERAPEUTICS INC
Common Stock P - Purchase 100,000 18,088,597 0.56 13.90 1,389,500 251,341,055

2018-03-05 2018-03-01 4 FOLD AMICUS THERAPEUTICS INC
Common Stock P - Purchase 100,000 17,988,597 0.56 13.69 1,369,000 246,263,893

2018-02-21 2018-02-16 4 MOTS Motus GI Holdings, Inc.
Series A Convertible Preferred Stock C - Conversion -256,386 0 -100.00

2018-02-21 2018-02-16 4 MOTS Motus GI Holdings, Inc.
Common Stock P - Purchase 1,000,000 2,800,541 55.54 5.00 5,000,000 14,002,705

2018-02-21 2018-02-16 4 MOTS Motus GI Holdings, Inc.
Common Stock C - Conversion 256,386 1,800,541 16.60

2018-02-21 2018-02-16 4 MOTS Motus GI Holdings, Inc.
Warrant (right to buy) J - Other 180,055 180,055

2018-02-20 2018-02-15 4 LJPC LA JOLLA PHARMACEUTICAL CO
Common Stock P - Purchase 50,000 3,613,611 1.40 32.42 1,621,000 117,153,269

2018-02-15 2018-02-14 4 LJPC LA JOLLA PHARMACEUTICAL CO
Common Stock P - Purchase 100,000 3,563,611 2.89 32.69 3,269,000 116,494,444

2018-02-15 2018-02-13 4 LJPC LA JOLLA PHARMACEUTICAL CO
Common Stock P - Purchase 75,000 3,463,611 2.21 32.75 2,456,250 113,433,260

2018-02-13 3 MOTS Motus GI Holdings, Inc.
Common Stock 3,088,310

2018-02-13 3 MOTS Motus GI Holdings, Inc.
Common Stock 3,088,310

2018-02-13 3 MOTS Motus GI Holdings, Inc.
Common Stock 3,088,310

2018-02-13 3 MOTS Motus GI Holdings, Inc.
Common Stock 3,088,310

2018-01-30 2018-01-30 4 SLDB Solid Biosciences Inc.
Common Stock P - Purchase 20,000 3,927,222 0.51 27.33 546,520 107,315,268

2018-01-30 2018-01-30 4 SLDB Solid Biosciences Inc.
Common Stock P - Purchase 1,000,000 3,907,222 34.40 16.00 16,000,000 62,515,552

2018-01-25 2018-01-25 4 ALBO ALBIREO PHARMA, INC.
Common Stock P - Purchase 275,000 1,595,000 20.83 33.00 9,075,000 52,635,000

2018-01-25 3 SLDB Solid Biosciences, LLC
Common Stock 5,814,444

2018-01-25 3 SLDB Solid Biosciences, LLC
Common Stock 5,814,444

2018-01-25 3 SLDB Solid Biosciences, LLC
Common Stock 5,814,444

2018-01-25 3 SLDB Solid Biosciences, LLC
Common Stock 5,814,444

2018-01-18 2018-01-18 4 CORI Corium International, Inc.
Common Stock P - Purchase 310,000 6,357,133 5.13 12.80 3,968,000 81,371,302

2018-01-18 2018-01-17 4 CORI Corium International, Inc.
Common Stock P - Purchase 149,650 6,047,133 2.54 12.24 1,831,716 74,016,908

2018-01-18 2018-01-16 4 CORI Corium International, Inc.
Common Stock P - Purchase 50,350 5,897,483 0.86 11.83 595,640 69,767,224

2017-12-19 2017-12-19 4 GBT Global Blood Therapeutics, Inc.
Common Stock P - Purchase 175,000 4,889,066 3.71 38.00 6,650,000 185,784,508

2017-12-18 3 LJPC LA JOLLA PHARMACEUTICAL CO
Common Stock 6,777,222

2017-12-18 3 LJPC LA JOLLA PHARMACEUTICAL CO
Common Stock 6,777,222

2017-12-18 3 LJPC LA JOLLA PHARMACEUTICAL CO
Common Stock 6,777,222

2017-12-18 3 LJPC LA JOLLA PHARMACEUTICAL CO
Common Stock 6,777,222

2017-12-15 3 GBT Global Blood Therapeutics, Inc.
Common Stock 9,428,132

2017-12-15 3 GBT Global Blood Therapeutics, Inc.
Common Stock 9,428,132

2017-12-15 3 GBT Global Blood Therapeutics, Inc.
Common Stock 9,428,132

2017-12-15 3 GBT Global Blood Therapeutics, Inc.
Common Stock 9,428,132

2017-12-04 3 ALBO ALBIREO PHARMA, INC.
Common stock 2,640,000

2017-12-04 3 ALBO ALBIREO PHARMA, INC.
Common stock 2,640,000

2017-12-04 3 ALBO ALBIREO PHARMA, INC.
Common stock 2,640,000

2017-12-04 3 ALBO ALBIREO PHARMA, INC.
Common stock 2,640,000

2017-11-15 3 ADMA ADMA BIOLOGICS, INC.
Common stock, par value $0.0001 per share 7,642,204

2017-11-15 3 ADMA ADMA BIOLOGICS, INC.
Common stock, par value $0.0001 per share 7,642,204

2017-11-15 3 ADMA ADMA BIOLOGICS, INC.
Common stock, par value $0.0001 per share 7,642,204

2017-11-15 3 ADMA ADMA BIOLOGICS, INC.
Common stock, par value $0.0001 per share 7,642,204

2017-11-01 3/A QTNT Quotient Ltd
Ordinary Shares 6,033,020

2017-10-30 2017-10-26 4 VBIV VBI Vaccines Inc/BC
Common Stock P - Purchase 3,100,000 9,345,725 49.63 3.05 9,455,000 28,504,461

2017-10-26 3 QTNT Quotient Ltd
Ordinary Shares 12,086,040

2017-10-26 3 QTNT Quotient Ltd
Ordinary Shares 12,086,040

2017-10-26 3 QTNT Quotient Ltd
Ordinary Shares 12,086,040

2017-10-26 3 QTNT Quotient Ltd
Ordinary Shares 12,086,040

2017-10-03 2017-09-29 4 ZGNX ZOGENIX, INC.
Common Stock P - Purchase 22,055 3,670,357 0.60 27.67 610,341 101,571,991

2017-10-03 2017-09-29 4 ZGNX ZOGENIX, INC.
Common Stock P - Purchase 8,920 3,648,302 0.25 40.14 358,081 146,455,976

2017-10-03 2017-09-29 4 ZGNX ZOGENIX, INC.
Common Stock P - Purchase 12,586 3,639,382 0.35 39.22 493,600 142,730,011

2017-10-03 2017-09-29 4 ZGNX ZOGENIX, INC.
Common Stock P - Purchase 8,112 3,626,796 0.22 38.56 312,791 139,845,990

2017-10-03 2017-09-29 4 ZGNX ZOGENIX, INC.
Common Stock P - Purchase 6,153 3,618,684 0.17 37.14 228,530 134,402,266

2017-10-03 2017-09-29 4 ZGNX ZOGENIX, INC.
Common Stock P - Purchase 3,800 3,612,531 0.11 36.26 137,805 131,006,630

2017-10-03 2017-09-29 4 ZGNX ZOGENIX, INC.
Common Stock P - Purchase 6,000 3,608,731 0.17 34.91 209,475 125,989,821

2017-10-03 2017-09-29 4 ZGNX ZOGENIX, INC.
Common Stock P - Purchase 8,260 3,602,731 0.23 33.86 279,665 121,980,185

2017-10-03 2017-09-29 4 ZGNX ZOGENIX, INC.
Common Stock P - Purchase 15,937 3,594,471 0.45 32.96 525,311 118,479,875

2017-10-03 2017-09-29 4 ZGNX ZOGENIX, INC.
Common Stock P - Purchase 102,199 3,578,534 2.94 31.90 3,260,240 114,158,455

2017-10-03 2017-09-29 4 ZGNX ZOGENIX, INC.
Common Stock P - Purchase 28,033 3,476,335 0.81 31.19 874,220 108,410,898

2017-10-03 2017-10-03 4 ZGNX ZOGENIX, INC.
Common Stock P - Purchase 300,000 3,970,357 8.17 37.50 11,250,000 148,888,388

2017-09-25 2017-09-22 4 VSAR Versartis, Inc.
Common Stock S - Sale -350,000 2,099,563 -14.29 3.35 -1,172,500 7,033,536

2017-09-25 2017-09-22 4 VSAR Versartis, Inc.
Common Stock S - Sale -500,000 2,449,563 -16.95 3.27 -1,633,250 8,001,498

2017-09-25 2017-09-22 4 VSAR Versartis, Inc.
Common Stock S - Sale -250,000 2,949,563 -7.81 3.17 -792,500 9,350,115

2017-09-25 2017-09-22 4 VSAR Versartis, Inc.
Common Stock S - Sale -250,000 3,199,563 -7.25 3.03 -757,250 9,691,476

2017-09-25 2017-09-22 4 VSAR Versartis, Inc.
Common Stock S - Sale -300,000 3,449,563 -8.00 3.09 -926,250 10,650,526

2017-09-25 2017-09-21 4 VSAR Versartis, Inc.
Common Stock S - Sale -353,421 3,749,563 -8.61 3.56 -1,258,143 13,348,069

2017-09-25 2017-09-21 4 VSAR Versartis, Inc.
Common Stock S - Sale -126,579 4,102,984 -2.99 3.74 -473,659 15,353,366

2017-09-21 2017-09-19 4 ALDX Aldeyra Therapeutics, Inc.
Common Stock P - Purchase 200,000 3,085,458 6.93 7.25 1,450,000 22,369,570

2017-07-14 2017-07-13 4 FOLD AMICUS THERAPEUTICS INC
Common Stock P - Purchase 1,500,000 17,888,597 9.15 12.25 18,375,000 219,135,313

2017-07-05 2017-06-30 4 CORI Corium International, Inc.
Common Stock P - Purchase 301,004 5,847,133 5.43 7.70 2,319,236 45,052,160

2017-07-05 2017-06-30 4 ALDX Aldeyra Therapeutics, Inc.
Common Stock P - Purchase 296,007 2,885,458 11.43 4.60 1,361,632 13,273,107

2017-07-05 2017-06-30 4 ZGNX ZOGENIX, INC.
Common Stock P - Purchase 175,653 3,448,302 5.37 14.45 2,538,186 49,827,964

2017-06-21 2017-06-19 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock S - Sale -875,000 4,533,728 -16.18 2.40 -2,100,000 10,880,947

2017-05-25 2017-05-25 4 CORI Corium International, Inc.
Common Stock P - Purchase 1,902,400 5,546,129 52.21 6.25 11,890,000 34,663,306

2017-05-25 3 CORI Corium International, Inc.
Common Stock 7,287,458

2017-05-25 3 CORI Corium International, Inc.
Common Stock 7,287,458

2017-05-25 3 CORI Corium International, Inc.
Common Stock 7,287,458

2017-05-25 3 CORI Corium International, Inc.
Common Stock 7,287,458

2017-05-18 3 ZGNX ZOGENIX, INC.
Common Stock 6,545,298

2017-05-18 3 ZGNX ZOGENIX, INC.
Common Stock 6,545,298

2017-05-18 3 ZGNX ZOGENIX, INC.
Common Stock 6,545,298

2017-05-18 3 ZGNX ZOGENIX, INC.
Common Stock 6,545,298

2017-03-14 2017-02-13 4/A VSAR Versartis, Inc.
Common Stock P - Purchase 59,133 4,229,563 1.42 15.51 917,425 65,619,978

2017-03-14 2017-02-10 4/A VSAR Versartis, Inc.
Common Stock P - Purchase 34,883 4,170,430 0.84 14.94 521,281 62,321,655

2017-02-15 2017-02-14 4 ALDX Aldeyra Therapeutics, Inc.
Common Stock P - Purchase 893,025 2,589,451 52.64 4.50 4,018,612 11,652,530

2017-02-14 2017-02-13 4 VSAR Versartis, Inc.
Common Stock P - Purchase 59,133 4,228,563 1.42 15.51 917,425 65,604,464

2017-02-14 2017-02-10 4 VSAR Versartis, Inc.
Common Stock P - Purchase 34,883 4,169,430 0.84 14.94 521,281 62,306,711

2017-02-10 2017-02-09 4 VSAR Versartis, Inc.
Common Stock P - Purchase 41,211 4,134,547 1.01 14.27 587,928 58,984,688

2017-02-10 2017-02-08 4 VSAR Versartis, Inc.
Common Stock P - Purchase 104,612 4,093,336 2.62 13.51 1,413,319 55,301,379

2017-01-04 2016-12-30 4 VSAR Versartis, Inc.
Common Stock P - Purchase 94,750 4,013,411 2.42 14.66 1,388,846 58,828,578

2017-01-04 2016-12-30 4 FOLD AMICUS THERAPEUTICS INC
Common Stock P - Purchase 94,750 16,293,847 0.58 4.96 470,055 80,833,775

2017-01-04 2016-12-30 4/A VSAR Versartis, Inc.
Common Stock P - Purchase 71,063 3,989,724 1.81 14.66 1,041,641 58,481,374

2016-12-30 2016-12-29 4 VSAR Versartis, Inc.
Common Stock P - Purchase 47,375 3,918,661 1.22 14.37 680,589 56,295,484

2016-12-30 2016-12-29 4 FOLD AMICUS THERAPEUTICS INC
Common Stock P - Purchase 94,750 16,293,847 0.58 4.85 459,916 79,090,333

2016-12-30 2016-12-28 4 FOLD AMICUS THERAPEUTICS INC
Common Stock P - Purchase 47,375 16,199,097 0.29 4.91 232,706 79,569,964

2016-12-27 2016-12-23 4 FOLD AMICUS THERAPEUTICS INC
Common Stock P - Purchase 37,900 16,151,722 0.24 4.92 186,582 79,514,927

2016-12-27 2016-12-23 4 FOLD AMICUS THERAPEUTICS INC
Common Stock P - Purchase 47,375 16,113,822 0.29 4.72 223,468 76,008,898

2016-12-23 2016-12-22 4 FOLD AMICUS THERAPEUTICS INC
Common Stock P - Purchase 189,500 16,066,447 1.19 4.51 854,834 72,475,742

2016-12-08 2016-12-06 4 VBIV VBI VACCINES INC.
Warrant P - Purchase 1,341,282 2,068,824 184.36 3.36 4,500,001 6,940,905

2016-12-08 2016-12-06 4 VBIV VBI VACCINES INC.
Warrant P - Purchase 363,771 727,542 100.00 4.13 1,502,374 3,004,748

2016-12-08 2016-12-06 4 VBIV VBI VACCINES INC.
Common Stock P - Purchase 3,383,955 6,213,314 119.60 3.05 10,321,063 18,950,608

2016-12-02 3 FOLD AMICUS THERAPEUTICS INC
Common Stock 26,447,894

2016-12-02 3 FOLD AMICUS THERAPEUTICS INC
Common Stock 26,447,894

2016-12-02 3 FOLD AMICUS THERAPEUTICS INC
Common Stock 26,447,894

2016-12-02 3 FOLD AMICUS THERAPEUTICS INC
Common Stock 26,447,894

2016-12-02 3/A FOLD AMICUS THERAPEUTICS INC
Common Stock 15,876,947

2016-10-05 3/A VSAR Versartis, Inc.
Common Stock 3,871,286

2016-09-30 2016-09-29 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock S - Sale -97,200 5,386,410 -1.77 3.88 -377,117 20,898,194

2016-09-30 2016-09-28 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock S - Sale -119,300 5,483,610 -2.13 3.96 -472,380 21,712,902

2016-09-28 3 VSAR Versartis, Inc.
Common Stock 7,594,838

2016-09-28 3 VSAR Versartis, Inc.
Common Stock 7,594,838

2016-09-28 3 VSAR Versartis, Inc.
Common Stock 7,594,838

2016-09-28 3 VSAR Versartis, Inc.
Common Stock 7,594,838

2016-09-16 2016-09-15 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock S - Sale -115,923 5,602,910 -2.03 3.63 -420,511 20,324,556

2016-09-16 2016-09-15 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock S - Sale -276,927 5,718,833 -4.62 3.73 -1,032,301 21,318,094

2016-08-26 2016-08-25 4 FOLD AMICUS THERAPEUTICS INC
Common Stock S - Sale -1,100,000 14,139,444 -7.22 6.81 -7,491,000 96,289,614

2016-05-26 2016-05-26 4 ALDX Aldeyra Therapeutics, Inc.
Common Stock P - Purchase 700,000 1,940,458 56.43 5.00 3,500,000 9,702,290

2015-11-19 2015-11-18 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock S - Sale -42,300 5,995,760 -0.70 5.35 -226,132 32,052,733

2015-11-19 2015-11-17 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock S - Sale -133,900 6,038,060 -2.17 5.36 -717,409 32,350,718

2015-11-09 2015-11-06 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock S - Sale -17,100 6,171,960 -0.28 4.47 -76,365 27,562,739

2015-11-09 2015-11-05 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock S - Sale -75,000 6,189,060 -1.20 4.62 -346,260 28,573,652

2015-11-05 2015-10-28 4 ALDX Aldeyra Therapeutics, Inc.
Common Stock P - Purchase 45,100 1,240,458 3.77 6.50 293,150 8,062,977

2015-10-28 2015-10-26 4 ALDX Aldeyra Therapeutics, Inc.
Common Stock P - Purchase 50,000 1,195,358 4.37 6.46 323,150 7,725,599

2015-10-26 2015-10-22 4 ALDX Aldeyra Therapeutics, Inc.
Common Stock P - Purchase 18,020 1,145,358 1.60 6.47 116,661 7,415,048

2015-10-22 2015-10-20 4 ALDX Aldeyra Therapeutics, Inc.
Common Stock P - Purchase 22,797 1,127,338 2.06 6.44 146,858 7,262,311

2015-10-22 2015-10-20 4 ALDX Aldeyra Therapeutics, Inc.
Common Stock P - Purchase 14,348 1,104,541 1.32 6.30 90,335 6,954,190

2015-10-22 3 ALDX Aldeyra Therapeutics, Inc.
Common Stock 2,180,386

2015-10-22 3 ALDX Aldeyra Therapeutics, Inc.
Common Stock 2,180,386

2015-10-22 3 ALDX Aldeyra Therapeutics, Inc.
Common Stock 2,180,386

2015-10-22 3 ALDX Aldeyra Therapeutics, Inc.
Common Stock 2,180,386

2015-10-08 2015-10-07 4 FOLD AMICUS THERAPEUTICS INC
Common Stock P - Purchase 50,000 15,239,444 0.33 6.27 313,500 95,551,314

2015-10-07 2015-10-06 4 FOLD AMICUS THERAPEUTICS INC
Common Stock P - Purchase 7,000 15,189,444 0.05 6.34 44,380 96,301,075

2015-10-07 2015-10-06 4 FOLD AMICUS THERAPEUTICS INC
Common Stock P - Purchase 14,000 15,182,444 0.09 6.47 90,580 98,230,413

2015-10-07 2015-10-06 4 FOLD AMICUS THERAPEUTICS INC
Common Stock P - Purchase 14,000 15,168,444 0.09 6.65 93,100 100,870,153

2015-10-07 2015-10-06 4 FOLD AMICUS THERAPEUTICS INC
Common Stock P - Purchase 43,000 15,154,444 0.28 6.34 272,620 96,079,175

2015-10-07 2015-10-06 4 FOLD AMICUS THERAPEUTICS INC
Common Stock P - Purchase 86,000 15,111 -121.32 6.47 556,420 97,771

2015-10-07 2015-10-06 4 FOLD AMICUS THERAPEUTICS INC
Common Stock P - Purchase 86,000 15,025,444 0.58 6.65 571,900 99,919,203

2015-10-07 2015-10-05 4 FOLD AMICUS THERAPEUTICS INC
Common Stock P - Purchase 35,000 14,939,444 0.23 6.76 236,600 100,990,641

2015-10-07 2015-10-05 4 FOLD AMICUS THERAPEUTICS INC
Common Stock P - Purchase 35,000 14,904,444 0.24 6.85 239,750 102,095,441

2015-10-07 2015-10-05 4 FOLD AMICUS THERAPEUTICS INC
Common Stock P - Purchase 215,000 14,869,444 1.47 6.76 1,453,400 100,517,441

2015-10-07 2015-10-05 4 FOLD AMICUS THERAPEUTICS INC
Common Stock P - Purchase 215,000 14,654,444 1.49 6.85 1,472,750 100,382,941

2015-09-11 2015-09-09 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock S - Sale -310,000 6,264,060 -4.72 4.18 -1,294,777 26,163,099

2015-08-18 2015-08-14 4 VBIV VBI VACCINES INC.
Common Stock P - Purchase 650,000 3,260,356 24.90 2.08 1,352,000 6,781,540

2014-11-19 2014-11-19 4 FOLD AMICUS THERAPEUTICS INC
Common Stock P - Purchase 2,100,000 14,439,444 17.02 6.50 13,650,000 93,856,386

2014-08-04 3 VBIV VBI VACCINES INC.
Common Stock 4,540,808

2014-08-04 3 VBIV VBI VACCINES INC.
Common Stock 4,540,808

2014-07-01 2014-06-30 4 FOLD AMICUS THERAPEUTICS INC
Common Stock P - Purchase 530,000 12,339,444 4.49 3.50 1,855,000 43,188,054

2014-07-01 2014-06-30 4 FOLD AMICUS THERAPEUTICS INC
Common Stock P - Purchase 3,470,000 11,809,444 41.61 3.50 12,145,000 41,333,054

2014-05-30 3 FOLD AMICUS THERAPEUTICS INC
Common Stock 16,678,888

2014-05-30 3 FOLD AMICUS THERAPEUTICS INC
Common Stock 16,678,888

2014-05-30 3 FOLD AMICUS THERAPEUTICS INC
Common Stock 16,678,888

2014-05-30 3 FOLD AMICUS THERAPEUTICS INC
Common Stock 16,678,888

2013-11-12 2013-11-07 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock P - Purchase 6,500 6,574,060 0.10 6.50 42,238 42,718,899

2013-11-12 2013-11-07 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock P - Purchase 93,500 6,567,560 1.44 6.50 607,572 42,676,662

2013-11-12 2013-11-06 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock P - Purchase 6,500 6,474,060 0.10 6.52 42,358 42,188,859

2013-11-12 2013-11-06 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock P - Purchase 93,500 6,467,560 1.47 6.52 609,302 42,146,501

2013-11-06 2013-11-04 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock P - Purchase 3,250 6,374,060 0.05 6.84 22,220 43,579,448

2013-11-06 2013-11-04 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock P - Purchase 46,750 6,370,810 0.74 6.84 319,630 43,557,228

2013-11-06 2013-11-04 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock P - Purchase 6,825 6,324,060 0.11 6.88 46,959 43,512,062

2013-11-06 2013-11-04 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock P - Purchase 98,175 6,317,235 1.58 6.88 675,483 43,465,104

2013-11-04 2013-11-01 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock P - Purchase 150,218 6,219,060 2.48 7.17 1,077,033 44,589,416

2013-11-04 2013-11-01 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock P - Purchase 10,442 6,068,842 0.17 7.17 74,867 43,512,383

2013-11-04 2013-10-31 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock P - Purchase 8,000 6,058,400 0.13 6.69 53,546 40,550,083

2013-11-04 2013-10-31 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock P - Purchase 192,000 6,050,400 3.28 6.69 1,285,094 40,496,537

2013-09-09 2013-09-05 4 AEGR Aegerion Pharmaceuticals, Inc.
Common Stock S - Sale -50,000 2,823,426 -1.74 89.20 -4,460,000 251,849,599

2013-09-09 2013-09-05 4 AEGR Aegerion Pharmaceuticals, Inc.
Common Stock S - Sale -700,000 2,873,426 -19.59 89.20 -62,440,000 256,309,599

2013-09-09 2013-06-15 4 AEGR Aegerion Pharmaceuticals, Inc.
Call option (right to buy) X - Other -1,000 0 -100.00

2013-09-09 2013-06-15 4 AEGR Aegerion Pharmaceuticals, Inc.
Call option (right to buy) X - Other -1,000 0 -100.00

2013-09-09 2013-06-15 4 AEGR Aegerion Pharmaceuticals, Inc.
Common Stock X - Other 100,000 3,573,426 2.88 25.00 2,500,000 89,335,650

2013-09-09 2013-06-15 4 AEGR Aegerion Pharmaceuticals, Inc.
Common Stock X - Other 100,000 3,473,426 2.96 25.00 2,500,000 86,835,650

2013-07-24 2013-07-23 4 ACRX ACELRX PHARMACEUTICALS INC
Common Stock P - Purchase 850,000 5,858,400 16.97 11.65 9,902,500 68,250,360

2013-03-20 2013-03-16 4 RPRX REPROS THERAPEUTICS INC.
Call option (right to sell) E - Other 500 22,000 2.33

2013-03-20 2013-03-16 4 RPRX REPROS THERAPEUTICS INC.
Call option (right to sell) E - Other 500 22,000 2.33

2013-03-20 2013-03-16 4 RPRX REPROS THERAPEUTICS INC.
Call option (right to sell) E - Other 500 22,500 2.27

2013-03-20 2013-03-16 4 RPRX REPROS THERAPEUTICS INC.
Call option (right to sell) E - Other 500 23,000 2.22

2013-03-20 2013-03-16 4 RPRX REPROS THERAPEUTICS INC.
Call option (right to sell) E - Other 500 23,500 2.17

2013-03-20 2013-03-16 4 RPRX REPROS THERAPEUTICS INC.
Call option (right to sell) E - Other 1,000 24,000 4.35

2013-03-20 2013-03-16 4 RPRX REPROS THERAPEUTICS INC.
Call option (right to sell) E - Other 1,000 24,000 4.35

2013-03-20 2013-03-16 4 RPRX REPROS THERAPEUTICS INC.
Call option (right to sell) E - Other 1,000 25,000 4.17

2013-03-20 2013-03-16 4 RPRX REPROS THERAPEUTICS INC.
Call option (right to sell) E - Other 1,500 26,000 6.12

2013-03-20 2013-03-16 4 RPRX REPROS THERAPEUTICS INC.
Call option (right to sell) E - Other 2,000 27,500 7.84

2013-03-20 2013-03-16 4 RPRX REPROS THERAPEUTICS INC.
Call option (right to sell) E - Other 2,000 27,500 7.84

2013-03-20 2013-03-16 4 RPRX REPROS THERAPEUTICS INC.
Call option (right to sell) E - Other 6,000 29,500 25.53

2013-03-20 2013-03-16 4 RPRX REPROS THERAPEUTICS INC.
Call option (right to sell) E - Other 1,000 36,000 2.86

2013-03-20 2013-03-16 4 RPRX REPROS THERAPEUTICS INC.
Call option (right to sell) E - Other 4,000 40,000 11.11

2013-03-20 2013-03-15 4 RPRX REPROS THERAPEUTICS INC.
Put option (right to sell) X - Other 500 44,000 1.15

2013-03-20 2013-03-15 4 RPRX REPROS THERAPEUTICS INC.
Put option (right to sell) X - Other 500 44,000 1.15

2013-03-20 2013-03-15 4 RPRX REPROS THERAPEUTICS INC.
Put option (right to sell) X - Other 500 44,500 1.14

2013-03-20 2013-03-15 4 RPRX REPROS THERAPEUTICS INC.
Put option (right to sell) X - Other 500 45,000 1.12

2013-03-20 2013-03-15 4 RPRX REPROS THERAPEUTICS INC.
Put option (right to sell) X - Other 1,000 45,500 2.25

2013-03-20 2013-03-15 4 RPRX REPROS THERAPEUTICS INC.
Put option (right to sell) X - Other 1,000 45,500 2.25

2013-03-20 2013-03-15 4 RPRX REPROS THERAPEUTICS INC.
Put option (right to sell) X - Other 500

2013-03-20 2013-03-15 4 RPRX REPROS THERAPEUTICS INC.
Put option (right to sell) X - Other 1,000 47,500 2.15

2013-03-20 2013-03-15 4 RPRX REPROS THERAPEUTICS INC.
Put option (right to sell) X - Other 1,000 48,500 2.11

2013-03-20 2013-03-15 4 RPRX REPROS THERAPEUTICS INC.
Put option (right to sell) X - Other 1,500 49,500 3.12

2013-03-20 2013-03-15 4 RPRX REPROS THERAPEUTICS INC.
Put option (right to sell) X - Other 1,500 49,500 3.12

2013-03-20 2013-03-15 4 RPRX REPROS THERAPEUTICS INC.
Put option (right to sell) X - Other 4,000 51,000 8.51

2013-03-20 2013-03-15 4 RPRX REPROS THERAPEUTICS INC.
Put option (right to sell) X - Other 4,000 51,000 8.51

2013-03-20 2013-03-15 4 RPRX REPROS THERAPEUTICS INC.
Put option (right to sell) X - Other 1,000 55,000 1.85

2013-03-20 2013-03-15 4 RPRX REPROS THERAPEUTICS INC.
Put option (right to sell) X - Other 2,000 56,000 3.70

2013-03-20 2013-03-15 4 RPRX REPROS THERAPEUTICS INC.
Common Stock X - Other -50,000 812,560 -5.80 10.00 -500,000 8,125,600

2013-03-20 2013-03-15 4 RPRX REPROS THERAPEUTICS INC.
Common Stock X - Other -50,000 812,560 -5.80 10.00 -500,000 8,125,600

2013-03-20 2013-03-15 4 RPRX REPROS THERAPEUTICS INC.
Common Stock X - Other -50,000 862,560 -5.48 12.50 -625,000 10,782,000

2013-03-20 2013-03-15 4 RPRX REPROS THERAPEUTICS INC.
Common Stock X - Other -50,000 862,560 -5.48 12.50 -625,000 10,782,000

2013-03-20 2013-03-15 4 RPRX REPROS THERAPEUTICS INC.
Common Stock X - Other -50,000 862,560 -5.48 12.50 -625,000 10,782,000

2013-03-20 2013-03-15 4 RPRX REPROS THERAPEUTICS INC.
Common Stock X - Other -100,000 962,560 -9.41 12.50 -1,250,000 12,032,000

2013-03-20 2013-03-15 4 RPRX REPROS THERAPEUTICS INC.
Common Stock X - Other -100,000 962,560 -9.41 12.50 -1,250,000 12,032,000

2013-03-20 2013-03-15 4 RPRX REPROS THERAPEUTICS INC.
Common Stock X - Other -100,000 962,560 -9.41 12.50 -1,250,000 12,032,000

2013-03-20 2013-03-15 4 RPRX REPROS THERAPEUTICS INC.
Common Stock X - Other -100,000 1,162,560 -7.92 10.00 -1,000,000 11,625,600

2013-03-20 2013-03-15 4 RPRX REPROS THERAPEUTICS INC.
Common Stock X - Other -150,000 1,362,560 -9.92 12.50 -1,875,000 17,032,000

2013-03-20 2013-03-15 4 RPRX REPROS THERAPEUTICS INC.
Common Stock X - Other -400,000 1,512,560 -20.91 12.50 -5,000,000 18,907,000

2013-03-20 2013-03-15 4 RPRX REPROS THERAPEUTICS INC.
Common Stock X - Other -400,000 1,512,560 -20.91 12.50 -5,000,000 18,907,000

2013-03-20 2013-03-15 4 RPRX REPROS THERAPEUTICS INC.
Common Stock X - Other -200,000 2,012,560 -9.04 12.50 -2,500,000 25,157,000

2013-03-20 2013-03-15 4 RPRX REPROS THERAPEUTICS INC.
Common Stock X - Other -150,000 2,612,560 -5.43 15.00 -2,250,000 39,188,400

2013-03-20 2013-03-15 4 RPRX REPROS THERAPEUTICS INC.
Common Stock X - Other -100,000 2,762,560 -3.49 10.00 -1,000,000 27,625,600

2013-03-06 2013-03-05 4 RPRX REPROS THERAPEUTICS INC.
Put option (right to sell) P - Purchase 500 64,500 0.78 2.76 1,380 178,020

2013-03-06 2013-03-04 4 RPRX REPROS THERAPEUTICS INC.
Put option (right to sell) P - Purchase 1,000 64,000 1.59 1.94 1,945 124,480

2013-03-06 2013-03-04 4 AEGR Aegerion Pharmaceuticals, Inc.
Call option (right to buy) P - Purchase 1,000 2,000 100.00 8.26 8,260 16,520

2013-03-06 2013-03-04 4 AEGR Aegerion Pharmaceuticals, Inc.
Call option (right to buy) P - Purchase 1,000 2,000 100.00 8.26 8,260 16,520

2013-02-27 2013-02-25 4 RPRX REPROS THERAPEUTICS INC.
Put option (right to sell) P - Purchase 500 63,000 0.80 0.90 450 56,700

2013-02-27 2013-02-25 4 RPRX REPROS THERAPEUTICS INC.
Call option (obligation to sell) S - Sale -500 62,500 -0.79 1.05 -525 65,625

2013-02-21 2013-02-20 4 RPRX REPROS THERAPEUTICS INC.
Put option (right to sell) P - Purchase 500 62,000 0.81 0.78 390 48,360

2013-02-21 2013-02-20 4 RPRX REPROS THERAPEUTICS INC.
Call option (obligation to sell) S - Sale -500 61,500 -0.81 1.04 -520 63,960

2013-02-21 2013-02-19 4 RPRX REPROS THERAPEUTICS INC.
Put option (right to sell) P - Purchase 1,000 61,000 1.67 0.79 790 48,190

2013-02-21 2013-02-19 4 RPRX REPROS THERAPEUTICS INC.
Call option (obligation to sell) S - Sale -1,000 60,000 -1.64 0.89 -890 53,400

2013-02-13 2013-02-11 4 RPRX REPROS THERAPEUTICS INC.
Put option (right to sell) P - Purchase 1,000 59,000 1.72 2.08 2,080 122,720

2013-02-13 2013-02-11 4 RPRX REPROS THERAPEUTICS INC.
Call option (obligation to sell) S - Sale -1,000 58,000 -1.69 0.38 -380 22,040

2013-02-08 2013-02-07 4 RPRX REPROS THERAPEUTICS INC.
Put option (right to sell) P - Purchase 1,500 57,000 2.70 2.33 3,495 132,810

2013-02-08 2013-02-07 4 RPRX REPROS THERAPEUTICS INC.
Call option (obligation to sell) S - Sale -1,500 55,500 -2.63 0.27 -405 14,985

2013-02-08 2013-02-06 4 RPRX REPROS THERAPEUTICS INC.
Put option (right to sell) P - Purchase 4,000 54,000 8.00 1.65 6,600 89,100

2013-02-08 2013-02-06 4 RPRX REPROS THERAPEUTICS INC.
Call option (obligation to sell) S - Sale -2,000 50,000 -3.85 0.55 -1,100 27,500

2013-02-06 2013-02-05 4 RPRX REPROS THERAPEUTICS INC.
Call option (obligation to sell) S - Sale -6,000 48,000 -11.11 0.69 -4,140 33,120

2013-02-06 2013-02-04 4 RPRX REPROS THERAPEUTICS INC.
Call option (obligation to sell) S - Sale -500 42,000 -1.18 2.05 -1,025 86,100

2013-02-05 2013-02-01 4 AEGR Aegerion Pharmaceuticals, Inc.
Common Stock P - Purchase 50,000 3,373,426 1.50 27.79 1,389,400 93,740,762

2013-02-04 2013-02-01 4 RPRX REPROS THERAPEUTICS INC.
Call option (obligation to sell) S - Sale -1,000 41,500 -2.35 0.80 -800 33,200

2013-02-01 2013-01-31 4 RPRX REPROS THERAPEUTICS INC.
Put option (right to sell) P - Purchase 1,000 40,500 2.53 1.45 1,450 58,725

2013-02-01 2013-01-31 4 RPRX REPROS THERAPEUTICS INC.
Call option (obligation to sell) S - Sale -1,000 39,500 -2.47 0.88 -875 34,562

2013-02-01 2013-01-30 4 RPRX REPROS THERAPEUTICS INC.
Put option (right to sell) P - Purchase 2,000 38,500 5.48 1.32 2,650 51,012

2013-02-01 2013-01-30 4 RPRX REPROS THERAPEUTICS INC.
Call option (obligation to sell) S - Sale -2,000 36,500 -5.19 1.05 -2,100 38,325

2013-01-30 2013-01-29 4 RPRX REPROS THERAPEUTICS INC.
Put option (right to sell) P - Purchase 4,000 34,500 13.11 1.71 6,840 58,995

2013-01-30 2013-01-29 4 RPRX REPROS THERAPEUTICS INC.
Call option (right to buy) P - Purchase 500 30,500 1.67 0.05 25 1,525

2013-01-30 2013-01-29 4 RPRX REPROS THERAPEUTICS INC.
Call option (right to buy) P - Purchase 500 30,000 1.69 0.10 50 3,000

2013-01-30 2013-01-29 4 RPRX REPROS THERAPEUTICS INC.
Call option (obligation to sell) S - Sale -4,000 29,500 -11.94 0.80 -3,200 23,600

2013-01-30 2013-01-28 4 RPRX REPROS THERAPEUTICS INC.
Put option (right to sell) P - Purchase 2,000 25,500 8.51 1.50 3,000 38,250

2013-01-30 2013-01-28 4 RPRX REPROS THERAPEUTICS INC.
Put option (right to sell) P - Purchase 2,000 23,500 9.30 1.85 3,700 43,475

2013-01-30 2013-01-28 4 RPRX REPROS THERAPEUTICS INC.
Put option (right to sell) P - Purchase 2,000 21,500 10.26 0.65 1,300 13,979

2013-01-30 2013-01-28 4 RPRX REPROS THERAPEUTICS INC.
Put option (right to sell) P - Purchase 1,500 19,500 8.33 2.87 4,300 55,901

2013-01-30 2013-01-28 4 RPRX REPROS THERAPEUTICS INC.
Put option (right to sell) P - Purchase 1,000 18,000 5.88 0.80 800 14,400

2013-01-30 2013-01-28 4 RPRX REPROS THERAPEUTICS INC.
Call option (obligation to sell) S - Sale -1,000 17,000 -5.56 1.19 -1,190 20,230

2013-01-30 2013-01-28 4 RPRX REPROS THERAPEUTICS INC.
Call option (obligation to sell) S - Sale -1,000 16,000 -5.88 2.43 -2,428 38,846

2013-01-30 2013-01-28 4 RPRX REPROS THERAPEUTICS INC.
Call option (obligation to sell) S - Sale -1,000 15,000 -6.25 0.80 -800 12,000

2013-01-30 2013-01-28 4 RPRX REPROS THERAPEUTICS INC.
Call option (obligation to sell) S - Sale -2,000 14,000 -12.50 1.47 -2,935 20,545

2013-01-30 2013-01-28 4 RPRX REPROS THERAPEUTICS INC.
Call option (obligation to sell) S - Sale -2,000 12,000 -14.29 1.00 -2,001 12,004

2013-01-30 2013-01-28 4 RPRX REPROS THERAPEUTICS INC.
Call option (obligation to sell) S - Sale -2,000 10,000 -16.67 0.88 -1,757 8,787

2013-01-23 2013-01-22 4 RPRX REPROS THERAPEUTICS INC.
Call option (obligation to sell) S - Sale -500 8,000 -5.88 0.80 -400 6,400

2013-01-23 2013-01-22 4 RPRX REPROS THERAPEUTICS INC.
Call option (obligation to sell) S - Sale -500 7,500 -6.25 1.40 -702 10,531

2013-01-22 2013-01-18 4 AEGR Aegerion Pharmaceuticals, Inc.
Common Stock P - Purchase 50,000 3,323,426 1.53 27.62 1,381,000 91,793,026

2013-01-18 2013-01-17 4 AEGR Aegerion Pharmaceuticals, Inc.
Common Stock P - Purchase 25,000 3,273,426 0.77 26.73 668,142 87,484,601

2013-01-18 2013-01-17 4 AEGR Aegerion Pharmaceuticals, Inc.
Common Stock P - Purchase 25,000 3,273,426 0.77 26.73 668,142 87,484,601

2013-01-15 2013-01-11 4 AEGR Aegerion Pharmaceuticals, Inc.
Common Stock P - Purchase 150,000 3,223,426 4.88 26.64 3,996,000 85,872,069

2013-01-15 2013-01-11 4 AEGR Aegerion Pharmaceuticals, Inc.
Common Stock P - Purchase 200,000 3,073,426 6.96 27.66 5,531,220 84,998,977

2013-01-15 2013-01-11 4 AEGR Aegerion Pharmaceuticals, Inc.
Common Stock P - Purchase 125,000 2,873,426 4.55 26.64 3,330,000 76,548,069

2013-01-11 2013-01-10 4 RPRX REPROS THERAPEUTICS INC.
Call option (obligation to sell) S - Sale -2,000 7,000 -22.22 1.89 -3,780 13,230

2013-01-04 2013-01-04 4 RPRX REPROS THERAPEUTICS INC.
Call option (obligation to sell) S - Sale -1,000 5,000 -16.67 1.20 -1,200 6,000

2013-01-04 2013-01-04 4 RPRX REPROS THERAPEUTICS INC.
Call option (obligation to sell) S - Sale -1,000 4,000 -20.00 1.91 -1,910 7,640

2013-01-04 2013-01-03 4 RPRX REPROS THERAPEUTICS INC.
Call option (obligation to sell) S - Sale -2,000 3,000 -40.00 1.35 -2,700 4,050

2013-01-04 2013-01-03 4 RPRX REPROS THERAPEUTICS INC.
Call option (obligation to sell) S - Sale -1,000 1,000 -50.00 2.01 -2,010 2,010

2012-12-13 3 ACRX ACELRX PHARMACEUTICALS INC
Common Stock 5,008,400

2012-12-05 2012-12-04 4 AEGR Aegerion Pharmaceuticals, Inc.
Common Stock P - Purchase 20,000 2,615,293 0.77 21.27 425,400 55,627,282

2012-12-03 2012-11-28 4 AEGR Aegerion Pharmaceuticals, Inc.
COMMON STOCK P - Purchase 70,000 2,565,293 2.81 21.76 1,523,200 55,820,776

2012-12-03 2012-11-21 4 AEGR Aegerion Pharmaceuticals, Inc.
COMMON STOCK P - Purchase 20,000 2,495,293 0.81 20.75 415,000 51,777,330

2012-12-03 2012-11-20 4 AEGR Aegerion Pharmaceuticals, Inc.
COMMON STOCK P - Purchase 20,000 2,475,293 0.81 21.01 420,200 52,005,906

2012-12-03 2012-11-15 4 AEGR Aegerion Pharmaceuticals, Inc.
COMMON STOCK P - Purchase 10,000 2,455,293 0.41 19.50 195,000 47,878,214

2012-12-03 2012-11-07 4 AEGR Aegerion Pharmaceuticals, Inc.
COMMON STOCK P - Purchase 30,000 2,445,293 1.24 21.12 633,600 51,644,588

2012-12-03 2012-11-29 4 AEGR Aegerion Pharmaceuticals, Inc.
COMMON STOCK P - Purchase 30,000 2,595,293 1.17 22.71 681,300 58,939,104

2012-12-03 2012-10-19 4 AEGR Aegerion Pharmaceuticals, Inc.
CALL OPTION (OBLIGATION TO SELL) X - Other -2,475 0 -100.00

2012-12-03 2012-10-19 4 AEGR Aegerion Pharmaceuticals, Inc.
COMMON STOCK X - Other -247,500 2,347,233 -9.54 17.50 -4,331,250 41,076,578

2012-12-03 3 AEGR Aegerion Pharmaceuticals, Inc.
COMMON STOCK 2,415,293

2012-12-03 3 AEGR Aegerion Pharmaceuticals, Inc.
COMMON STOCK 133,133

2012-12-03 3 AEGR Aegerion Pharmaceuticals, Inc.
COMMON STOCK 2,594,733

2012-12-03 3 AEGR Aegerion Pharmaceuticals, Inc.
COMMON STOCK 133,133

2012-05-15 2012-05-14 4 RPRX REPROS THERAPEUTICS INC.
Common Stock P - Purchase 59,500 2,862,560 2.12 7.38 439,283 21,133,994

2012-05-14 2012-05-11 4 RPRX REPROS THERAPEUTICS INC.
Common Stock P - Purchase 25,000 2,803,060 0.90 6.35 158,800 17,805,037

2012-05-14 2012-05-11 4 RPRX REPROS THERAPEUTICS INC.
Common Stock P - Purchase 145,000 2,778,060 5.51 6.35 921,040 17,646,237

2012-05-11 2012-05-10 4 RPRX REPROS THERAPEUTICS INC.
Common Stock P - Purchase 15,000 2,633,060 0.57 4.82 72,300 12,691,349

2012-05-11 2012-05-10 4 RPRX REPROS THERAPEUTICS INC.
Common Stock P - Purchase 310,000 2,618,060 13.43 4.82 1,493,797 12,615,646

2008-12-03 2008-11-19 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares S - Sale -9,600,000 20,580,260 -31.81 0.15 -1,466,880 3,144,664

2008-12-03 2008-11-18 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares S - Sale -299,570 0 -100.00 0.15 -45,774

2008-12-03 2008-11-18 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares S - Sale -400,000 299,570 -57.18 0.15 -61,120 45,774

2008-12-03 2008-11-18 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares S - Sale -1,943,250 699,570 -73.53 0.14 -273,804 98,569

2008-12-03 2008-11-18 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares S - Sale -400,000 2,642,820 -13.15 0.16 -64,560 426,551

2008-12-03 2008-11-18 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares S - Sale -29,740 3,042,820 -0.97 0.16 -4,729 483,808

2008-12-03 2008-11-18 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares S - Sale -2,696,450 30,180,260 -8.20 0.15 -412,018 4,611,544

2008-12-03 2008-11-18 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares S - Sale -24,681,360 32,876,710 -42.88 0.14 -3,477,604 4,632,328

2008-06-19 2008-06-10 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 2,040 3,072,560 0.07 3.23 6,589 9,924,369

2008-06-19 2008-06-10 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 48,960 57,558,070 0.09 3.23 158,141 185,912,566

2008-06-11 2008-06-09 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 1,340 3,070,520 0.04 3.36 4,502 10,316,947

2008-06-11 2008-06-09 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 32,260 57,509,110 0.06 3.36 108,394 193,230,610

2008-06-11 2008-06-06 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 4,000 3,069,180 0.13 3.43 13,720 10,527,287

2008-06-11 2008-06-06 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 96,000 57,476,850 0.17 3.43 329,280 197,145,596

2008-06-11 2008-06-05 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 8,000 3,065,180 0.26 3.15 25,200 9,655,317

2008-06-11 2008-06-05 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 4,000 3,057,180 0.13 3.37 13,480 10,302,697

2008-06-11 2008-06-05 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 192,000 57,380,850 0.34 3.15 604,800 180,749,678

2008-06-11 2008-06-05 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinarry Shares P - Purchase 96,000 57,188,850 0.17 3.37 323,520 192,726,424

2008-05-06 2008-05-02 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 2,000 3,036,140 0.07 3.88 7,760 11,780,223

2008-05-06 2008-05-02 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 48,000 56,683,890 0.08 3.88 186,240 219,933,493

2008-05-06 2008-05-01 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 4,200 3,034,140 0.14 3.75 15,750 11,378,025

2008-05-06 2008-05-01 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 100,800 56,635,890 0.18 3.75 378,000 212,384,588

2008-04-16 2008-04-10 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 10,000 3,015,650 0.33 3.56 35,579 10,729,381

2008-04-16 2008-04-10 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 90,000 56,191,770 0.16 3.58 322,011 201,048,534

2008-03-20 2008-03-18 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 6,650 2,984,350 0.22 3.12 20,749 9,311,769

2008-03-20 2008-03-18 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 156,350 55,797,070 0.28 3.12 487,843 174,098,018

2008-03-20 2008-03-14 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 12,000 2,977,700 0.40 3.32 39,856 9,889,835

2008-03-20 2008-03-14 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 15,780 2,965,700 0.53 3.33 52,566 9,879,340

2008-03-20 2008-03-14 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary shares P - Purchase 188,000 55,640,720 0.34 3.32 624,404 184,799,523

2008-03-20 2008-03-14 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary shares P - Purchase 247,220 55,452,720 0.45 3.33 823,539 184,724,101

2008-03-20 2008-03-13 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 6,000 2,949,920 0.20 3.37 20,240 9,950,965

2008-03-20 2008-03-13 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 8,820 2,943,920 0.30 3.38 29,814 9,951,333

2008-03-20 2008-03-12 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 9,000 2,935,100 0.31 3.37 30,295 9,879,840

2008-03-20 2008-03-12 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary shares P - Purchase 17,400 2,926,100 0.60 3.35 58,292 9,802,728

2008-03-19 2008-03-13 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 94,000 55,205,500 0.17 3.37 317,090 186,224,713

2008-03-19 2008-03-13 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 138,180 55,111,500 0.25 3.38 467,090 186,293,403

2008-03-19 2008-03-12 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 272,600 54,973,320 0.50 3.35 913,237 184,166,119

2008-03-19 2008-03-12 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 141,000 54,700,720 0.26 3.37 474,620 184,128,094

2008-03-19 2008-03-11 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 11,900 2,908,700 0.41 3.30 39,327 9,612,672

2008-03-19 2008-03-11 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 30,000 2,896,800 1.05 3.31 99,351 9,593,333

2008-03-19 2008-03-11 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 107,100 54,559,720 0.20 3.30 353,944 180,308,963

2008-03-19 2008-03-11 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 470,000 54,452,620 0.87 3.31 1,556,499 180,330,742

2008-03-19 2008-03-10 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 25,200 2,866,800 0.89 3.28 82,568 9,393,070

2008-03-19 2008-03-10 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 30,000 2,841,600 1.07 3.15 94,500 8,951,040

2008-03-19 2008-03-10 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 30,000 2,811,600 1.08 3.25 97,368 9,125,329

2008-03-19 2008-03-10 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 394,800 5,398,260 7.89 3.28 1,293,562 17,687,399

2008-03-19 2008-03-10 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 470,000 53,587,820 0.88 3.15 1,480,500 168,801,633

2008-03-19 2008-03-10 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 470,000 53,117,820 0.89 3.25 1,525,432 172,399,197

2008-03-19 2008-03-07 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 60,000 2,781,600 2.20 3.74 224,268 10,397,064

2008-03-19 2008-03-07 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 9,020 2,721,600 0.33 3.65 32,893 9,924,859

2008-03-19 2008-03-07 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 141,440 52,647,820 0.27 3.65 515,789 191,990,805

2008-03-19 2008-03-07 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 940,000 52,506,380 1.82 3.74 3,513,532 196,258,347

2008-03-19 2008-03-06 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 39,300 2,712,580 1.47 3.86 151,824 10,479,239

2008-03-19 2008-03-06 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 15,600 2,673,280 0.59 3.73 58,146 9,964,117

2008-03-19 2008-03-06 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 244,400 51,566,380 0.48 3.73 910,952 192,203,368

2008-03-19 2008-03-06 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 615,700 51,321,980 1.21 3.86 2,378,572 198,267,073

2008-03-10 2008-03-05 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 34,200 2,657,680 1.30 3.94 134,700 10,467,538

2008-03-10 2008-03-05 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 535,800 50,706,280 1.07 3.94 2,110,302 199,711,754

2008-03-10 2008-03-04 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 6,640 2,623,480 0.25 3.99 26,490 10,466,111

2008-03-10 2008-03-04 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 18,000 2,616,840 0.69 3.98 71,656 10,417,378

2008-03-10 2008-03-04 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 282,000 50,170,480 0.57 3.98 1,122,614 199,723,664

2008-03-10 2008-03-04 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 104,060 49,888,480 0.21 3.99 415,137 199,025,102

2008-02-29 2008-02-27 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 6,600 2,598,840 0.25 4.01 26,484 10,428,365

2008-02-29 2008-02-27 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 103,400 49,784,420 0.21 4.01 414,913 199,769,942

2008-02-28 2008-02-26 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 3,790 2,592,240 0.15 3.95 14,970 10,239,348

2008-02-28 2008-02-26 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 24,000 2,588,450 0.94 3.91 93,742 10,110,227

2008-02-28 2008-02-26 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 59,390 49,681,020 0.12 3.95 234,590 196,240,029

2008-02-28 2008-02-26 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 376,000 49,621,630 0.76 3.91 1,468,618 193,817,125

2008-02-28 2008-02-25 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 46,500 2,564,450 1.85 3.87 179,871 9,919,805

2008-02-28 2008-02-25 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 6,000 2,517,950 0.24 3.86 23,159 9,718,783

2008-02-28 2008-02-25 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 94,000 49,245,630 0.19 3.86 362,821 190,078,283

2008-02-28 2008-02-25 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 728,500 49,151,630 1.50 3.87 2,817,984 190,128,335

2008-02-28 2008-02-22 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 12,000 2,511,950 0.48 3.95 47,431 9,928,734

2008-02-28 2008-02-22 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 30,000 2,499,950 1.21 3.95 118,374 9,864,303

2008-02-28 2008-02-22 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 28,380 2,469,950 1.16 3.95 112,101 9,756,302

2008-02-28 2008-02-22 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 188,000 48,432,130 0.39 3.95 743,089 191,432,837

2008-02-28 2008-02-22 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 470,000 48,235,130 0.98 3.95 1,854,526 190,326,176

2008-02-28 2008-02-22 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 444,620 47,765,130 0.94 3.95 1,756,249 188,672,264

2008-02-22 2008-02-20 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 100 2,441,570 0.00 3.84 384 9,375,629

2008-02-22 2008-02-20 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 900 47,320,510 0.00 3.84 3,456 181,710,758

2008-02-19 2008-02-13 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 360 2,441,470 0.01 3.81 1,371 9,297,606

2008-02-19 2008-02-13 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 5,640 473,196,910 0.00 3.81 21,478 1,802,028,473

2008-02-08 2008-02-07 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary shares P - Purchase 600 3,441,110 0.02 3.40 2,038 11,686,010

2008-02-08 2008-02-07 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary shares P - Purchase 9,400 47,313,970 0.02 3.40 31,922 160,678,242

2008-02-08 2008-02-06 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 21,000 2,440,510 0.87 3.71 77,914 9,054,780

2008-02-08 2008-02-06 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 120 2,419,510 0.00 3.68 442 8,903,797

2008-02-08 2008-02-06 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 329,000 47,304,570 0.70 3.71 1,220,656 175,509,416

2008-02-08 2008-02-06 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary shares P - Purchase 1,880 46,975,570 0.00 3.68 6,918 172,870,098

2008-02-06 2008-02-05 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary shares P - Purchase 9,060 2,419,390 0.38 3.79 34,314 9,163,198

2008-02-06 2008-02-05 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary shares P - Purchase 6,060 2,410,330 0.25 3.75 22,725 9,038,738

2008-02-06 2008-02-05 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary shares P - Purchase 141,940 46,973,690 0.30 3.79 537,584 177,908,154

2008-02-06 2008-02-05 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary shares P - Purchase 94,940 46,831,750 0.20 3.75 356,025 175,619,062

2008-02-06 2008-02-04 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary shares P - Purchase 8,400 2,404,270 0.35 3.87 32,495 9,300,678

2008-02-06 2008-02-04 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary shares P - Purchase 33,000 2,320,270 1.44 3.88 128,056 9,003,808

2008-02-06 2008-02-04 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary shares P - Purchase 131,600 46,736,810 0.28 3.87 509,081 180,796,676

2008-02-06 2008-02-04 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary shares P - Purchase 517,000 46,605,210 1.12 3.88 2,006,218 180,851,517

2008-02-05 2008-02-01 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 42,000 2,322,870 1.84 3.69 155,022 8,573,713

2008-02-05 2008-02-01 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 658,000 46,088,210 1.45 3.69 2,428,678 170,111,583

2008-02-05 2008-01-31 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 30,000 2,320,870 1.31 3.43 102,987 7,967,315

2008-02-05 2008-01-31 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 23,640 2,290,870 1.04 3.50 82,723 8,016,441

2008-02-05 2008-01-31 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 470,000 45,430,210 1.05 3.43 1,613,463 155,957,368

2008-02-05 2008-01-31 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 370,360 44,960,210 0.83 3.50 1,296,001 157,329,263

2008-02-01 2008-01-30 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 15,000 2,267,230 0.67 3.23 48,456 7,324,060

2008-02-01 2008-01-30 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 235,000 44,589,850 0.53 3.23 759,144 144,043,051

2008-01-30 2008-01-29 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 6,000 2,252,230 0.27 3.23 19,379 7,274,252

2008-01-30 2008-01-29 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 94,000 44,354,850 0.21 3.23 303,601 143,257,295

2008-01-30 2008-01-28 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 600 2,246,230 0.03 3.23 1,938 7,255,323

2008-01-30 2008-01-28 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 40,200 2,245,630 1.82 3.21 129,203 7,217,455

2008-01-30 2008-01-28 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 9,400 44,260,850 0.02 3.23 30,362 142,962,546

2008-01-30 2008-01-28 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 629,800 44,251,450 1.44 3.21 2,024,177 142,224,160

2008-01-29 2008-01-25 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 12,000 2,205,430 0.55 3.24 38,856 7,141,182

2008-01-29 2008-01-25 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 188,000 43,621,650 0.43 3.24 608,744 141,246,903

2008-01-28 2008-01-24 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 42,300 2,193,430 1.97 2.99 126,477 6,558,356

2008-01-28 2008-01-24 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 13,800 2,151,130 0.65 2.98 41,124 6,410,367

2008-01-28 2008-01-24 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 66,270 43,433,650 0.15 2.99 198,147 129,866,614

2008-01-28 2008-01-24 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 216,200 42,770,950 0.51 2.98 644,276 127,457,431

2008-01-28 2008-01-23 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 18,000 2,137,330 0.85 2.88 51,908 6,163,632

2008-01-28 2008-01-23 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 282,000 42,554,750 0.67 2.88 813,232 122,719,388

2008-01-25 2008-01-22 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 790 2,119,330 0.04 2.90 2,293 6,151,355

2008-01-25 2008-01-22 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 12,520 42,272,750 0.03 2.90 36,339 122,696,657

2008-01-25 2008-01-18 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 7,560 2,118,540 0.36 3.16 23,888 6,694,163

2008-01-25 2008-01-18 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 11,820 2,110,980 0.56 3.13 36,994 6,606,945

2008-01-25 2008-01-18 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 118,440 42,260,230 0.28 3.16 374,247 133,533,875

2008-01-25 2008-01-18 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 185,180 42,141,790 0.44 3.13 579,576 131,895,374

2008-01-25 2008-01-17 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 11,460 2,099,160 0.55 3.01 34,444 6,309,235

2008-01-25 2008-01-17 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 9,240 2,087,700 0.44 3.06 28,240 6,380,638

2008-01-25 2008-01-17 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 144,760 41,956,610 0.35 3.06 442,430 128,231,987

2008-01-25 2008-01-17 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 179,540 41,811,850 0.43 3.01 539,625 125,669,696

2008-01-25 2008-01-16 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 27,600 2,078,460 1.35 3.06 84,346 6,351,774

2008-01-25 2008-01-16 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 180 2,008,860 0.01 3.16 568 6,341,368

2008-01-25 2008-01-16 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 432,400 41,632,310 1.05 3.10 1,340,440 129,060,161

2008-01-25 2008-01-16 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 2,820 41,199,910 0.01 3.16 8,902 130,055,756

2008-01-25 2008-01-15 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 42,000 2,050,680 2.09 3.11 130,712 6,382,126

2008-01-25 2008-01-15 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 15,000 2,008,680 0.75 3.06 45,909 6,147,766

2008-01-25 2008-01-15 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 658,000 41,197,090 1.62 3.11 2,047,828 128,213,583

2008-01-25 2008-01-15 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 235,000 40,539,090 0.58 3.06 719,241 124,073,939

2008-01-18 2008-01-16 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 27,600 2,078,460 1.35 3.10 85,560 6,443,226

2008-01-18 2008-01-16 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 180 2,050,860 0.01 3.16 568 6,473,950

2008-01-18 2008-01-16 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 432,400 41,632,310 1.05 3.10 1,340,440 129,060,161

2008-01-18 2008-01-16 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 2,820 41,199,910 0.01 3.16 8,902 130,055,756

2008-01-18 2008-01-15 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 42,000 2,050,680 2.09 3.11 130,712 6,382,126

2008-01-18 2008-01-15 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 15,000 2,008,680 0.75 3.06 45,909 6,147,766

2008-01-18 2008-01-15 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 658,000 41,197,090 1.62 3.11 2,047,828 128,213,583

2008-01-18 2008-01-15 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 235,000 40,539,000 0.58 3.06 719,241 124,073,663

2008-01-15 2008-01-14 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 22,200 1,993,680 1.13 3.41 75,724 6,800,442

2008-01-15 2008-01-14 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 347,800 40,304,090 0.87 3.41 1,186,346 137,477,251

2008-01-15 2008-01-11 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 28,320 1,971,480 1.46 3.39 96,076 6,688,246

2008-01-15 2008-01-11 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 443,680 39,956,290 1.12 3.39 1,505,184 135,551,714

2008-01-11 2008-01-10 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 69,000 1,943,160 3.68 3.30 227,748 6,413,788

2008-01-11 2008-01-10 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 1,081,000 39,521,610 2.81 3.30 3,568,057 130,448,978

2008-01-11 2008-01-09 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 36,000 1,874,160 1.96 3.27 117,896 6,137,687

2008-01-11 2008-01-09 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 24,060 1,838,160 1.33 3.30 79,283 6,057,105

2008-01-11 2008-01-09 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 564,000 37,431,610 1.53 3.27 1,847,044 122,584,780

2008-01-11 2008-01-09 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 376,940 37,867,610 1.01 3.30 1,242,093 124,781,348

2008-01-11 2008-01-08 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 30,000 1,814,100 1.68 3.26 97,743 5,910,519

2008-01-11 2008-01-07 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 20,000 1,784,100 1.13 2.87 57,372 5,117,869

2008-01-11 2008-01-07 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 81,600 1,764,100 4.85 3.11 253,401 5,478,236

2008-01-11 2008-01-07 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 6,000 1,682,500 0.36 3.10 18,600 5,215,750

2008-01-11 2008-01-07 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 1,278,400 37,020,670 3.58 3.11 3,969,943 114,963,989

2008-01-11 2008-01-07 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 94,000 35,742,270 0.26 3.10 291,400 110,801,037

2008-01-11 2008-01-07 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 180,000 35,648,270 0.51 2.87 516,348 102,260,627

2008-01-11 2007-01-08 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 470,000 37,490,670 1.27 3.26 1,531,307 122,148,352

2008-01-04 2008-01-02 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 1,222,000 35,045,270 3.61 2.89 3,531,580 101,280,830

2008-01-04 2007-01-02 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 78,000 1,649,500 4.96 2.89 225,420 4,767,055

2008-01-02 2007-12-31 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 69,000 1,571,500 4.59 2.74 188,750 4,298,838

2008-01-02 2007-12-31 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 1,081,000 33,823,270 3.30 2.74 2,957,076 92,523,555

2008-01-02 2007-12-28 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 48,000 1,502,500 3.30 2.69 129,226 4,045,030

2008-01-02 2007-12-28 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 752,000 32,742,270 2.35 2.69 2,024,534 88,148,739

2007-12-31 2007-12-27 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 18,000 1,454,500 1.25 2.60 46,717 3,775,009

2007-12-31 2007-12-27 4 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares P - Purchase 282,000 31,990,270 0.89 2.60 731,903 83,027,547

2007-12-31 3/A XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares 31,708,270

2007-12-07 3 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares 27,876,060

2007-12-07 3 XTLB XTL BIOPHARMACEUTICALS LTD
Ordinary Shares 1,436,500

2004-12-06 2004-12-03 4 BPA BIOSANTE PHARMACEUTICALS INC
Common Stock S - Sale -1,315,000 209,100 -86.28 4.72 -6,200,225 985,906

2004-12-06 2004-12-03 4 BPA BIOSANTE PHARMACEUTICALS INC
Common Stock S - Sale -50,000 1,524,100 -3.18 4.55 -227,500 6,934,655

2004-12-06 2004-12-03 4 BPA BIOSANTE PHARMACEUTICALS INC
Common Stock S - Sale -30,000 1,574,100 -1.87 4.35 -130,500 6,847,335

2004-12-06 2004-12-02 4 BPA BIOSANTE PHARMACEUTICALS INC
Common Stock S - Sale -273,550 1,604,100 -14.57 4.47 -1,222,221 7,167,119

2004-12-06 2004-12-02 4 BPA BIOSANTE PHARMACEUTICALS INC
Common Stock P - Purchase 2,000 1,877,650 0.11 3.98 7,960 7,473,047

2004-12-06 2004-12-02 4 BPA BIOSANTE PHARMACEUTICALS INC
Common Stock S - Sale -2,000 1,875,650 -0.11 4.47 -8,936 8,380,404

2004-12-06 2004-12-02 4 BPA BIOSANTE PHARMACEUTICALS INC
Common Stock S - Sale -25,000 1,877,650 -1.31 4.90 -122,500 9,200,485

2004-12-06 2004-12-02 4 BPA BIOSANTE PHARMACEUTICALS INC
Common Stock S - Sale -70,900 1,902,650 -3.59 4.47 -316,781 8,501,040

2004-12-06 2004-12-02 4 BPA BIOSANTE PHARMACEUTICALS INC
Common Stock S - Sale -28,550 0 -100.00 4.47 -127,561

2004-10-12 2004-10-08 4 BPA BIOSANTE PHARMACEUTICALS INC
Common Stock P - Purchase 14,900 1,973,550 0.76 9.87 146,991 19,469,465

2004-10-12 2004-10-08 4 BPA BIOSANTE PHARMACEUTICALS INC
Common Stock P - Purchase 1,000 27,950 3.71 9.87 9,865 275,732

2004-10-08 2004-10-07 4 BPA BIOSANTE PHARMACEUTICALS INC
Common Stock P - Purchase 9,000 1,958,650 0.46 10.11 90,964 19,796,271

2004-10-08 2004-10-07 4 BPA BIOSANTE PHARMACEUTICALS INC
Common Stock P - Purchase 1,000 26,950 3.85 10.11 10,107 272,386

2004-10-08 2004-10-06 4 BPA BIOSANTE PHARMACEUTICALS INC
Common Stock P - Purchase 9,000 1,949,650 0.46 9.90 89,112 19,304,070

2004-10-08 2004-10-06 4 BPA BIOSANTE PHARMACEUTICALS INC
Common Stock P - Purchase 1,000 25,950 4.01 9.90 9,901 256,939

2004-10-06 2004-10-05 4 BPA BIOSANTE PHARMACEUTICALS INC
Common Stock P - Purchase 15,800 1,940,650 0.82 9.90 156,417 19,212,047

2004-10-06 2004-10-05 4 BPA BIOSANTE PHARMACEUTICALS INC
Common Stock P - Purchase 1,700 24,950 7.31 9.90 16,830 247,000

2004-10-06 2004-10-04 4 BPA BIOSANTE PHARMACEUTICALS INC
Common Stock P - Purchase 13,100 1,924,850 0.69 9.72 127,341 18,710,889

2004-10-06 2004-10-04 4 BPA BIOSANTE PHARMACEUTICALS INC
Common Stock P - Purchase 1,400 23,250 6.41 9.72 13,609 226,006

2004-10-04 2004-10-01 4 BPA BIOSANTE PHARMACEUTICALS INC
Common Stock P - Purchase 19,400 1,911,750 1.03 9.59 186,046 18,333,682

2004-10-04 2004-10-01 4 BPA BIOSANTE PHARMACEUTICALS INC
Common Stock P - Purchase 2,100 21,850 10.63 9.59 20,139 209,542

2004-10-04 2004-09-30 4 BPA BIOSANTE PHARMACEUTICALS INC
Common Stock P - Purchase 9,000 1,892,350 0.48 8.96 80,680 16,963,972

2004-10-04 2004-09-30 4 BPA BIOSANTE PHARMACEUTICALS INC
Common Stock P - Purchase 1,000 19,750 5.33 8.96 8,964 177,049

2004-09-16 2004-09-14 4 BPA BIOSANTE PHARMACEUTICALS INC
Common Stock P - Purchase 22,100 1,883,350 1.19 7.69 169,843 14,473,921

2004-09-16 2004-09-14 4 BPA BIOSANTE PHARMACEUTICALS INC
Common Stock P - Purchase 2,400 18,750 14.68 7.69 18,444 144,098

2004-09-15 2004-09-13 4 BPA BIOSANTE PHARMACEUTICALS INC
Common Stock P - Purchase 23,400 1,861,250 1.27 7.17 167,734 13,341,626

2004-09-15 2004-09-13 4 BPA BIOSANTE PHARMACEUTICALS INC
Common Stock P - Purchase 2,500 16,350 18.05 7.17 17,920 117,198

2004-09-13 2004-09-09 4 BPA BIOSANTE PHARMACEUTICALS INC
Common Stock P - Purchase 4,300 1,837,850 0.23 6.85 29,455 12,589,272

2004-09-13 2004-09-09 4 BPA BIOSANTE PHARMACEUTICALS INC
Common Stock P - Purchase 400 13,850 2.97 6.85 2,740 94,872

2004-09-01 2004-08-31 4 BPA BIOSANTE PHARMACEUTICALS INC
Common Stock P - Purchase 9,000 1,833,550 0.49 6.84 61,563 12,542,032

2004-09-01 2004-08-30 4 BPA BIOSANTE PHARMACEUTICALS INC
Common Stock P - Purchase 9,000 1,824,550 0.50 6.84 61,537 12,475,178

2004-09-01 2004-08-30 4 BPA BIOSANTE PHARMACEUTICALS INC
Common Stock P - Purchase 1,000 13,450 8.03 6.84 6,837 91,963

2004-08-20 2004-08-19 4 BPA BIOSANTE PHARMACEUTICALS INC
Common Stock P - Purchase 700 12,450 5.96 5.84 4,091 72,765

2004-08-20 2004-08-19 4 BPA BIOSANTE PHARMACEUTICALS INC
Common Stock P - Purchase 6,200 1,815,550 0.34 5.84 36,237 10,611,164

2004-08-20 2004-08-18 4 BPA BIOSANTE PHARMACEUTICALS INC
Common Stock P - Purchase 4,500 11,750 62.07 5.83 26,214 68,447

2004-08-20 2004-08-18 4 BPA BIOSANTE PHARMACEUTICALS INC
Common Stock P - Purchase 40,500 1,809,350 2.29 5.83 235,925 10,540,007

2004-08-19 2004-08-16 4 BPA BIOSANTE PHARMACEUTICALS INC
Common Stock S - Sale -200 7,250 -2.68 5.50 -1,100 39,875

2004-08-19 2004-08-16 4 BPA BIOSANTE PHARMACEUTICALS INC
Common Stock P - Purchase 200 7,450 2.76 5.10 1,020 37,995

2004-08-16 2004-08-12 4 BPA BIOSANTE PHARMACEUTICALS INC
Common Stock P - Purchase 2,500 1,768,850 0.14 4.75 11,875 8,402,038

2004-08-13 2004-08-11 4 BPA BIOSANTE PHARMACEUTICALS INC
Common Stock P - Purchase 2,300 7,250 46.46 4.72 10,850 34,202

2004-08-13 2004-08-11 4 BPA BIOSANTE PHARMACEUTICALS INC
Common Stock P - Purchase 21,300 1,766,350 1.22 4.72 100,483 8,332,756

2004-07-21 2004-07-19 4 BPA BIOSANTE PHARMACEUTICALS INC
Common Stock P - Purchase 2,800 4,950 130.23 5.67 15,889 28,090

2004-07-21 2004-07-19 4 BPA BIOSANTE PHARMACEUTICALS INC
Common Stock P - Purchase 25,652 1,745,050 1.49 5.67 145,567 9,902,635

2004-07-19 2004-07-16 4 BPA BIOSANTE PHARMACEUTICALS INC
Common Stock P - Purchase 1,400 2,150 186.67 5.89 8,242 12,657

2004-07-19 2004-07-16 4 BPA BIOSANTE PHARMACEUTICALS INC
Common Stock P - Purchase 12,648 1,719,398 0.74 5.89 74,468 10,123,300

2004-07-19 2004-07-15 4 BPA BIOSANTE PHARMACEUTICALS INC
Common Stock P - Purchase 750 750 5.96 4,472 4,472

2004-07-19 2004-07-15 4 BPA BIOSANTE PHARMACEUTICALS INC
Common Stock P - Purchase 6,750 1,706,750 0.40 5.96 40,252 10,177,862

2004-05-18 2004-05-14 4/A BPA BIOSANTE PHARMACEUTICALS INC
Warrants P - Purchase 97,500 97,500

2004-05-18 2004-05-14 4/A BPA BIOSANTE PHARMACEUTICALS INC
Common Stock P - Purchase 650,000 1,700,000 61.90 6.00 3,900,000 10,200,000

2004-05-12 2004-05-11 4 BPA BIOSANTE PHARMACEUTICALS INC
Common Stock P - Purchase 650,000 1,700,000 61.90 6.00 3,900,000 10,200,000

2004-02-12 3 ANTR.OB ANTARES PHARMA INC
Common Stock, $0.01 par value per share 2,700,000

2004-02-05 2004-02-03 4 BPA BIOSANTE PHARMACEUTICALS INC
Common Stock S - Sale -87,400 1,050,000 -7.68 6.44 -562,576 6,758,640

2004-01-23 2004-01-23 4 BPA BIOSANTE PHARMACEUTICALS INC
Common Stock S - Sale -35,000 1,137,400 -2.99 5.62 -196,700 6,392,188

2004-01-23 2004-01-22 4 BPA BIOSANTE PHARMACEUTICALS INC
Common Stock S - Sale -100,000 1,172,400 -7.86 5.68 -568,000 6,659,232

2004-01-23 2004-01-21 4 BPA BIOSANTE PHARMACEUTICALS INC
Common Stock S - Sale -5,000 1,272,400 -0.39 5.65 -28,250 7,189,060

2004-01-23 2004-01-21 4 BPA BIOSANTE PHARMACEUTICALS INC
Common Stock S - Sale -15,000 1,277,400 -1.16 5.84 -87,600 7,460,016

2004-01-23 2004-01-21 4 BPA BIOSANTE PHARMACEUTICALS INC
Common Stock S - Sale -100,000 1,292,400 -7.18 5.66 -566,000 7,314,984

2003-08-13 3 BISP.OB BIOSANTE PHARMACEUTICALS INC
Common Stock, par value $0.0001 225,000

2003-08-13 3 BISP.OB BIOSANTE PHARMACEUTICALS INC
Common Stock, par value $0.0001 1,392,400

P

Compra de mercado aberto ou privada de ativo não-derivativo ou derivativo

S

Venda de mercado aberto ou privada de ativo não-derivativo ou derivativo

A

Concessão, premiação, ou outra aquisição de ativos da empresa (como uma opção)

C

Conversão de derivativo

D

Venda ou transferência de ativos de volta para a empresa

F

Pagamento do preço de exercício ou responsabilidade fiscal utilizando parte dos ativos recebidos da empresa

G

Doação de ativos pelo ou para o insider

K

Swaps de capital e transações de hedge similares

M

Exercício ou conversão de ativo derivativo recebido da empresa (como uma opção)

V

Uma transação voluntariamente reportada no Formulário 4

J

Outro (acompanhado de uma nota explicativa descrevendo a transação)

Data de Negociação	Ticker	Insider	Ações Reportadas	Preço Reportado	Ações Ajustadas	Preço Ajustado	Base de Custos	Dias para Mín	Preço em Mín	Máxima Perda Evitada ($)	Máxima Perda Evitada (%)
2025-05-01	ACRV	PERCEPTIVE ADVISORS LLC	298,886	1.3400	298,886	1.3400	400,507	29	1.0500	-86,677	-21.64
2025-04-30	ACRV	PERCEPTIVE ADVISORS LLC	437,881	1.4100	437,881	1.4100	617,412
2025-04-29	ACRV	PERCEPTIVE ADVISORS LLC	250,000	1.4100	250,000	1.4100	352,500
2025-04-28	ACRV	PERCEPTIVE ADVISORS LLC	215,283	1.5600	215,283	1.5600	335,841
2025-04-25	ACRV	PERCEPTIVE ADVISORS LLC	1,054,669	1.9500	1,054,669	1.9500	2,056,605

Data de Negociação	Ticker	Insider	Ações Reportadas	Preço Reportado	Ações Ajustadas	Preço Ajustado	Base de Custos	Dias para Máx	Preço em Máx	Lucro Máx ($)	Retorno Máx (%)
2020-03-19	ADMA	PERCEPTIVE ADVISORS LLC	500,000	2.1000	500,000	2.1000	1,050,000	133	3.7400	820,000	78.10
2020-02-11	ADMA	PERCEPTIVE ADVISORS LLC	4,563,700	3.5000	4,563,700	3.5000	15,972,950
2019-05-21	ADMA	PERCEPTIVE ADVISORS LLC	4,000,000	4.0000	4,000,000	4.0000	16,000,000

Data de Negociação	Ticker	Insider	Ações Reportadas	Preço Reportado	Ações Ajustadas	Preço Ajustado	Base de Custos	Dias para Mín	Preço em Mín	Máxima Perda Evitada ($)	Máxima Perda Evitada (%)
2021-09-30	ADMA	PERCEPTIVE ADVISORS LLC	137,495	1.1200	137,495	1.1200	153,994	11	1.09	-4,124	-2.68
2021-09-29	ADMA	PERCEPTIVE ADVISORS LLC	82,505	1.1600	82,505	1.1600	95,706
2021-09-28	ADMA	PERCEPTIVE ADVISORS LLC	40,603	1.2200	40,603	1.2200	49,536
2021-09-27	ADMA	PERCEPTIVE ADVISORS LLC	250,000	1.2300	250,000	1.2300	307,500
2021-09-24	ADMA	PERCEPTIVE ADVISORS LLC	250,000	1.2600	250,000	1.2600	315,000
2021-09-23	ADMA	PERCEPTIVE ADVISORS LLC	780,000	1.2700	780,000	1.2700	990,600
2021-08-19	ADMA	PERCEPTIVE ADVISORS LLC	350,352	1.2400	350,352	1.2400	434,436
2021-08-18	ADMA	PERCEPTIVE ADVISORS LLC	552,380	1.2900	552,380	1.2900	712,570
2021-08-17	ADMA	PERCEPTIVE ADVISORS LLC	879,092	1.3500	879,092	1.3500	1,186,774

Data de Negociação	Ticker	Insider	Ações Reportadas	Preço Reportado	Ações Ajustadas	Preço Ajustado	Base de Custos	Dias para Máx	Preço em Máx	Lucro Máx ($)	Retorno Máx (%)
2024-04-05	ALDX	PERCEPTIVE ADVISORS LLC	37,712	4.7400	37,712	4.7400	178,755	341	6.9800	84,476	47.26
2024-04-04	ALDX	PERCEPTIVE ADVISORS LLC	140,281	4.6700	140,281	4.6700	655,112
2024-04-03	ALDX	PERCEPTIVE ADVISORS LLC	309,847	4.0900	309,847	4.0900	1,267,274
2024-04-02	ALDX	PERCEPTIVE ADVISORS LLC	186,051	3.4400	186,051	3.4400	640,015
2024-04-01	ALDX	PERCEPTIVE ADVISORS LLC	8,374	3.2500	8,374	3.2500	27,216
2022-08-10	ALDX	PERCEPTIVE ADVISORS LLC	15,000	7.8500	15,000	7.8500	117,750
2022-08-09	ALDX	PERCEPTIVE ADVISORS LLC	100,000	7.5000	100,000	7.5000	750,000
2022-08-08	ALDX	PERCEPTIVE ADVISORS LLC	97,000	7.2400	97,000	7.2400	702,280
2022-08-05	ALDX	PERCEPTIVE ADVISORS LLC	141,000	6.9500	141,000	6.9500	979,950
2022-08-04	ALDX	PERCEPTIVE ADVISORS LLC	95,100	6.1700	95,100	6.1700	586,767
2022-08-03	ALDX	PERCEPTIVE ADVISORS LLC	100,000	5.8400	100,000	5.8400	584,000
2022-08-02	ALDX	PERCEPTIVE ADVISORS LLC	412,406	5.5900	412,406	5.5900	2,305,350
2022-08-01	ALDX	PERCEPTIVE ADVISORS LLC	144,185	5.0500	144,185	5.0500	728,134
2022-07-29	ALDX	PERCEPTIVE ADVISORS LLC	222,123	5.0300	222,123	5.0300	1,117,279
2022-07-28	ALDX	PERCEPTIVE ADVISORS LLC	119,392	5.0000	119,392	5.0000	596,960
2021-05-03	ALDX	PERCEPTIVE ADVISORS LLC	1,200,000	12.5000	1,200,000	12.5000	15,000,000
2021-01-19	ALDX	PERCEPTIVE ADVISORS LLC	1,368,421	9.5000	1,368,421	9.5000	13,000,000
2021-01-08	ALDX	PERCEPTIVE ADVISORS LLC	347,332	9.2100	347,332	9.2100	3,198,928
2021-01-08	ALDX	PERCEPTIVE ADVISORS LLC	152,668	10.2100	152,668	10.2100	1,558,740
2021-01-08	ALDX	PERCEPTIVE ADVISORS LLC	50,000	7.6000	50,000	7.6000	380,000
2021-01-07	ALDX	PERCEPTIVE ADVISORS LLC	500,000	8.1300	500,000	8.1300	4,065,000
2020-07-09	ALDX	PERCEPTIVE ADVISORS LLC	3,200,000	4.2500	3,200,000	4.2500	13,600,000
2017-09-19	ALDX	PERCEPTIVE ADVISORS LLC	200,000	7.2500	200,000	7.2500	1,450,000
2017-06-30	ALDX	PERCEPTIVE ADVISORS LLC	296,007	4.6000	296,007	4.6000	1,361,632
2017-02-14	ALDX	PERCEPTIVE ADVISORS LLC	893,025	4.5000	893,025	4.5000	4,018,612
2016-05-26	ALDX	PERCEPTIVE ADVISORS LLC	700,000	5.0000	700,000	5.0000	3,500,000
2015-10-28	ALDX	PERCEPTIVE ADVISORS LLC	45,100	6.5000	45,100	6.5000	293,150
2015-10-26	ALDX	PERCEPTIVE ADVISORS LLC	50,000	6.4630	50,000	6.4630	323,150
2015-10-22	ALDX	PERCEPTIVE ADVISORS LLC	18,020	6.4740	18,020	6.4740	116,661
2015-10-20	ALDX	PERCEPTIVE ADVISORS LLC	14,348	6.2960	14,348	6.2960	90,335
2015-10-20	ALDX	PERCEPTIVE ADVISORS LLC	22,797	6.4420	22,797	6.4420	146,858

Data de Negociação	Ticker	Insider	Ações Reportadas	Preço Reportado	Ações Ajustadas	Preço Ajustado	Base de Custos	Dias para Mín	Preço em Mín	Máxima Perda Evitada ($)	Máxima Perda Evitada (%)
2025-04-03	ALDX	PERCEPTIVE ADVISORS LLC	3,400,000	1.4200	3,400,000	1.4200	4,828,000	348	1.2400	-612,000	-12.68
2023-10-18	ALDX	PERCEPTIVE ADVISORS LLC	306,499	1.7400	306,499	1.7400	533,308
2023-10-16	ALDX	PERCEPTIVE ADVISORS LLC	2,450,000	1.6000	2,450,000	1.6000	3,920,000

Data de Negociação	Ticker	Insider	Ações Reportadas	Preço Reportado	Ações Ajustadas	Preço Ajustado	Base de Custos	Dias para Máx
2004-12-02	BPA	EDELMAN JOSEPH	2,000	3.9800	2,000	3.9800	7,960	730
2004-10-08	BPA	EDELMAN JOSEPH	1,000	9.8652	1,000	9.8652	9,865
2004-10-08	BPA	EDELMAN JOSEPH	14,900	9.8652	14,900	9.8652	146,991
2004-10-07	BPA	EDELMAN JOSEPH	1,000	10.1071	1,000	10.1071	10,107
2004-10-07	BPA	EDELMAN JOSEPH	9,000	10.1071	9,000	10.1071	90,964
2004-10-06	BPA	EDELMAN JOSEPH	1,000	9.9013	1,000	9.9013	9,901
2004-10-06	BPA	EDELMAN JOSEPH	9,000	9.9013	9,000	9.9013	89,112
2004-10-05	BPA	EDELMAN JOSEPH	1,700	9.8998	1,700	9.8998	16,830
2004-10-05	BPA	EDELMAN JOSEPH	15,800	9.8998	15,800	9.8998	156,417
2004-10-04	BPA	EDELMAN JOSEPH	1,400	9.7207	1,400	9.7207	13,609
2004-10-04	BPA	EDELMAN JOSEPH	13,100	9.7207	13,100	9.7207	127,341
2004-10-01	BPA	EDELMAN JOSEPH	2,100	9.5900	2,100	9.5900	20,139
2004-10-01	BPA	EDELMAN JOSEPH	19,400	9.5900	19,400	9.5900	186,046
2004-09-30	BPA	EDELMAN JOSEPH	1,000	8.9645	1,000	8.9645	8,964
2004-09-30	BPA	EDELMAN JOSEPH	9,000	8.9645	9,000	8.9645	80,680
2004-09-14	BPA	EDELMAN JOSEPH	2,400	7.6852	2,400	7.6852	18,444
2004-09-14	BPA	EDELMAN JOSEPH	22,100	7.6852	22,100	7.6852	169,843
2004-09-13	BPA	EDELMAN JOSEPH	2,500	7.1681	2,500	7.1681	17,920
2004-09-13	BPA	EDELMAN JOSEPH	23,400	7.1681	23,400	7.1681	167,734
2004-09-09	BPA	EDELMAN JOSEPH	400	6.8500	400	6.8500	2,740
2004-09-09	BPA	EDELMAN JOSEPH	4,300	6.8500	4,300	6.8500	29,455
2004-08-31	BPA	EDELMAN JOSEPH	9,000	6.8403	9,000	6.8403	61,563
2004-08-30	BPA	EDELMAN JOSEPH	1,000	6.8374	1,000	6.8374	6,837
2004-08-30	BPA	EDELMAN JOSEPH	9,000	6.8374	9,000	6.8374	61,537
2004-08-19	BPA	EDELMAN JOSEPH	6,200	5.8446	6,200	5.8446	36,237
2004-08-19	BPA	EDELMAN JOSEPH	700	5.8446	700	5.8446	4,091
2004-08-18	BPA	EDELMAN JOSEPH	40,500	5.8253	40,500	5.8253	235,925
2004-08-18	BPA	EDELMAN JOSEPH	4,500	5.8253	4,500	5.8253	26,214
2004-08-16	BPA	EDELMAN JOSEPH	200	5.1000	200	5.1000	1,020
2004-08-12	BPA	EDELMAN JOSEPH	2,500	4.7500	2,500	4.7500	11,875
2004-08-11	BPA	EDELMAN JOSEPH	21,300	4.7175	21,300	4.7175	100,483
2004-08-11	BPA	EDELMAN JOSEPH	2,300	4.7175	2,300	4.7175	10,850
2004-07-19	BPA	EDELMAN JOSEPH	25,652	5.6747	25,652	5.6747	145,567
2004-07-19	BPA	EDELMAN JOSEPH	2,800	5.6747	2,800	5.6747	15,889
2004-07-16	BPA	EDELMAN JOSEPH	12,648	5.8877	12,648	5.8877	74,468
2004-07-16	BPA	EDELMAN JOSEPH	1,400	5.8870	1,400	5.8870	8,242
2004-07-15	BPA	EDELMAN JOSEPH	6,750	5.9633	6,750	5.9633	40,252
2004-07-15	BPA	EDELMAN JOSEPH	750	5.9633	750	5.9633	4,472
2004-05-14	BPA	EDELMAN JOSEPH	650,000	6.0000	650,000	6.0000	3,900,000

Data de Negociação	Ticker	Insider	Ações Reportadas	Preço Reportado	Ações Ajustadas	Preço Ajustado	Base de Custos	Dias para Mín
2004-12-03	BPA	EDELMAN JOSEPH	30,000	4.3500	30,000	4.3500	130,500	730
2004-12-03	BPA	EDELMAN JOSEPH	50,000	4.5500	50,000	4.5500	227,500
2004-12-03	BPA	EDELMAN JOSEPH	1,315,000	4.7150	1,315,000	4.7150	6,200,225
2004-12-02	BPA	EDELMAN JOSEPH	28,550	4.4680	28,550	4.4680	127,561
2004-12-02	BPA	EDELMAN JOSEPH	70,900	4.4680	70,900	4.4680	316,781
2004-12-02	BPA	EDELMAN JOSEPH	25,000	4.9000	25,000	4.9000	122,500
2004-12-02	BPA	EDELMAN JOSEPH	2,000	4.4680	2,000	4.4680	8,936
2004-12-02	BPA	EDELMAN JOSEPH	273,550	4.4680	273,550	4.4680	1,222,221
2004-08-16	BPA	EDELMAN JOSEPH	200	5.5000	200	5.5000	1,100
2004-02-03	BPA	EDELMAN JOSEPH	87,400	6.4368	87,400	6.4368	562,576
2004-01-23	BPA	EDELMAN JOSEPH	35,000	5.6200	35,000	5.6200	196,700
2004-01-22	BPA	EDELMAN JOSEPH	100,000	5.6800	100,000	5.6800	568,000
2004-01-21	BPA	EDELMAN JOSEPH	100,000	5.6600	100,000	5.6600	566,000
2004-01-21	BPA	EDELMAN JOSEPH	15,000	5.8400	15,000	5.8400	87,600
2004-01-21	BPA	EDELMAN JOSEPH	5,000	5.6500	5,000	5.6500	28,250

Data de Negociação	Ticker	Insider	Ações Reportadas	Preço Reportado	Ações Ajustadas	Preço Ajustado	Base de Custos	Dias para Máx	Preço em Máx	Lucro Máx ($)	Retorno Máx (%)
2022-04-18	CRNX	PERCEPTIVE ADVISORS LLC	157,515	22.2200	157,515	22.2200	3,499,983	2	23.2200	157,515	4.50
2021-10-25	CRNX	PERCEPTIVE ADVISORS LLC	1,200,000	19.8000	1,200,000	19.8000	23,760,000
2021-04-08	CRNX	PERCEPTIVE ADVISORS LLC	304,136	16.4400	304,136	16.4400	4,999,996
2020-04-17	CRNX	PERCEPTIVE ADVISORS LLC	1,071,428	14.0000	1,071,428	14.0000	14,999,992
2018-07-20	CRNX	PERCEPTIVE ADVISORS LLC	400,000	17.0000	400,000	17.0000	6,800,000
2018-07-20	CRNX	PERCEPTIVE ADVISORS LLC	400,000	17.0000	400,000	17.0000	6,800,000
2018-07-18	CRNX	PERCEPTIVE ADVISORS LLC	307,648	21.3000	307,648	21.3000	6,552,902

Data de Negociação	Ticker	Insider	Ações Reportadas	Preço Reportado	Ações Ajustadas	Preço Ajustado	Base de Custos	Dias para Máx	Preço em Máx	Lucro Máx ($)	Retorno Máx (%)
2023-12-29	ATHA	PERCEPTIVE ADVISORS LLC	163,954	2.3800	16,395	23.8000	390,211	69	4.1500	-322,171	-82.56
2023-12-28	ATHA	PERCEPTIVE ADVISORS LLC	409,598	2.4400	40,960	24.4000	999,419
2023-12-27	ATHA	PERCEPTIVE ADVISORS LLC	32,134	2.2800	3,213	22.8000	73,266
2022-06-30	ATHA	PERCEPTIVE ADVISORS LLC	1,101,362	2.9900	110,136	29.9000	3,293,072
2022-06-29	ATHA	PERCEPTIVE ADVISORS LLC	270,000	2.9900	27,000	29.9000	807,300
2021-01-25	ATHA	PERCEPTIVE ADVISORS LLC	311,111	22.5000	31,111	225.0000	6,999,998
2020-09-22	ATHA	PERCEPTIVE ADVISORS LLC	1,058,824	17.0000	105,882	170.0000	18,000,008

Data de Negociação	Ticker	Insider	Ações Reportadas	Preço Reportado	Ações Ajustadas	Preço Ajustado	Base de Custos	Dias para Máx	Preço em Máx	Lucro Máx ($)	Retorno Máx (%)
2023-05-31	LYRA	PERCEPTIVE ADVISORS LLC	3,610,832	2.4925	72,217	124.6250	8,999,999	301	6.5300	-8,528,428	-94.76
2022-04-12	LYRA	PERCEPTIVE ADVISORS LLC	5,924,170	4.2200	118,483	211.0000	24,999,997
2020-05-05	LYRA	PERCEPTIVE ADVISORS LLC	625,000	16.0000	12,500	800.0000	10,000,000

Data de Negociação	Ticker	Insider	Ações Reportadas	Preço Reportado	Ações Ajustadas	Preço Ajustado	Base de Custos	Dias para Mín	Preço em Mín	Máxima Perda Evitada ($)	Máxima Perda Evitada (%)
2025-11-13	LYRA	PERCEPTIVE ADVISORS LLC	28,597	3.9001	28,597	3.9001	111,531	123	0.4950	-97,375	-87.31
2025-11-13	LYRA	PERCEPTIVE ADVISORS LLC	3,213	3.9001	3,213	3.9001	12,531
2025-11-12	LYRA	PERCEPTIVE ADVISORS LLC	7,862	4.0594	7,862	4.0594	31,915
2025-11-12	LYRA	PERCEPTIVE ADVISORS LLC	883	4.0594	883	4.0594	3,584
2025-11-11	LYRA	PERCEPTIVE ADVISORS LLC	4,783	4.3146	4,783	4.3146	20,637
2025-11-11	LYRA	PERCEPTIVE ADVISORS LLC	537	4.3146	537	4.3146	2,317
2025-11-10	LYRA	PERCEPTIVE ADVISORS LLC	16,633	4.5398	16,633	4.5398	75,510
2025-11-10	LYRA	PERCEPTIVE ADVISORS LLC	1,869	4.5398	1,869	4.5398	8,485
2025-11-07	LYRA	PERCEPTIVE ADVISORS LLC	17,746	4.7467	17,746	4.7467	84,235
2025-11-07	LYRA	PERCEPTIVE ADVISORS LLC	1,993	4.7467	1,993	4.7467	9,460
2025-11-06	LYRA	PERCEPTIVE ADVISORS LLC	28,902	5.1799	28,902	5.1799	149,709
2025-11-06	LYRA	PERCEPTIVE ADVISORS LLC	3,247	5.1799	3,247	5.1799	16,819

Data de Negociação	Ticker	Insider	Ações Reportadas	Preço Reportado	Ações Ajustadas	Preço Ajustado	Base de Custos	Dias para Máx	Preço em Máx	Lucro Máx ($)	Retorno Máx (%)
2024-08-12	MGTX	PERCEPTIVE ADVISORS LLC	1,250,000	4.0000	1,250,000	4.0000	5,000,000	336	8.8900	6,112,500	122.25
2023-05-05	MGTX	PERCEPTIVE ADVISORS LLC	4,347,826	5.7500	4,347,826	5.7500	25,000,000
2020-11-23	MGTX	PERCEPTIVE ADVISORS LLC	500,000	12.8500	500,000	12.8500	6,425,000
2019-08-12	MGTX	PERCEPTIVE ADVISORS LLC	425,531	23.5000	425,531	23.5000	9,999,978
2019-03-01	MGTX	PERCEPTIVE LIFE SCIENCES MASTER FUND LTD	1,304,348	13.8000	1,304,348	13.8000	18,000,002
2018-06-12	MGTX	PERCEPTIVE ADVISORS LLC	1,333,333	15.0000	1,333,333	15.0000	19,999,995
2018-06-08	MGTX	PERCEPTIVE ADVISORS LLC	50,000	15.2200	50,000	15.2200	761,000

Data de Negociação	Ticker	Insider	Ações Reportadas	Preço Reportado	Ações Ajustadas	Preço Ajustado	Base de Custos	Dias para Máx	Preço em Máx	Lucro Máx ($)	Retorno Máx (%)
2021-12-08	NAUT	PERCEPTIVE ADVISORS LLC	200,000	5.3600	200,000	5.3600	1,072,000	15	6.04	136,000	12.69
2021-06-09	NAUT	PERCEPTIVE ADVISORS LLC	5,500,000	10.0000	5,500,000	10.0000	55,000,000
2021-06-03	ARYA	PERCEPTIVE ADVISORS LLC	330,050	10.0500	330,050	10.0500	3,317,002
2021-05-24	NAUT	PERCEPTIVE ADVISORS LLC	7,063	10.0500	7,063	10.0500	70,983
2021-05-20	ARYA	PERCEPTIVE ADVISORS LLC	159,925	10.0500	159,925	10.0500	1,607,246

Data de Negociação	Ticker	Insider	Ações Reportadas	Preço Reportado	Ações Ajustadas	Preço Ajustado	Base de Custos	Dias para Mín	Preço em Mín	Máxima Perda Evitada ($)	Máxima Perda Evitada (%)
2021-01-22	SCYX	PERCEPTIVE ADVISORS LLC	285,151	8.1600	35,644	65.2800	2,326,832	257	4.94	-2,150,756	-92.43
2021-01-22	SCYX	PERCEPTIVE ADVISORS LLC	33,849	8.9500	4,231	71.6000	302,949
2021-01-21	SCYX	PERCEPTIVE ADVISORS LLC	95,000	7.3800	11,875	59.0400	701,100
2021-01-20	SCYX	PERCEPTIVE ADVISORS LLC	185,000	7.4300	23,125	59.4400	1,374,550

Data de Negociação	Ticker	Insider	Ações Reportadas	Preço Reportado	Ações Ajustadas	Preço Ajustado	Base de Custos	Dias para Máx	Preço em Máx	Lucro Máx ($)	Retorno Máx (%)
2025-02-19	SLDB	PERCEPTIVE ADVISORS LLC	5,000,000	4.0300	5,000,000	4.0300	20,150,000	160	7.0700	15,200,000	75.43
2024-01-11	SLDB	PERCEPTIVE ADVISORS LLC	3,410,713	5.5300	3,410,713	5.5300	18,861,243
2021-03-23	SLDB	PERCEPTIVE ADVISORS LLC	2,608,695	5.7500	173,913	86.2500	14,999,996
2019-07-25	SLDB	PERCEPTIVE ADVISORS LLC	2,822,581	4.6500	188,172	69.7500	13,125,002
2018-01-30	SLDB	PERCEPTIVE ADVISORS LLC	1,000,000	16.0000	66,667	240.0000	16,000,000
2018-01-30	SLDB	PERCEPTIVE ADVISORS LLC	20,000	27.3260	1,333	409.8900	546,520

Data de Negociação	Ticker	Insider	Ações Reportadas	Preço Reportado	Ações Ajustadas	Preço Ajustado	Base de Custos	Dias para Máx	Preço em Máx	Lucro Máx ($)	Retorno Máx (%)
2013-11-07	ACRX	PERCEPTIVE ADVISORS LLC	93,500	6.4981	4,675	129.9620	607,572	118	260.6	610,733	100.52
2013-11-07	ACRX	PERCEPTIVE ADVISORS LLC	6,500	6.4981	325	129.9620	42,238
2013-11-06	ACRX	PERCEPTIVE ADVISORS LLC	93,500	6.5166	4,675	130.3320	609,302
2013-11-06	ACRX	PERCEPTIVE ADVISORS LLC	6,500	6.5166	325	130.3320	42,358
2013-11-04	ACRX	PERCEPTIVE ADVISORS LLC	98,175	6.8804	4,909	137.6080	675,483
2013-11-04	ACRX	PERCEPTIVE ADVISORS LLC	6,825	6.8804	341	137.6080	46,959
2013-11-04	ACRX	PERCEPTIVE ADVISORS LLC	46,750	6.8370	2,338	136.7400	319,630
2013-11-04	ACRX	PERCEPTIVE ADVISORS LLC	3,250	6.8370	162	136.7400	22,220
2013-11-01	ACRX	PERCEPTIVE ADVISORS LLC	10,442	7.1698	522	143.3960	74,867
2013-11-01	ACRX	PERCEPTIVE ADVISORS LLC	150,218	7.1698	7,511	143.3960	1,077,033
2013-10-31	ACRX	PERCEPTIVE ADVISORS LLC	192,000	6.6932	9,600	133.8640	1,285,094
2013-10-31	ACRX	PERCEPTIVE ADVISORS LLC	8,000	6.6932	400	133.8640	53,546
2013-07-23	ACRX	PERCEPTIVE ADVISORS LLC	850,000	11.6500	42,500	233.0000	9,902,500

Data de Negociação	Ticker	Insider	Ações Reportadas	Preço Reportado	Ações Ajustadas	Preço Ajustado	Base de Custos	Dias para Mín	Preço em Mín	Máxima Perda Evitada ($)	Máxima Perda Evitada (%)
2017-06-19	ACRX	PERCEPTIVE ADVISORS LLC	875,000	2.4000	43,750	48.0000	2,100,000	235	34	-612,500	-29.17
2016-09-29	ACRX	PERCEPTIVE ADVISORS LLC	97,200	3.8798	4,860	77.5960	377,117
2016-09-28	ACRX	PERCEPTIVE ADVISORS LLC	119,300	3.9596	5,965	79.1920	472,380
2016-09-15	ACRX	PERCEPTIVE ADVISORS LLC	276,927	3.7277	13,846	74.5540	1,032,301
2016-09-15	ACRX	PERCEPTIVE ADVISORS LLC	115,923	3.6275	5,796	72.5500	420,511
2015-11-18	ACRX	PERCEPTIVE ADVISORS LLC	42,300	5.3459	2,115	106.9180	226,132
2015-11-17	ACRX	PERCEPTIVE ADVISORS LLC	133,900	5.3578	6,695	107.1560	717,409
2015-11-06	ACRX	PERCEPTIVE ADVISORS LLC	17,100	4.4658	855	89.3160	76,365
2015-11-05	ACRX	PERCEPTIVE ADVISORS LLC	75,000	4.6168	3,750	92.3360	346,260
2015-09-09	ACRX	PERCEPTIVE ADVISORS LLC	310,000	4.1767	15,500	83.5340	1,294,777

Data de Negociação	Ticker	Insider	Ações Reportadas	Preço Reportado	Ações Ajustadas	Preço Ajustado	Base de Custos	Dias para Máx	Preço em Máx	Lucro Máx ($)	Retorno Máx (%)
2023-12-29	VRCA	PERCEPTIVE ADVISORS LLC	115,774	7.2400	11,577	72.4000	838,204	136	9.5600	-727,527	-86.80
2023-12-28	VRCA	PERCEPTIVE ADVISORS LLC	126,116	7.0800	12,612	70.8000	892,901
2023-12-27	VRCA	PERCEPTIVE ADVISORS LLC	79,726	7.2000	7,973	72.0000	574,027
2023-12-26	VRCA	PERCEPTIVE ADVISORS LLC	54,652	6.4900	5,465	64.9000	354,691
2023-12-22	VRCA	PERCEPTIVE ADVISORS LLC	250,000	6.6700	25,000	66.7000	1,667,500
2023-12-21	VRCA	PERCEPTIVE ADVISORS LLC	200,000	6.1700	20,000	61.7000	1,234,000
2023-12-19	VRCA	PERCEPTIVE ADVISORS LLC	277,008	5.3600	27,701	53.6000	1,484,763
2023-12-18	VRCA	PERCEPTIVE ADVISORS LLC	456,923	5.4100	45,692	54.1000	2,471,953
2023-12-15	VRCA	PERCEPTIVE ADVISORS LLC	500,000	5.9700	50,000	59.7000	2,985,000
2022-07-05	VRCA	PERCEPTIVE ADVISORS LLC	1,428,571	2.1000	142,857	21.0000	2,999,999
2018-06-19	VRCA	PERCEPTIVE ADVISORS LLC	1,000,000	15.0000	100,000	150.0000	15,000,000

Data de Negociação	Ticker	Insider	Ações Reportadas	Preço Reportado	Ações Ajustadas	Preço Ajustado	Base de Custos	Dias para Máx	Preço em Máx	Lucro Máx ($)	Retorno Máx (%)
2021-01-28	VYNE	PERCEPTIVE ADVISORS LLC	4,219,409	2.3700	383,583	26.0700	9,999,999	19	182.16	59,873,298	598.73
2020-06-09	MNLO	PERCEPTIVE ADVISORS LLC	2,702,702	1.8500	245,700	20.3500	4,999,999

Data de Negociação	Ticker	Insider	Ações Reportadas	Preço Reportado	Ações Ajustadas	Preço Ajustado	Base de Custos	Dias para Mín	Preço em Mín	Máxima Perda Evitada ($)	Máxima Perda Evitada (%)
2021-08-16	VYNE	PERCEPTIVE ADVISORS LLC	250,000	1.7400	13,889	31.3200	435,000	360	5.472	-359,005	-82.53
2021-08-13	VYNE	PERCEPTIVE ADVISORS LLC	250,000	1.8400	13,889	33.1200	460,000
2021-08-12	VYNE	PERCEPTIVE ADVISORS LLC	338,897	2.2300	18,828	40.1400	755,740
2021-05-06	VYNE	PERCEPTIVE ADVISORS LLC	1,000,000	3.6700	55,556	66.0600	3,670,000

Perceptive Life Sciences Master Fund Ltd - Insider Trading Tracker

Introdução

Rentabilidade Média de Negociação

Empresas com Posições Internas Reportadas

Como Interpretar os Gráficos

Compras Internas ACRV / Acrivon Therapeutics, Inc. - Análise de Lucro de Curto Prazo

Vendas Internas ACRV / Acrivon Therapeutics, Inc. - Análise de Perda de Curto Prazo

Compras Internas ADMA / ADMA Biologics, Inc. - Análise de Lucro de Curto Prazo

Vendas Internas ADMA / ADMA Biologics, Inc. - Análise de Perda de Curto Prazo

Compras Internas AIS / Tidal Trust III - VistaShares Artificial Intelligence Supercycle ETF - Análise de Lucro de Curto Prazo

Vendas Internas AIS / Tidal Trust III - VistaShares Artificial Intelligence Supercycle ETF - Análise de Perda de Curto Prazo

Compras Internas ALDX / Aldeyra Therapeutics, Inc. - Análise de Lucro de Curto Prazo

Vendas Internas ALDX / Aldeyra Therapeutics, Inc. - Análise de Perda de Curto Prazo

Compras Internas ANIP / ANI Pharmaceuticals, Inc. - Análise de Lucro de Curto Prazo

Vendas Internas ANIP / ANI Pharmaceuticals, Inc. - Análise de Perda de Curto Prazo

Compras Internas CRNX / Crinetics Pharmaceuticals, Inc. - Análise de Lucro de Curto Prazo

Vendas Internas CRNX / Crinetics Pharmaceuticals, Inc. - Análise de Perda de Curto Prazo

Compras Internas CYPH / Cypherpunk Technologies Inc. - Análise de Lucro de Curto Prazo

Vendas Internas CYPH / Cypherpunk Technologies Inc. - Análise de Perda de Curto Prazo

Compras Internas IMTX / Immatics N.V. - Análise de Lucro de Curto Prazo

Vendas Internas IMTX / Immatics N.V. - Análise de Perda de Curto Prazo

Compras Internas LONA / LeonaBio, Inc. - Análise de Lucro de Curto Prazo

Vendas Internas LONA / LeonaBio, Inc. - Análise de Perda de Curto Prazo

Compras Internas LYRA / Lyra Therapeutics, Inc. - Análise de Lucro de Curto Prazo

Vendas Internas LYRA / Lyra Therapeutics, Inc. - Análise de Perda de Curto Prazo

Compras Internas MGTX / MeiraGTx Holdings plc - Análise de Lucro de Curto Prazo

Vendas Internas MGTX / MeiraGTx Holdings plc - Análise de Perda de Curto Prazo

Compras Internas NAUT / Nautilus Biotechnology, Inc. - Análise de Lucro de Curto Prazo

Vendas Internas NAUT / Nautilus Biotechnology, Inc. - Análise de Perda de Curto Prazo

Compras Internas OBIO / Orchestra BioMed Holdings, Inc. - Análise de Lucro de Curto Prazo

Vendas Internas OBIO / Orchestra BioMed Holdings, Inc. - Análise de Perda de Curto Prazo

Compras Internas SCYX / SCYNEXIS, Inc. - Análise de Lucro de Curto Prazo

Vendas Internas SCYX / SCYNEXIS, Inc. - Análise de Perda de Curto Prazo

Compras Internas SLDB / Solid Biosciences Inc. - Análise de Lucro de Curto Prazo

Vendas Internas SLDB / Solid Biosciences Inc. - Análise de Perda de Curto Prazo

Compras Internas TLPH / Talphera, Inc. - Análise de Lucro de Curto Prazo

Vendas Internas TLPH / Talphera, Inc. - Análise de Perda de Curto Prazo

Compras Internas VRCA / Verrica Pharmaceuticals Inc. - Análise de Lucro de Curto Prazo

Vendas Internas VRCA / Verrica Pharmaceuticals Inc. - Análise de Perda de Curto Prazo

Compras Internas VYNE / VYNE Therapeutics Inc. - Análise de Lucro de Curto Prazo

Vendas Internas VYNE / VYNE Therapeutics Inc. - Análise de Perda de Curto Prazo

Histórico de Negociações Insider